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Rheumatoid arthritis (RA) is a prevalent autoimmune disease, which affects approximately one 
percent of all types of human populations (1;2). Generally, this immune-mediated disease is asso-
ciated with symmetrically inflammation, destruction of the joints leading to overall functional im-
pairment and (serious) comorbidity, like cardiovascular events (3-6). 
Generally, the etiology of this inflammatory disease remains unclear due to the complexity of inte-
racting factors representing a multifactor process. Still, important risk- and protective factors have 
been elucidated which are associated with development or severity of RA (7-11). These factors can be 
divided in two groups: environmental- and genetic factors. It has been demonstrated that these 
factors act synergistically in causing RA. Specifically, this phenomenon was highlighted by an inte-
raction between smoking and HLA-DR risk alleles in RA patients (12;13). Likewise, it was observed 
that an environmental factor, like smoking, could increase the genetic risk course for RA. These 
interactions provide additional difficulties in clear understanding RA’s etiology.   
Similarly to etiology, the RA’s pathophysiology is not fully understood. Hypothetically, after the sti-
mulation of an environmental trigger, T-cells of the CD4+ type stimulate monocytes, macrophages 
and synovial fibroblasts to secrete three important pro-inflammatory mediators: Tumor Necrosis 
Factor alpha (TNFα), interleukin 1 (IL-1) and interleukin 6 (IL-6). It is thought that TNFα has a cen-
tral place in the inflammatory cascade of RA leading to progression of inflammation and eventually 
erosion of bone and cartilage. Also, TNFα is recognized to be involved in stimulation of cytokine 
production (including its own), enhancing expression of adhesion molecules, neutrophil activation 























Figure 1. Pathophysiology and accessory therapeutic agents in rheumatoid arthritis 
Abbreviation(s): IL1= interleukin 1, IL6= interleukin 6, MMP= matrix metalloproteinases,  
TNF= tumor necrosis factor. 
Treatment of rheumatoid arthritis  
 
In the last decades treatment outcome of RA has been successfully improved due to:  
-1- the expanding knowledge of the disease’s pathophysiology, which elucidated important key play-
ers in the inflammatory process as potential targets for therapy (14-16); -2- development of new 
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agents based on newly discovered targets leading to improved response percentages and facilitating 
a range of equivalent treatment modalities in drug therapy (e.g. for effectively switching to inflix-
imab after failure of etanercept) (17;18); -3- the development of easy-to-use diagnostic tools to 
measure efficacy of therapy (19-22); -4- the recognition and acknowledgement that disability and 
joint damage occurs in an early state (6;23-25); -5- therapeutic strategy for RA patients that is fo-
cused on strictly- and early management of RA’s disease course (26-28).  
Despite an increasing knowledge on RA’s etiology and pathogenesis, a therapy resulting in remedy 
of the disease is not achieved to date. Alternatively, treatment is aimed at remission of disease, by 
suppressing pro-inflammatory particles, like cytokines and lymphocytes (16;29). Notably, a widen-
ing arsenal of therapeutics has been developed, which have a general focus on modifying RA’s dis-
ease course to alleviate pain, to suppress inflammation, to prevent joint damage and loss of function 
in order to postpone disability (Figure 1) (30). Hereby, an important role in modification of treat-
ment outcome is being played by disease modifying antirheumatic drugs (DMARDs). Two types of 
DMARDs take a central place in the rheumatology clinics: methotrexate (MTX) and TNF inhibitors. 
Despite the fact that the mechanism of action of these drugs remains partially unclear, DMARDs 
have proven to be effective treatment modalities according to several disease activity measurements 
in clinical trials (26;31-36). For this reason, rheumatologists have increasingly prescribed both types 
of drugs. However, highly differential response rates in overall clinical efficacy and/or toxicity have 
been demonstrated in clinical trials with MTX and TNF inhibitors. Specifically, 40-70% and/or 15-
30% in RA patients treated with MTX and TNF inhibitors fail to achieve a satisfactory response 
and/or develop adverse drug events, respectively (26;31-36). Because of the substantial differences 
in individual responses and also the knowledge that reduction of disease activity leads to less pro-
gression of RA, it is beneficial to predict which patients have a increased chance for responding to 
the different treatment modalities. Consequently, several studies have been performed considering 
an influence of demographic, clinical and immunological variables on treatment outcome to 
DMARDs (37-41). Similarly, genetic influences on response to DMARDs have also been explored 
(42-47). Generally, genetic factors are estimated to account for 15-30% of interindividual differences 
in drug metabolism and response. In this way, pharmacogenetics has the potential to increase drug 
efficacy and to ameliorate adverse drug events by applying genetic determinants of therapeutic re-





Pharmacogenetics is defined as the study of variability in drug responses attributed to genetic fac-
tors in different populations (48;49). In this context, the pharmacogenetics of most drugs is likely to 
be comparable to the genetics of complex diseases, like RA. In both cases numerous proteins are 
involved in complex pathways, and in this way one clear genetic explanation is not available (50).    
The complete DNA sequence across the human genome, which consists of approximately 3.1 billion 
base pairs, has been determined. Approximately 99.9% of base pairs in the human genome are iden-
tical among individuals, whereas the remaining 0.1% reflects the individual differences in variants 
which may lead to differences in susceptibility to specific diseases and response to specific drugs. 
Single nucleotide polymorphisms (SNP) have been recognized as useful markers of genetic poly-
morphism. SNPs comprise genetic variation with a single-base difference between individuals re-
sulting in due to alteration, deletion or insertion of the base (e.g. replacement of guanine by ade-
nine). SNPs are widely distributed at a frequency of about one SNP in every 300–500 bases, which 
is approximately 1.5 million of this type of variants across the human genome. Hereby, SNPs are 
estimated to account for 90% of all genetic mutations (51;52). 
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Generally, in pharmacogenetics SNPs are involved in differences in drug response by affecting the 
expression of genes or by altering the types of amino acids and affecting their activities (49;53). In 
addition, as multiple SNPs exist within a single gene, several combinations of these polymorphisms 
(expressed by linkage disequilibrium- e.g. haplotypes) are important to consider in order to explain 
genetic variation as a whole in pharmacogenetic research (51).  
10
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Outline of this Thesis 
 
The primary objective of this thesis is to assess the role of pharmacogenetics in the variation of 
treatment outcome in patients diagnosed with rheumatoid arthritis and treated with disease mod-
ifying antirheumatic drugs. Hereby, this thesis is divided in two parts: pharmacogenetics of metho-
trexate and of adalimumab in RA patients. 
 
Part 1: Pharmacogenetics of methotrexate 
 
In Chapter 2 an overview is presented of the previously performed studies concerning genetic va-
riability contributing to differences in response to MTX in RA treatment.   
 
As it is generally accepted that MTX may act in RA through inhibition of folate pathway enzymes, 
other reports indicate that efficacy may also be related to the release of endogenous antiinflammato-
ry adenosine. With this hypothesis, the relationship between SNPs in genes related to adenosine 
release and MTX treatment outcome in patients with recent-onset RA is explored in chapter 3. 
 
So far, most genetic variants are selected for analysis based upon their hypothetical relation to the 
mechanism of MTX or inflammatory process in RA (chapters 2), such as genetic variants in the 
adenosine pathway (chapter 3). Ideally, functional genetic variants are chosen because the altera-
tion in protein function is thought to influence drug action and thus may explain interindividual 
differences in drug response. Chapter 4 assesses the role of SNPs with proven functional conse-
quences. These SNPs are located in genes, which are thought to be related with the mechanism of 
action of MTX and/or immunopathogenesis of RA. In addition, replication analyses are performed 
in chapter 4, since previously applied endpoints for efficacy from other research reports are availa-
ble. These replication analyses are important, since pharmacogenetic studies have the potential to 
result in reporting false positive findings. 
 
Previously, a clinical pharmacogenetic predictive model was developed for predicting the efficacy of 
MTX monotherapy in patients with recent-onset RA comprising the Dutch BeSt Cohort. The model 
consists of non-genetic factors sex, rheumatoid factor and smoking status, Disease Activity Score 
(DAS) before starting MTX and 4 genetic polymorphisms (MTHFD1 1958G>A, AMPD1 34C>T, 
ITPA 94A>C and ATIC 347C>G). The performance of this model is validated in a second Dutch 
cohort (chapter 5) and in a Swedish cohort (chapter 6).   
 
Chapter 7 evaluates the role of the haplotypes comprising the SNPs MTHFR 1298A>C and 
MTHFR 677C>T in treatment outcome to MTX in RA. Specifically, in this chapter optimalization of 
a previously designed pharmacogenetic model is aimed with addition of the number of haplotypes 
comprising MTHFR 1298A-677C alleles as additional criterion. Furthermore, the predictive value of 
the haplotype is compared with other genetic polymorphisms in predicting MTX efficacy. 
 
 
Part 2: Pharmacogenetics of adalimumab 
 
In Chapter 8 an overview is given of the previously performed studies concerning genetic variabili-
ty contributing to differences in response to TNF inhibitors in RA treatment. 
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In the next chapter, SNP selection for pharmacogenetic association studies is discussed. Additional-
ly, a pharmacogenetic pathway approach is presented together with proposed criteria for systematic 
selection of SNPs. This method is applied for the selection of potential interesting SNPs within genes 
related involved in the mechanism of action of adalimumab and/or inflammatory process of RA 
(chapter 9).  
 
Chapter 10 puts the presented systematically selection of SNPs in chapter 9 into practice: efficacy 
of treatment with adalimumab is associated with genetic variants selected by a pharmacogenetic 
pathway approach using a custom made antiTNFα SNP array.  
Furthermore, SNPs, which were previously associated with genetic susceptibility to RA and/or 




Chapters 11 and 12 provide a summary of this thesis (chapter 11) and present a general discussion 
including a perspective on future research (chapter 12).  
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Over the last decades important progress is being made regarding disease modifying anti-rheumatic 
drugs (DMARDs), like methotrexate (MTX), in the treatment of rheumatoid arthritis (RA). Never-
theless, a substantial part of the patients fail to achieve a good response and/or experience toxicity, 
which limits further treatment leading to progression of inflammation and destruction of joints. 
These high interindividual differences in drug response gave rise to the need for prognostic markers 
in order to individualize and optimize therapy with these anti-rheumatic agents. Besides demo-
graphic and clinical factors, studies in the research field of pharmacogenetics have reported poten-
tial markers associated with clinical response on treatment with MTX. However, publicized conflict-
ing results and underlying interpretation difficulties inhibit drawing definitive conclusions. Present-
ly, clinical implementation of pharmacogenetics as an important step for individualizing drug thera-
py in RA is not feasible yet. Replication and prospective validation in large patient cohorts are re-
quired before pharmacogenetics can be used in clinical practice. This review provides the current 









Pharmacogenetics of methotrexate in rheumatoid arthritis
Introduction 
 
Rheumatoid arthritis has a prevalence of ~1% in the Western population (1). This autoimmune dis-
ease is characterized by a chronic inflammatory process within the synovial joints, progressive (ra-
diological) joint damage and significant functional impairment (2). In the last decades patients have 
been treated with traditional disease modifying anti-rheumatic drugs (DMARDs) including metho-
trexate (MTX), sulphasalazine and leflunomide, or a combination of DMARDs. More recently, 
growing evidence for the central role of tumour-necrosis factor alpha (TNFα) in the pathogenesis of 
RA has led to the introduction of TNF inhibitors, such as etanercept, infliximab and adalimumab 
(3). These biological DMARDs have proven to play an important role in the treatment of persistent 
RA in patients, who achieve an incomplete response or develop adverse drug events to traditional 
DMARDs (4-6). In addition, biologicals with alternate mechanisms of actions such as rituximab, 
abatacept and tocilizumab have recently been developed, (7-9). To date, the place in RA therapy of 
these new agents is less established. 
Ideally, RA therapy is based on strict monitoring of disease activity and tight control treatment in 
order to prevent progression of joint damage and functional disability (10). Namely, it is established 
that high and variable disease activity is related to increasing joint damage and that effective inter-
vention stops this progression (11;12). In current clinical practice, newly diagnosed RA patients are 
treated with traditional DMARDs, in which methotrexate (MTX) is the drug of first choice (13;14). 
In case of unfavourable response, side effects and/or drug toxicity, alteration of dose regimen or 
drug therapy towards a combination of DMARDs and/or biologicals is recommended.(4;15;16).  
Still, different response rates are seen in RA patients treated with MTX. Substantial percentages of 
30-40% of RA patients fail to achieve a satisfactory response. Moreover, 15-30% of the patients de-
velop adverse drug events (16-18). These different responses lead to studies identifying influence of 
demographic, clinical and immunological variables on treatment outcome with MTX (19). Next to 
these factors, genetic influences have also been explored in the last decade. Generally, pharmacoge-
netics has the potential to increase drug efficacy and to ameliorate adverse events (20;21). There-
fore, its application might be of great clinical benefit for individuals affected with RA. Studies have 
reported associations between single nucleotide polymorphisms (SNPs) in genes encoding enzymes 
related to the pharmacokinetics and pharmacodynamics of MTX and treatment outcome (22-25). 
The ultimate aim of using pharmacogenetic markers is to predict the probability of a wanted or un-
wanted drug response in individual patients (20;21).  
This review presents an overview of genetic variability contributing to differences in response to 
MTX in RA treatment.  
 
 
Pharmacogenetics of methotrexate 
 
Although the exact mechanism of action of MTX is unclear, numerous enzymes have demonstrated 
to be important for its anti-proliferative and immunosuppressive effects (26;27). Before MTX is 
being metabolized inside the cell, MTX enters the cell e.g. by the transporter-enzyme reduced folate 
carrier (RFC). Efflux from the cell is facilitated by ATP-binding cassette (ABC) transporters, e.g. 
ABCC1 to 5 and ABCG2 and (less proven by) ABCB1 (28;29). If MTX enters the cell, the drug is po-
lyglutamated, meaning that groups of glutamic acid are added to MTX. This process is catalyzed by 
the enzyme folylpolyglutamate synthetase (FPGS) and reversed by gammaglutamyl hydrolase 
(GGH), respectively.  
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Polyglutamated MTX (MTXPGs) inhibits several enzymes directly such as thymidylate synthase 
(TYMS), dehydrofolate reductase (DHFR), whereas indirect inhibition occurs on methylenetetrahy-
drofolate reductase (MTHFR), a key enzyme in the folate pathway (26). MTXPGs also inhibit the 
conversion of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) to formyl-AICAR, which is 
facilitated by the enzyme AICAR transformylase (ATIC). Accumulation of AICAR has a direct inhibi-
tory effect on other enzymes, like adenosine monophosphate deaminase (AMPD1). This accumula-
tion may lead to the release of adenosine, a potential anti-inflammatory agent (30;31).  
To date, SNP selection for pharmacogenetic association studies concerning MTX is done within 
genes encoding enzymes in these hypothetical pathways regarding MTX’s mechanism of action. 
However, the association of polymorphisms in these pathway genes have yielded mixed results. 
Table 1 presents the pharmacogenetic data of RA patients treated with MTX monotherapy. 
Regarding transport enzymes, association studies of MTX treatment outcome to genetic polymor-
phisms in the genes ABCB1, RFC and ABCC2 have been performed (25;32-40). It has been found 
that SNPs in the transporters ABCB1 and RFC associate with MTX efficacy and toxicity. However, 
conflicting data were seen. For example, studies with the ABCB1 3435 C>T have reported that the 
genotype TT was associated with efficacy (34) and inefficacy (36). In addition, one study detected an 
association of the TT genotype with toxicity (40). For ABCC2, no associations of SNPs with toxicity 
were found (25).   
The best-studied SNPs concerning MTX treatment outcome are at the positions 677C>T and 
1298A>C within the gene coding for the folate key-enzyme MTHFR (24;25;37;39-47). This enzyme 
catalyzes the conversion of homocysteine to methionine for a variety of metabolic reactions (30). 
Functional studies have elucidated that these two polymorphisms are associated with diminished 
enzyme activity of MTHFR leading to homocysteinemia (48). In fact, it is demonstrated that a de-
crease in activity could lead to homocysteinemia and eventually could be related to toxicity, e.g. in-
fluencing the gastrointestinal tract in  RA patients on MTX therapy (48). As a consequence, several 
reports studied the association of MTHFR 677C>T and 1298A>C with toxicity. Regarding MTHFR 
677C>T, seven studies found no association with overall MTX-induced toxicity (37;41-43;47-49), 
whereas other studies found associations with GI toxicity for the CT genotype (48), increased MTX 
discontinuation due to increased liver enzyme levels for 677 T-allele carriers (24), alopecia in Afro-
Americans (25), and overall toxicity (24;45;46). In other studies, MTHFR 1298 A-allele carriers 
were related to side effects in two reports (41;42), whereas two groups found no association (43;45) 
and two groups detected an association between 1298 C-allele carriers with overall toxicity and ga-
strointestinal toxicity (37;49).  
Additionally, associations with MTX efficacy were assessed in most of the studies, involving MTHFR 
genetics. Of the seven studies performed, only three studies found that patients genotyped for 
MTHFR 677CC were more likely to achieve a good response, defined as a decrease or an obtained 
absolute value of disease activity score (DAS) (37;44;49). Also, reports on MTHFR 1298A>C provide 
inconclusive results. One report found associations with efficacy of the 1298AA genotype and a de-
crease in DAS (37). In contrast, three studies reported an association between C-allele carriers and 
disease improvement as defined as the likelihood to be treated with a higher dose, a tendency for 
remission or decrease in ESR and/or CRP level (44-46). Still, five reports did not find associations of 
MTHFR 1298A>C with efficacy (40-43;49). The enzymes methylenetetrahydrofolate dehydroge-
nase (MTHFD1), methylenetetrahydrofolate (SHMT1), and thymidylate synthase enhancer region 
(TSER) are indirectly influenced by MTXPGs (26). Regarding efficacy, one SNP in the MTHFD1 
gene could be related with inefficacy to MTX treatment (39). Yet, for SHMT1 and TSER an associa-
tion with a single genetic polymorphism within each gene and developing side effects and alopecia 
in specific was demonstrated (47) (table 1). 
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Two direct targets of MTX are the enzymes DHFR and TYMS (26;30). Regarding DHFR, one study 
was performed in which no associations with efficacy or toxicity were found (37). For TYMS, four 
studies were performed (36;39;40;43). Only, one study reported an association of a polymorphism, 
6 basepair (bp) deletion, within the 3’UTR region of the gene and achieving good response, defined 
as likelihood to be treated with a higher dose or decrease in CRP level (43).   
Recently an association between MTX and HLA-G antigens, defined as nonclassical major histo-
compatibility complex class Ib molecules important for maintaining anti-inflammatory conditions, 
was found in an in vitro study (50). The HLA-G 14 bp deletion is thought to increase HLA-G mRNA 
and protein stability, possibly leading to prolonged anti-inflammatory actions. Therefore, MTX may 
act synergistic with this deletion. It was shown that MTX induces soluble HLA-G, whereas a homo-
zygous deletion of 14bp in this HLA-gene was more frequently detected in patients with response to 
MTX. However, the role of the HLA-G 14 bp polymorphism in vivo in clinical response to MTX re-
mains conflicting (50-52).  
Generally, regarding MTX-induced toxicity, no associations between polymorphisms in the pathway 
enzymes including, TYMS, DHFR, AMPD1, ITPA genes and the occurrence of side effects in RA 
patients exist (36;37;40;53) (Table 1). 
Direct involved in MTX’s polyglutamation are the enzymes FPGS and GGH. Two SNPs, 114G>A and 
1994A>G, in the FPGS gene were not reported to be related to efficacy or toxicity in RA patients 
(54). Concerning GGH, in three studies no significant effect of three SNPs, -401C>T, 452C>T and 
16C>T, with efficacy was demonstrated (39;49;54). However, an association of GGH -401C>T with 
toxicity was seen in one study (49).  
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Gene Function Genetic polymor-
phism(s) 
Clinical effect on: 
Toxicity Efficacy 
MTHFR 
Catalyzes methylene THF to 
methyl-THF; indirect target 
MTX 
 677C>T 
- Effect on GI toxicity (48); T-allele 
associated with toxicity and in-
creased liver enzyme levels 
(24;45;46); No association with 
toxicity (37;48;40-43;47;49) 
-No association with 
efficacy 
(24;25;40;42;43); 
Association with efficacy 
(37;44;49)  
1298 A>C 
A-allele associated with toxicity 
(41;42); C-allele associated with 
toxicity and GI toxicity (37;40;49); 
No association with toxicity (43;45) 
No association with 
efficacy 
(40;42;43;45;49); 
Association with efficacy 
(37;46); May affect 
efficacy (44) 
ATIC 
Conversion of AICAR to 10-
formyl-AICAR; target of polyg-
lutamated MTX 
347C>G 
GG associated with toxicity and GI 
toxicity  (47;49;53); No effect on 
toxicity (36) 
Association with efficacy 
(39;53;47); No associa-
tion with efficacy 
(36;49) 
DHFR Reduction of DHF to THF; target of MTX -473G>A, 35389G>A No effect on efficacy or toxicity (37) 
MTHFD1 
catalyzes interconversion of 1-
carbon derivatives of THF; 
indirect target MTX 
1958G>A * AA associated with 
inefficacy (39) 
SHMT1 
catalyzes conversion of serine 
and THF to glycine and methy-
lene-THF: indirect target MTX 
1420C>T 
No association with toxicity (47;49); 
CC associated with alopecia and CNS 
side effects (47) 
No association with 
efficacy (39); CC asso-
ciated with efficacy (49);  
TSER Enhancer region of TYMS; indirect target of MTX ‘5 UTR 28bp repeat 
No association with toxicity (43;49); 
Association with toxicity and alope-
cia (47) 
No association with 
efficacy (39;43;49)  
TYMS Conversion of dUMP to dTMP; target of MTX ‘3 UTR 6bp deletion No effect on toxicity (36;40) 
May affect MTX efficacy 
(as defined by MTX 
dose and CRP level) 
(43); 
No effect on efficacy (as 
defined by  MTX dose) 
(36;40)  
AMPD1 Conversion of AMP to ADP and ATP; indirect target MTX 34C>T No association with  toxicity (53) 
T-allele associated with 
efficacy (39;53) 
MTR 
Methylation of homocysteine 
to methionine; indirect target 
MTX 
2756A>G 
No association with toxicity (40;53); 
AA associated with toxicity (49) 
No association with 
efficacy (40;49;53) 
MTRR 
Methylation of cofactors re-
quired for MTR action; indirect 
target MTX 
66A>G 
No association with toxicity (40;53); 
GG associated  with toxicity (49) 
No effect on efficacy 
(40;49;53) 
ITPA Conversion IMP to ITP; indi-rect target MTX 94C>A No association with toxicity (53) 




Adenosine A2a receptor 
5 SNPs (4 in intron+ 1 in 
downstream) 
All SNPs associated with Toxicity 
(55);  Two SNPs with GI toxicity (55) * 
FPGS 
Adding polyglutamates to 
MTX; prolonging cellular 
retention MTX 
1994A>G, 114G>A No effect on efficacy or toxicity (54) 
GGH 
Conversion of long chain 
polyglutamated MTX into 
short chain by removing polyg-
lutamates 
452C>T, 16C>T No effect on toxicity (54) 
May affect efficacy (54);  
No association with 
efficacy (39)  
- 401C>T CC associated with toxicity (49) 
No association with 
efficacy (49);  
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Table 1. Pharmacogenetic association studies of methotrexate with treatment outcome in rheu-
matoid arthritis 
 
* = No information on association(s) with specific efficacy or toxicity was present regarding this SNP under study 
Abbreviations and accessory full names of formal genes can be relocated in the NCBI gene database  
 
 
Because, it is thought that MTX has an influence on adenosine pathway, SNPs within genes coding 
for AMPD1, ATIC, MTR, MTRR, ITPA were correlated with treatment outcome in several studies 
(36;40;47;53). Our group identified significant associations with clinical response, defined as an 
absolute value of DAS of less than 2.4, and the SNPs AMPD1 34C>T, ATIC 347C>G, ITPA 94C>A. 
In the toxicity analysis, only ATIC GG was associated with toxicity (53).  
In general, several studies demonstrated no effect of MTR and MTRR on MTX efficacy (40;49;53). 
Regarding toxicity, in only one study (49) a relation between MTR 2756A>G and MTRR 66A>G and 
toxicity in a small group of patients was seen. However in two previously performed studies this was 
not reported (40;53). Since, the anti-inflammatory effects of adenosine are mediated by adenosine 
receptors, one group studied polymorphisms in genes coding for the adenosine receptor (ADO-
RA2A) in relation with MTX therapy outcome. Five SNPs, were reported to be associated with ad-
verse events on MTX. Specifically, two SNPs were related with gastrointestinal side effects (55) (Ta-
ble 1). 
Several nongenetic factors have been reported to influence efficacy of MTX treatment over the last 
years. These factors include demographic, life-style and clinical determinants such as disease activi-
ty at baseline, gender and smoking. Still, associations of these factors have not been translated into 
clinical tools in order to guide MTX treatment in RA patients. However, recently, a pharmacogenetic 
model in combination with clinical factors to predict MTX efficacy in recent-onset RA was devel-
oped (39). In this study it was reported that the clinical factors gender, rheumatoid factor combined 
with smoking status and disease activity at baseline were predictive for MTX response. The included 
genetic factors were the SNPs AMPD1 C>T, ATIC 347C>G, ITPA 94 A>C and MTHFD 1958G>A. 
The prediction resulted in the classification of 60% of the RA patients into MTX responders and 
nonresponders, with 95% and 86% as true positive and negative response rates, respectively. Evalu-
ation of this predictive model in a second group of 38 RA patients supported our results (39). Still, 
this model needs further prospective validation before its implementation in clinical practice. 
  
 
ABCB1 Efflux transporter on cells; efflux of MTX 
3435C>T 
ABCB1 3435 TT associated with 
toxicity (40); No association with 
toxicity (36) 
No association with 
efficacy (40);  TT asso-
ciated with efficacy (34); 
TT associated with 
inefficacy (36) 
+1236C>T, 2677G>T No effect on efficacy or toxicity (25;40) 
RFC Folate entry in the cell 
-43T>C,  696C>T * No effect on efficacy 
(32) 
80G>A 
RFC1 80GG associated with toxicity 
(40); No association with toxicity 
(36;49;53) 
No effect on efficacy 
(32;36;37;40;49); RFC 
80A-allele associated 
with efficacy (35)  
ABCC2 Efflux transporter on cells of MTX 
1249 G>A, 1058 G>A, IVS23 
+56 T>C No effect on  toxicity (25) * 
HLA-G Persistence of anti-inflammatory conditions 14bp deletion * 
-14/ -14 bp associated 
with efficacy (50;51) . No 
effect on efficacy (52) 
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Conclusion 
 
MTX has been demonstrated to be effective drugs in the treatment of RA. Still, various percentages 
in efficacy and toxicity are seen. Unfortunately, these interindividual differences cannot be predicted 
in individual patients and markers such as polymorphisms, are necessary to individualize and op-
timize drug treatment. Yet, most pharmacogenetic studies performed have an insufficient sample 
size (power) to detect true associations with treatment response. In addition, other factors, like non-
genetic factors, ethnicity and clear endpoints, influence treatment outcome. Particularly, disease 
activity score (DAS) at baseline determines to a large extend the response of RA patients treated 
with DMARD therapy as was demonstrated from previous studies. Also regarding clear endpoints, 
various use of disease activity parameters and/or cutoff levels for the definition of response, e.g. 
elevated liver enzyme levels in the case of side effects and an absolute value of DAS in the case of 
efficacy, may contribute to different results. In order to optimally compare studies or perform meta-
analyses, criteria regarding efficacy and toxicity should be standardized. Finally, opposite or alterna-
tive results found may be explained by differences in SNP allele frequencies between various ethnic 
populations, which makes these association studies unlikely to compare.  
Therefore, definitive conclusions about the role of genetic prognostic factors in treatment outcome 
to MTX cannot be drawn. Large randomized prospective studies are required to effectively replicate 
and validate these findings, before a pharmacogenetic approach is applicable in daily clinical prac-
tice. 
26
Pharmacogenetics of methotrexate in rheumatoid arthritis
References
 
(1) Symmons DP. Epidemiology of rheumatoid arthritis: 
determinants of onset, persistence and outcome. Best Pract 
Res Clin Rheumatol 2002 December;16(5):707-22. 
(2) Choy EH, Panayi GS. Cytokine pathways and joint 
inflammation in rheumatoid arthritis. N Engl J Med 2001 
March 22;344(12):907-16. 
(3) O'dell JR. Therapeutic strategies for rheumatoid arthri-
tis. N Engl J Med 2004 June 17;350(25):2591-602. 
(4) Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst 
D, Weisman MH et al. Sustained improvement over two 
years in physical function, structural damage, and signs 
and symptoms among patients with rheumatoid arthritis 
treated with infliximab and methotrexate. Arthritis Rheum 
2004 April;50(4):1051-65. 
(5) Yount S, Sorensen MV, Cella D, Sengupta N, Grober J, 
Chartash EK. Adalimumab plus methotrexate or standard 
therapy is more effective than methotrexate or standard 
therapies alone in the treatment of fatigue in patients with 
active, inadequately treated rheumatoid arthritis. Clin Exp 
Rheumatol 2007 November;25(6):838-46. 
(6) van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, 
Pedersen R et al. Efficacy and safety of combination etaner-
cept and methotrexate versus etanercept alone in patients 
with rheumatoid arthritis with an inadequate response to 
methotrexate: the ADORE study. Ann Rheum Dis 2006 
November;65(11):1478-83. 
(7) Kremer JM, Genant HK, Moreland LW, Russell AS, 
Emery P, bud-Mendoza C et al. Effects of abatacept in 
patients with methotrexate-resistant active rheumatoid 
arthritis: a randomized trial. Ann Intern Med 2006 June 
20;144(12):865-76. 
(8) Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, 
Balint G et al. Double-blind randomized controlled clinical 
trial of the interleukin-6 receptor antagonist, tocilizumab, 
in European patients with rheumatoid arthritis who had an 
incomplete response to methotrexate. Arthritis Rheum 
2006 September;54(9):2817-29. 
(9) Emery P, Fleischmann R, Filipowicz-Sosnowska A, 
Schechtman J, Szczepanski L, Kavanaugh A et al. The 
efficacy and safety of rituximab in patients with active 
rheumatoid arthritis despite methotrexate treatment: 
results of a phase IIB randomized, double-blind, placebo-
controlled, dose-ranging trial. Arthritis Rheum 2006 
May;54(5):1390-400. 
(10) Vencovsky J, Huizinga TW. Rheumatoid arthritis: the 
goal rather than the health-care provider is key. Lancet 
2006 February 11;367(9509):450-2. 
(11) Welsing PM, Landewe RB, van Riel PL, Boers M, van 
Gestel AM, van der LS et al. The relationship between 
disease activity and radiologic progression in patients with 
rheumatoid arthritis: a longitudinal analysis. Arthritis 
Rheum 2004 July;50(7):2082-93. 
(12) O'dell JR. Treating rheumatoid arthritis early: a win-
dow of opportunity? Arthritis Rheum 2002 Febru-
ary;46(2):283-5. 
(13) Cronstein BN. Low-dose methotrexate: a mainstay in 
the treatment of rheumatoid arthritis. Pharmacol Rev 2005 
June;57(2):163-72. 
(14) Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. 
Methotrexate as the "anchor drug" for the treatment of 
early rheumatoid arthritis. Clin Exp Rheumatol 2003 
September;21(5 Suppl 31):S179-S185. 
(15) Klareskog L, van der HD, de Jager JP, Gough A, Kal-
den J, Malaise M et al. Therapeutic effect of the combina-
tion of etanercept and methotrexate compared with each 
treatment alone in patients with rheumatoid arthritis: 
double-blind randomised controlled trial. Lancet 2004 
February 28;363(9410):675-81. 
(16) Breedveld FC, Weisman MH, Kavanaugh AF, Cohen 
SB, Pavelka K, van VR et al. The PREMIER study: A multi-
center, randomized, double-blind clinical trial of combina-
tion therapy with adalimumab plus methotrexate versus 
methotrexate alone or adalimumab alone in patients with 
early, aggressive rheumatoid arthritis who had not had 
previous methotrexate treatment. Arthritis Rheum 2006 
January;54(1):26-37. 
(17) Klareskog L, van der HD, de Jager JP, Gough A, Kal-
den J, Malaise M et al. Therapeutic effect of the combina-
tion of etanercept and methotrexate compared with each 
treatment alone in patients with rheumatoid arthritis: 
double-blind randomised controlled trial. Lancet 2004 
February 28;363(9410):675-81. 
(18) Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila 
M, Kautiainen H, Korpela M et al. Comparison of combina-
tion therapy with single-drug therapy in early rheumatoid 
arthritis: a randomised trial. FIN-RACo trial group. Lancet 
1999 May 8;353(9164):1568-73. 
(19) Matteson EL, Weyand CM, Fulbright JW, Christian-
son TJ, McClelland RL, Goronzy JJ. How aggressive should 
initial therapy for rheumatoid arthritis be? Factors asso-
ciated with response to 'non-aggressive' DMARD treatment 
27
Pharmacogenetics of methotrexate in rheumatoid arthritis
and perspective from a 2-yr open label trial. Rheumatology 
(Oxford) 2004 May;43(5):619-25. 
(20) Eichelbaum M, Ingelman-Sundberg M, Evans WE. 
Pharmacogenomics and Individualized Drug Therapy. 
Annu Rev Med 2006;57:119-37.  
(21) Evans WE, McLeod HL. Pharmacogenomics--drug 
disposition, drug targets, and side effects. N Engl J Med 
2003 February 6;348(6):538-49. 
(22) Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, 
Wang J et al. The influence of genetic variation in the HLA-
DRB1 and LTA-TNF regions on the response to treatment 
of early rheumatoid arthritis with methotrexate or etaner-
cept. Arthritis Rheum 2004 September;50(9):2750-6. 
(23) Padyukov L, Lampa J, Heimburger M, Ernestam S, 
Cederholm T, Lundkvist I et al. Genetic markers for the 
efficacy of tumour necrosis factor blocking therapy in 
rheumatoid arthritis. Ann Rheum Dis 2003 
June;62(6):526-9. 
(24) van Ede AE, Laan RF, Blom HJ, Huizinga TW, 
Haagsma CJ, Giesendorf BA et al. The C677T mutation in 
the methylenetetrahydrofolate reductase gene: a genetic 
risk factor for methotrexate-related elevation of liver en-
zymes in rheumatoid arthritis patients. Arthritis Rheum 
2001 November; 44(11):2525-30. 
(25) Ranganathan P, Culverhouse R, Marsh S, Mody A, 
Scott-Horton TJ, Brasington R et al. Methotrexate (MTX) 
pathway gene polymorphisms and their effects on MTX 
toxicity in Caucasian and African American patients with 
rheumatoid arthritis. J Rheumatol 2008 April;35(4):572-9. 
(26) Chan ES, Cronstein BN. Molecular action of metho-
trexate in inflammatory diseases. Arthritis Res 
2002;4(4):266-73. 
(27) Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. 
Anti-inflammatory mechanisms of methotrexate in rheu-
matoid arthritis. Ann Rheum Dis 2001 August;60(8):729-
35. 
(28) Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, 
Peters GJ, Noordhuis P et al. Antifolate resistance mediated 
by the multidrug resistance proteins MRP1 and MRP2. 
Cancer Res 1999 June 1;59(11):2532-5. 
(29) Norris MD, De GD, Haber M, Kavallaris M, Madafiglio 
J, Gilbert J et al. Involvement of MDR1 P-glycoprotein in 
multifactorial resistance to methotrexate. Int J Cancer 1996 
March 1;65(5):613-9. 
(30) Cronstein BN. Low-dose methotrexate: a mainstay in 
the treatment of rheumatoid arthritis. Pharmacol Rev 2005 
June;57(2):163-72. 
(31) Montesinos MC, Yap JS, Desai A, Posadas I, McCrary 
CT, Cronstein BN. Reversal of the antiinflammatory effects 
of methotrexate by the nonselective adenosine receptor 
antagonists theophylline and caffeine: evidence that the 
antiinflammatory effects of methotrexate are mediated via 
multiple adenosine receptors in rat adjuvant arthritis. 
Arthritis Rheum 2000 March;43(3):656-63. 
(32) Chatzikyriakidou A, Georgiou I, Voulgari PV, Papado-
poulos CG, Tzavaras T, Drosos AA. Transcription regulato-
ry polymorphism -43T>C in the 5'-flanking region of 
SLC19A1 gene could affect rheumatoid arthritis patient 
response to methotrexate therapy. Rheumatol Int 2007 
September;27(11):1057-61. 
(33) Dervieux T, Furst D, Lein DO, Capps R, Smith K, 
Caldwell J et al. Pharmacogenetic and metabolite mea-
surements are associated with clinical status in patients 
with rheumatoid arthritis treated with methotrexate: 
results of a multicentred cross sectional observational 
study. Ann Rheum Dis 2005 August;64(8):1180-5. 
(34) Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny 
B, Gornik W et al. The effect of 3435C>T MDR1 gene 
polymorphism on rheumatoid arthritis treatment with 
disease-modifying antirheumatic drugs. Eur J Clin Phar-
macol 2006 November;62(11):933-7. 
(35) Drozdzik M, Rudas T, Pawlik A, Gornik W, Kurzawski 
M, Herczynska M. Reduced folate carrier-1 80G>A poly-
morphism affects methotrexate treatment outcome in 
rheumatoid arthritis. Pharmacogenomics J 2007 Decem-
ber;7(6):404-7. 
(36) Takatori R, Takahashi KA, Tokunaga D, Hojo T, 
Fujioka M, Asano T et al. ABCB1 C3435T polymorphism 
influences methotrexate sensitivity in rheumatoid arthritis 
patients. Clin Exp Rheumatol 2006 September;24(5):546-
54. 
(37) Wessels JA, de Vries-Bouwstra JK, Heijmans BT, 
Slagboom PE, Goekoop-Ruiterman YP, Allaart CF et al. 
Efficacy and toxicity of methotrexate in early rheumatoid 
arthritis are associated with single-nucleotide polymor-
phisms in genes coding for folate pathway enzymes. Arthri-
tis Rheum 2006 April;54(4):1087-95. 
(38) Dervieux T, Furst D, Lein DO, Capps R, Smith K, 
Walsh M et al. Polyglutamation of methotrexate with 
common polymorphisms in reduced folate carrier, ami-
noimidazole carboxamide ribonucleotide transformylase, 
and thymidylate synthase are associated with methotrexate 
effects in rheumatoid arthritis. Arthritis Rheum 2004 
September; 50(9):2766-74. 
(39) Wessels JA, van der Kooij SM, le CS, Kievit W, Barerra 
P, Allaart CF et al. A clinical pharmacogenetic model to 
predict the efficacy of methotrexate monotherapy in recent-
28
Pharmacogenetics of methotrexate in rheumatoid arthritis
onset rheumatoid arthritis. Arthritis Rheum 2007 
June;56(6):1765-75. 
(40) Bohanec Grabar P., Logar D, Lestan B, Dolzan V. 
Genetic determinants of methotrexate toxicity in rheuma-
toid arthritis patients: a study of polymorphisms affecting 
methotrexate transport and folate metabolism. Eur J Clin 
Pharmacol 2008 November;64(11):1057-68. 
(41) Berkun Y, Levartovsky D, Rubinow A, Orbach H, 
Aamar S, Grenader T et al. Methotrexate related adverse 
effects in patients with rheumatoid arthritis are associated 
with the A1298C polymorphism of the MTHFR gene. Ann 
Rheum Dis 2004 October;63(10):1227-31. 
(42) Hughes LB, Beasley TM, Patel H, Tiwari HK, Morgan 
SL, Baggott JE et al. Racial or ethnic differences in allele 
frequencies of single-nucleotide polymorphisms in the 
methylenetetrahydrofolate reductase gene and their influ-
ence on response to methotrexate in rheumatoid arthritis. 
Ann Rheum Dis 2006 September;65(9):1213-8. 
(43) Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N. 
Polymorphisms in the thymidylate synthase and methyle-
netetrahydrofolate reductase genes and sensitivity to the 
low-dose methotrexate therapy in patients with rheumato-
id arthritis. Int J Mol Med 2003 May;11(5):593-600. 
(44) Kurzawski M, Pawlik A, Safranow K, Herczynska M, 
Drozdzik M. 677C>T and 1298A>C MTHFR polymor-
phisms affect methotrexate treatment outcome in rheuma-
toid arthritis. Pharmacogenomics 2007 Novem-
ber;8(11):1551-9. 
(45) Taniguchi A, Urano W, Tanaka E, Furihata S, Kamit-
suji S, Inoue E et al. Validation of the associations between 
single nucleotide polymorphisms or haplotypes and res-
ponses to disease-modifying antirheumatic drugs in pa-
tients with rheumatoid arthritis: a proposal for prospective 
pharmacogenomic study in clinical practice. Pharmacoge-
net Genomics 2007 June;17(6):383-90. 
(46) Urano W, Taniguchi A, Yamanaka H, Tanaka E, 
Nakajima H, Matsuda Y et al. Polymorphisms in the me-
thylenetetrahydrofolate reductase gene were associated 
with both the efficacy and the toxicity of methotrexate used 
for the treatment of rheumatoid arthritis, as evidenced by 
single locus and haplotype analyses. Pharmacogenetics 
2002 April;12(3):183-90. 
(47) Weisman MH, Furst DE, Park GS, Kremer JM, Smith 
KM, Wallace DJ et al. Risk genotypes in folate-dependent 
enzymes and their association with methotrexate-related 
side effects in rheumatoid arthritis. Arthritis Rheum 2006 
February;54(2):607-12. 
(48) Haagsma CJ, Blom HJ, van Riel PL, van't Hof MA, 
Giesendorf BA, van Oppenraaij-Emmerzaal D et al. Influ-
ence of sulphasalazine, methotrexate, and the combination 
of both on plasma homocysteine concentrations in patients 
with rheumatoid arthritis. Ann Rheum Dis 1999 Febru-
ary;58(2):79-84. 
(49) Dervieux T, Greenstein N, Kremer J. Pharmacoge-
nomic and metabolic biomarkers in the folate pathway and 
their association with methotrexate effects during dosage 
escalation in rheumatoid arthritis. Arthritis Rheum 2006 
October;54(10):3095-103. 
(50) Rizzo R, Rubini M, Govoni M, Padovan M, Melchiorri 
L, Stignani M et al. HLA-G 14-bp polymorphism regulates 
the methotrexate response in rheumatoid arthritis. Phar-
macogenet Genomics 2006 September;16(9):615-23. 
(51) Baricordi OR, Govoni M, Rizzo R, Trotta F. In rheuma-
toid arthritis, a polymorphism in the HLA-G gene concurs 
in the clinical response to methotrexate treatment. Ann 
Rheum Dis 2007 August;66(8):1125-6. 
(52) Stamp LK, O'Donnell JL, Chapman PT, Barclay ML, 
Kennedy MA, Frampton CM et al. Lack of association 
between HLA-G 14 bp insertion/deletion polymorphism 
and response to long-term therapy with methotrexate 
response in rheumatoid arthritis. Ann Rheum Dis 2009 
January;68(1):154-5. 
(53) Wessels JA, Kooloos WM, De JR, de Vries-Bouwstra 
JK, Allaart CF, Linssen A et al. Relationship between genet-
ic variants in the adenosine pathway and outcome of me-
thotrexate treatment in patients with recent-onset rheuma-
toid arthritis. Arthritis Rheum 2006 Septem-
ber;54(9):2830-9. 
(54) van der Straaten RJ, Wessels JA, de Vries-Bouwstra 
JK, Goekoop-Ruiterman YP, Allaart CF, Bogaartz J et al. 
Exploratory analysis of four polymorphisms in human 
GGH and FPGS genes and their effect in methotrexate-
treated rheumatoid arthritis patients. Pharmacogenomics 
2007 February;8(2):141-50. 
(55) Hider SL, Thomson W, Mack LF, Armstrong DJ, 
Shadforth M, Bruce IN. Polymorphisms within the adeno-
sine receptor 2a gene are associated with adverse events in 

















Relationship between genetic variants in the adeno-
sine pathway and outcome of methotrexate treat-





Judith A.M. Wessels1, Wouter M. Kooloos1, Robert de Jonge2, Jeska K. de Vries-Bouwstra3, Cornelia 
F. Allaart4, Annelies Linssen5, Gerard Collee5, Peter de Sonnaville5, Jan Lindemans2, Tom W. J. Hui-
zinga4 and Henk-Jan Guchelaar1 
 
1 Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands. 
2 Department of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands. 
3 Department of Rheumatology, Vrije University Medical Center, Amsterdam, The Netherlands 
4 Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. 




















Among patients with rheumatoid arthritis (RA), there is a high degree of interindividual 
variability in the degree of response to methotrexate (MTX) treatment. This study was undertaken 
to explore polymorphisms in genes contributing to anti-inflammatory adenosine release as novel 
predictors of MTX treatment outcome. 
 
Methods. 
In 205 patients with newly diagnosed RA, 5 polymorphisms in 5 genes coding for enzymes related to 
the release of adenosine were analyzed. All patients received standardized MTX treatment (up to 25 
mg per week orally), combined with folic acid. MTX efficacy was evaluated by the Disease Activity 
Score (DAS) and compared among genotypes. The association between MTX-related adverse events 
and genotype was also assessed. The following polymorphisms were determined: AMPD1 34C>T, 
ATIC 347C>G, ITPA 94C>A, MTR 2756A>G, and MTRR 66A>G. When significant differences were 
found by chi-square analysis, odds ratios (ORs) and 95% confidence intervals were calculated. 
 
Results.  
Patients carrying the AMPD1 34T allele, ATIC 347CC, or ITPA 94CC were more likely to have a good 
clinical response, as defined by a DAS of <2,4 (OR [95% confidence interval] 2,1 [1,0–4,5], 2,5 [1,3–
4,7], and 2,7 [1,1–8.1], respectively). The likelihood of a good clinical response was increased if pa-
tients possessed all 3 favorable genotypes (OR 27.8 [95% confidence interval 3,2–250]). Regarding 
toxicity, only ATIC G allele carriers experienced a greater frequency of adverse events (OR 2,0 [95% 
confidence interval 1,1–3,7]). 
 
Conclusion. 
Polymorphisms in the AMPD1, ATIC, and ITPA genes are associated with good clinical response to 
MTX treatment. These findings indicate that genotyping may help in the identification of patients 
who will benefit most from MTX treatment and may assist clinicians in making treatment decisions 
regarding patients with recent-onset RA. 
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Introduction 
 
Patients with rheumatoid arthritis (RA) show considerable variation in their clinical course and 
response to treatment (1,2). Despite the fact that most clinical study findings support the use of 
combination therapy to optimally suppress disease activity, most patients with newly diagnosed RA 
begin with monotherapy; methotrexate (MTX) is the preferred first-line disease-modifying anti-
rheumatic drug (DMARD) (3–6).  
Although results of randomized controlled clinical trials indicate that MTX alters the clinical course 
of RA, only ~40% of the patients exhibit a good clinical response (7–9). While achieving good re-
sponse early in the disease process is key to minimizing the joint damage and functional decline 
characteristic of RA (6,10,11), it is not yet possible to predict which patients will respond to MTX. In 
most studies to date that have demonstrated MTX efficacy, predictors for response have not been 
specifically investigated. Clear predictors of response to MTX would be useful in directing treatment 
choices in the early phase of the disease.  
In candidate gene–driven pharmacogenetic studies, polymorphisms in genes coding for proteins 
involved in pharmacokinetic or pharmacodynamic pathways related to the drug under study are 
selected, and possible associations with treatment outcome are investigated (12–14). Specific to 
MTX, several studies have shown that single-nucleotide polymorphisms (SNPs) in genes coding for 
the folate pathway enzymes are associated with treatment response (15–17). Although MTX may act 
in RA through inhibition of folate pathway enzymes, more recent reports indicate that its efficacy 
may be related to the release of endogenous anti-inflammatory adenosine (18–20) (Figure 1).  
 
Figure 1. Simplified representation of the adenosine metabolism pathwaya,b,c 
a. Shown are enzymes and metabolites involved in the stepwise release of adenosine.  
b. Abbreviation(s): FAICAR= formyl–5-aminoimidazole-4-carboxamide ribonucleotide, ITPA= inosine triphos-
phate pyrophosphatase, IMP= inosine monophosphate, ATIC= aminoimidazole carboxamide ribonucleotide 
transformylase, MTXglu= methotrexate polyglutamate, AMPD= adenosine monophosphate deaminase, ADA= 
adenosine deaminase, SAH= S-adenosylhomocysteine, SAM= S-adenosylmethionine, MTRR= methionine syn-
thase reductase.  
c. See ref. 18 for detailed information on the mechanism of action of MTX. 
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Studies on clinical outcome in patients with other complex conditions such as cardiovascular diseas-
es have already alluded to the relevance of polymorphisms in genes coding for enzymes related to 
adenosine release (15,21–25). We hypothesized that genetic variants in these genes are associated 
with MTX treatment outcome. To investigate this, we assessed the relationship between SNPs in 
genes related to adenosine release and MTX treatment outcome in patients with recent-onset RA. 
 
 
Patients and Methods 
 
Role of the funding source  
The rheumatologists participating in the Foundation for Applied Rheumatology Research were re-
sponsible for the study design and data collection in the BeSt study. The authors are responsible for 
the current subcohort data analysis, including genotyping, interpretation of data, preparing this 
manuscript, and the decision to publish. Centocor and Schering-Plough did not participate in any of 
these activities.  
 
Patients  
The 247 patients enrolled in this study comprised a subcohort of the 508 patients participating in 
the BeSt (Behandelstrategieën voor Reumatoide Artritis [Treatment Strategies for Rheumatoid 
Arthritis]) study (26). Inclusion criteria for the study included fulfillment of the American College of 
Rheumatology (formerly, the American Rheumatism Association) 1987 revised criteria for RA (27), 
age of ≥18 years, and disease duration of <2 years. Patients also had to have active disease, defined 
as at least 6 swollen joints (of 66) and at least 6 tender joints (of 68), and either an erythrocyte sedi-
mentation rate (ESR) of ≥28 mm/hour or a score of >20 mm on a 100-mm visual analog scale 
(VAS) for patient assessment of global health (0 mm = best; 100 mm = worst). Individuals were 
ineligible for the BeSt study if they had previously been treated with DMARDs other than antima-
larial agents or were receiving concomitant treatment with an experimental drug. The local ethics 
committee at each participating hospital approved the study protocol, and all patients provided writ-
ten informed consent before enrollment into the study. 
 
Study design  
The BeSt study was a randomized, multicenter, single-blind, clinical study comparing the clinical 
efficacy of 4 different treatment strategies in early RA: sequential monotherapy starting with MTX 
(n = 126), step-up from MTX to combination therapy with MTX and sulfasalazine (SSZ) (n = 121), 
initial combination therapy with MTX, SSZ, and high-dose (with tapering) prednisolone (n = 133), 
or initial biologic therapy with infliximab plus MTX (n = 128). Only patients who had been allocated 
to single use of MTX (n = 247) were included in the current analysis.  
The primary goal of therapy in the BeSt study was clinical response as defined by a European 
League Against Rheumatism (EULAR) Disease Activity Score (DAS) of ≤2.4 (28,29). The DAS is a 
validated composite outcome measure consisting of the Ritchie Articular Index (RAI) (30), the 
number of swollen joints (of 44), general well-being as indicated by the patient on a VAS, and the 
ESR. A research nurse who was blinded with regard to the allocated treatment group assessed the 
DAS every 3 months.  
All patients included in this analysis started on a regimen of oral MTX 7.5 mg weekly, increasing to 
15 mg weekly after 4 weeks, in combination with folic acid (1 mg per day). In the event of insufficient 
clinical response (DAS ≤2.4) at the 3-month followup visit, the MTX dosage was increased stepwise 
to 25 mg weekly, given either orally or parenterally according to the rheumatologist’s judgment. If 
the clinical response remained insufficient at the 6-month followup visit, patients were treated ac-
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cording to the next step of the BeSt protocol, i.e., patients assigned to MTX sequential monotherapy 
were switched to SSZ 1,000 mg twice daily, and SSZ 1,000 mg twice daily was added to the MTX 
regimen for patients assigned to initial step-up combination therapy. Concomitant treatment with 
nonsteroidal antiinflammatory drugs and intraarticular injections of corticosteroids were allowed 
for all treatment groups. For the current analysis, clinical data from the first 6 months of followup 
were used to represent MTX treatment only. Responders were defined as patients with a DAS of 
≤2.4 (good clinical response) based on the EULAR response criteria (28,29), and nonresponders as 
patients with a DAS of ≤2.4 at the 6-month followup visit.  
Toxicity was evaluated by tabulating reported adverse drug events. Adverse drug events were spon-
taneously reported by the patients, were ascertained from nonspecific questioning by the investiga-
tor about the patient’s well-being, or were found upon physical examination or determination of 
clinical laboratory parameters during the study. In cases of adverse drug events, MTX treatment was 
continued at the lowest tolerated dose or, if MTX was not tolerated at all, the DMARD therapy was 
changed. The following noninfectious  adverse drug events were specifically evaluated: gastrointes-
tinal adverse drug events (defined as general well-being, nausea, vomiting, diarrhea, or constipa-
tion); liver adverse drug events (defined as elevated liver enzyme levels resulting in MTX dosage 
adjustment or discontinuation), pneumonitis, and skin and mucosal disorders. Patients were also 
monitored for leukopenia (white blood cell count <4 x 109/liter) and for elevations in levels of ala-
nine aminotransferase and alkaline phosphatase to >3 times the upper limit of normal (i.e., >135 
units/liter and >360 units/liter, respectively).  
Five SNPs in genes related to adenosine release (31) (Figure 1) were selected, taking into considera-
tion the following criteria: validated SNP, SNP causes nonsynonymous amino acid change, indica-
tions for clinical relevance from previous publications (15,21–25,32,33), and a preferred minimal 
genotype frequency of ~10%. The 5 selected genes were those coding for adenosine monophosphate 
deaminase (AMPD1), aminoimidazole carboxamide ribonucleotide transformylase (ATIC), inosine 
triphosphate pyrophosphatase (ITPA), methionine synthase (MTR), and methionine synthase re-
ductase (MTRR). The following SNPs were analyzed: MTRR 66A>G 
(rs1801394), MTR 2756A>G (rs1805087), AMPD1 34C>T (rs17602729), ITPA 94C>A (rs1127354), 
and ATIC 347C>G (rs2372536). 
DNA was isolated from peripheral white blood cells by a standard manual salting-out method. As a 
quality control, positive controls (Control DNA CEPH 347-02; Applied Biosystems, Foster City, CA) 
and negative controls (water) were used. In addition, 5–10% of samples were genotyped in dupli-
cate, and no inconsistencies were observed. 
Genotyping was performed using real-time polymerase chain reaction with TaqMan, according to 
the protocol provided by the manufacturer (Applied Biosystems). Genotype frequencies were in 
Hardy-Weinberg equilibrium, and the success rate was 99.5% for MTRR 66A>G, 100% for MTR 
2756A>G, 99.5% for AMPD1 34C>T, 99.5% for ITPA 94C>A, and 100% for ATIC 347C>G. Geno-
type distributions were as follows: for AMPD1 34C>T, 74% CC, 25% CT, 1% TT; for MTRR 66A>G, 
20% AA, 53% AG, 28% GG; for MTR 2756A>G, 70% AA, 27% AG, 2% GG; for ITPA 94C>A, 85% 
CC, 15% CA, 0% AA; and for ATIC 347C>G, 47% CC, 45% CG, 8%GG. 
 
Statistical analysis.  
Differences in baseline characteristics were analyzed by Student’s t-test for continuous variables or 
chi-square test for dichotomous variables. For response and toxicity, differences in genotype distri-
bution were tested by 3 x 2 cross-tabulations for each genotype, and by 2 x 2 cross-tabulations for 
carriers versus noncarriers, with analysis by 2-sided chi-square test. When genotype distributions 
differed, we used binary logistic analysis to calculate odds ratios 
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(ORs) for achieving good response or experiencing adverse drug events. Age and sex were identified 
as possible confounders and were used as covariates in all regression analyses. The 
primary efficacy end point was good clinical response (DAS ≤2.4) at 6 months. For classification as 
having good clinical response based on the DAS, patients had to be available for evaluation at a giv-
en time point; no values were carried forward. Secondary end points were good clinical improve-
ment, defined as a change of >1.2 in the DAS, and moderate clinical improvement, defined as a 
change of >0.6 in the DAS. Additionally, for efficacy analyses, the following possible confounding 
factors were identified: DAS at baseline, duration of joint symptoms before enrollment, duration of 
RA before enrollment, rheumatoid factor (RF) positivity, modified Sharp/van der Heijde radio-
graphic score (34) at baseline, ESR, RAI, and C-reactive protein level.  
For safety analyses, all patients whose MTX regimen was altered prior to the 6-month followup visit 
were assessed for adverse drug events after the change in therapy and were included in the safety 
analyses. Analyses of laboratory measurements were performed for completers only. In the toxicity 
regression analysis, the following potential confounding factors were tested: body weight, creatinine 
clearance rate, MTX dosage group (15 mg/week or 25 mg/week), and alcohol use. 
All statistical analyses were performed using SPSS 11.5 software (SPSS, Chicago, IL). Since 5 hypo-
theses were tested, Bonferroni adjustment was performed for multiple comparisons. Both adjusted 





Patient disposition and baseline characteristics. 
DNA samples could be obtained from 205 of the 247 patients randomized to receive MTX monothe-
rapy in the BeSt study. There were no statistically significant differences in baseline characteristics 
between patients with and those without available DNA samples (data not shown). Baseline demo-
graphic and disease characteristics of the 205 RA patients who were genotyped are 
presented in Table 1. The reported ethnicity distribution in the study population was 93% Caucasian 
(n = 191), 2.4% Asian (n = 5), 1.0% African (n = 2), and 3.4% other (n = 3 Hindustani, 3 Surinamese, 




Characteristics                                                                         Baseline value 
Demographic  
Gender  [female / male %] 68.8 / 31.2 
Age  [years] (sd) 54.6 (13.3) 
RF positivity [%] 67.3 
Disease duration in weeks [median]  (range) 2.0 (0-104.7) 
Measures of disease activity  
Duration of joint complaints in weeks [median] (range) 25.0 (1.1-584.3) 
DAS (sd) 4.5 ( 0.8) 
ESR [median mm/hr]  (range) 38 (2 - 143) 
CRP  [median mg/L] (range) 23 (0 - 238) 
RAI [median] (range) 13 (2 - 47) 
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Swollen joints [median] (range) 13 (3 - 36) 
Sharp van der Heijde score [median] (range) 4 (4 - 49.5) 
 
Table 1. Baseline demographic and disease characteristics among the 205 patients with genotyp-
ing data 
 
Abbreviation(s): DAS= Disease Activity Score in 44 joints, ESR= Erythrocyte Sedimentation Rate, RF= Rheuma-
toid factor, CRP= C-reactive protein, RAI=Ritchie Articular Index. 
 
 
Association of AMPD1 34C>T, ATIC 347C>G, and ITPA 94C>A polymorphisms with 
good clinical response to MTX therapy.  
At 6 months, 186 patients remained in the study, of whom 47% had a good clinical response (DAS 
≤2.4) (n = 87) (Figure 2). Among these responders, 43% were receiving MTX 15 mg weekly and 57% 
were receiving MTX 25 mg weekly.  
Three of the 5 selected genetic polymorphisms were associated with good clinical response at 6-
month followup (Figure 3). Patients carrying the AMPD1 T allele were 2)1 times more likely to 
achieve good clinical response when compared with patients possessing the AMPD1 CC variant. For 
ATIC and ITPA, associations between the CC genotype and good clinical response were found (Fig-
































Figure 2. Disposition of the patients 
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To assess whether these 3 favorable polymorphisms showed an additive effect with regard to re-
sponse to MTX therapy, additional analyses were performed for each combination of the AMPD1, 
ATIC, and ITPA genotypes. Among patients carrying the combinations AMPD1 T allele and ATIC 
CC (n = 22), AMPD1 T allele and ITPA CC (n = 41), and ATIC CC and ITPA CC (n = 82), the percen-
tages with good clinical response at 6 months increased to 68%, 63%, and 56%, respectively. Among 
the 16 patients who carried all 3 favorable genotypes, 88% achieved a good clinical response. Logis-
tic regression analyses revealed that the OR for achievement of good clinical response in this group 
was 27.8) The explained variance (R2) of these combined favorable genotypes for MTX treatment 
response was 24.2% (Figure 3). In contrast, if patients carried all 3 unfavorable genotypes, i.e., the 
AMPD1 CC and ITPA CA genotypes and the ATIC G allele (n = 10), the response rate at 6 months 
was only 10%.  
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Table 2. Methotrexate response and adverse drug events at 6 months by AMPD1, ATIC and ITPA 
genotypesa,b,c,d 
 
a. MTR and MTRR were not associated with methotrexate (MTX) efficacy or toxicity. Values are the number [%]. 
b. Genotype data missing on 1 of the 205 patients. 
c. Data on MTX dosage missing on 2 of the 87 responders at 6 months. 
d. Abbreviation(s): AMPD1 = adenosine monophosphate deaminase, ATIC = aminoimidazole carboxamide ribo-
nucleotide transformylase, ITPA = inosine triphosphate pyrophosphatase. 
 
 
After adjustment for multiple comparisons, the association of the ATIC CC genotype with MTX re-
sponse remained significant (P = 0.035), and the combination of favorable AMPD1, ATIC, and ITPA 
genotypes remained significantly associated with good clinical response (Figure 3). The regression 
analysis using the parameter good clinical improvement as opposed to good clinical response also 
revealed an association with the ATIC CC genotype in comparison with G allele carriers (OR 2.5 
[95% confidence interval 1.3– 4.8], P = 0.007). No associations between the MTRR and MTR poly-
morphisms and good clinical response were found (data not shown).  
In the regression analysis to predict good clinical response, only DAS at baseline and RF positivity 
appeared to be significant predictive factors (Figure 3). Patients who had a lower DAS at baseline 
and/or were RF negative were more likely to show good clinical response at 6 months. We also in-
vestigated whether the possible confounding factors were affected by genotype; no significant asso-
ciations between the possible confounding factors examined and genotype variants were observed. 
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Figure 3. Associations between AMPD1 34C>T, ATIC 347C>G, and ITPA 94C>A polymorphism 
and good clinical response to methotrexatea,b,c 
 
a. Data presented are odds ratios (ORs) (diamonds), 95% confidence intervals (95% CIs) (bars), and R2 values 
with correction for the potential confounding factors of age, sex, rheumatoid factor (Rheumafactor) positivity, and 
Disease Activity Score (DAS) at baseline. 
b. Odds ratios presented for age, sex, rheumatoid factor positivity, and DAS at baseline are results found without 
inclusion of genotypes as independent variables. 
c. * P< 0.05 after Bonferroni adjustment. 
 
 
Safety findings.  
Safety data were available on 200 patients at 6 months; 4 patients did not return for the 
6-month followup visit and 1 patient had moved away. Thirty percent of these patients (n = 60) ex-
perienced at least 1 adverse drug event during 6 months of treatment (Table 3). The percentage of 
patients experiencing an adverse drug event was similar in both dosage groups, although more pa-
tients receiving MTX 25 mg per week discontinued therapy due to adverse drug events.  
During 6 months of treatment, patients carrying the ATIC G allele were twice as likely to experience 
any adverse drug event compared with patients without the allele (Figure 4). However, after ad-
justment for multiple comparisons, the association between the ATIC G allele and adverse drug 
events did not remain significant. No other associations with MTX-induced adverse events were 
identified. In the logistic regression analysis, none of the identified potential confounding factors 
was predictive of adverse drug events.  
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Adverse Drug Event 
 
 
Frequency at 6 months 
Skin and mucosa disorders 17 (8.5%) 










Overall adverse drug events in total population 60 (30%) 
 
Table 3. Number of patients (percentage) with adverse drug events during six months of treat-
ment 
 
Values for overall adverse drug events are the number (%) of patients experiencing 1 event; values for the individ-
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Figure 4. Association between ATIC 347C>G polymorphism and the occurrence of adverse drug 
events during 6 months of methotrexate therapy 
 
Data presented are odds ratios (ORs) (diamonds), 95% confidence intervals (95% CIs) (bars), and R2 values with 
correction for the potential confounding factors of age and sex. 
 
 
We also examined the interaction between achievement of good clinical response (DAS ≤2.4) at 6 
months, the AMPD1, ATIC, and ITPA genotypes, and the occurrence of adverse drug events. Res-
ponders at 6 months (n = 87) were selected, and regression analyses were performed. In general, 
patients with good clinical response at 6 months experienced fewer adverse drug events compared 
with nonresponders (OR 0.45, 95% confidence interval 0.22–0.91). This finding was also observed 
in nonresponders carrying the ATIC G allele; the OR of adverse drug events was increased from 2.0 
to 2.8 (95% confidence interval 1.1–7.5) in this group. 
For responders carrying the AMPD1 T allele, the single ATIC CC or the single ITPA CC genotype, or 
combinations of these genotypes, no associations with the occurrence of adverse drug events were 
41
Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment 
                                                                                                    in patients with recent-onset rheumatoid arthritis
found. The numbers and percentages of patients experiencing adverse drug events by genotype for 
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Discussion 
 
Results of this analysis show an association between allelic variants in the adenosine monophos-
phate deaminase (AMPD), 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformy-
lase, and inosine triphosphate pyrophosphatase (ITPA) genes and clinical response to MTX therapy 
in patients with recent-onset RA. Patients carrying the AMPD1 T allele, the ATIC CC genotype, or 
the ITPA CC genotype are 2–3 times more likely to have a good clinical response, defined by a DAS 
of ≤2.4, following 6 months of MTX therapy. Additionally, the rate of good clinical response is in-
creased substantially in patients carrying the 3 favorable genotypes.  
With regard to the occurrence of adverse drug events, the only association found was with the ATIC 
G allele. This association was not significant after adjustment for multiple testing. No associations 
between methionine synthase or methionine synthase reductase and MTX efficacy or toxicity were 
found.  
Previously, only the contribution of the ATIC 347C>G polymorphism has been studied in relation to 
the efficacy and safety ofMTX. In 2 articles, Dervieux et al report that RA patients with a higher mu-
tation index respond better to MTX therapy (15,35). This composite mutation index was calculated 
for each patient by summing the scores for 3 SNPs in different genes, including ATIC. The patients 
with a higher mutation index showed a linear decline in the number of tender and swollen joints, the 
physician’s global assessment of disease activity on a VAS, and the Health Assessment Question-
naire (36). Furthermore, it was suggested that patients with the ATIC 347GG genotype had an in-
creased likelihood of response to MTX treatment. In addition, similar to our findings, Weisman et al 
showed that patients with the ATIC 347GG genotype more frequently experienced side effects over-
all, and specifically, gastrointestinal adverse drug events (37). 
It is difficult to compare these findings with our results since study designs and data analysis differ. 
We chose to assess the contribution of genetic markers predictive of treatment outcome in the BeSt 
study because that study had clear and objective outcome measures and standardized treatment 
regimens in a well-described population of patients with recent-onset RA (26). Multivariate data 
analysis with Bonferroni adjustment for multiple comparisons was performed after 6 months of 
treatment, with controlling for identified confounders of response. Moreover, the selected patients 
were all treated with MTX monotherapy for an identical time period, and had not used any 
DMARDs prior to enrollment.  
In contrast, other investigations have used crosssectional study designs with variable disease dura-
tions, MTX dosages, and treatment durations (15,35,37). In one study, combination DMARD thera-
py was allowed (37). Cross-sectional analyses reflect rheumatology practice, but population stratifi-
cation may have occurred by selecting patients who are still being treated with MTX. With the de-
sign of the present study, the influence of sequential monotherapy and other possible confounders 
of treatment outcome is excluded.  
The association of ATIC 347GG with side effects was established without controlling for confound-
ers (37). The associations of clinical efficacy and overall toxicity with higher pharmacogenetic index-
es were found in multivariate analysis in which other factors were included (15,35,37), but the com-
posite mutation indexes used were calculated with grouping of different genotypes in 2 of the 3 stu-
dies. Moreover, the pharmacogenetic index calculation is based on the assumption that the contri-
bution of every polymorphism is small, but that every polymorphism affects the response in the 
same direction with an equal, additive value. However, there are no data that support this assump-
tion. In summary, different study designs and statistical methods should be taken into account in 
comparing results from different pharmacogenetic studies. We believe our results are more applica-
ble to patients with recent-onset, non–DMARD-treated RA.  
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As with most genetic studies, the current study was not sufficiently powered to derive definitive con-
clusions. Further, while adjusting our results for multiple testing minimized false-positive associa-
tions, it also increased the chance of Type II error due to the conservative nature of the Bonferroni 
adjustment (38,39). Accordingly, we have presented both adjusted and unadjusted results.  
Our primary efficacy parameter was good clinical response at 6 months of MTX treatment; in other 
reports, remission has been described as the primary goal of therapy (7,40,41). To examine whether 
the identified genotypes for good clinical response at 6 months were also predictive of remission at 1 
year of followup, an additional analysis of patients carrying the ATIC CC genotype was performed. 
Results of this analysis showed that in 35% of the 97 patients carrying the ATIC CC genotype, dis-
ease was in remission, defined as a DAS <1.6, at 1 year; previous reports have indicated that remis-
sion has been achieved at 1 year in 10–25% of patients receiving MTX (8,42). This observation thus 
indicates that this variant may be associated with a prolonged and increased clinical response.  
Our data showed that MTX therapy was less beneficial for ATIC G allele carriers, ITPA A allele carri-
ers, and patients with the AMPD1 CC genotype. While 47% of the overall population exhibited good 
clinical response at 6 months, comparison of good clinical response among allelic variants showed 
that the response percentages were 58% in patients with the ATIC CC genotype and 37% in ATIC G 
allele carriers. Also, good clinical response was achieved with 6 months of MTX therapy in 50% of 
the patients with the ITPA CC genotype compared with 26% of the ITPA A allele carriers, and by 
60% of the AMPD1 T allele carriers compared with 42% of the patients with the AMPD1 CC geno-
type.  
These findings suggest that pharmacogenetic testing before initiation of therapy may help to guide 
clinical treatment decisions, for example, in identifying patients with all 3 favorable genotypes, in 
whom MTX treatment is more likely to be efficacious. As another example of such clinical use, we 
analyzed the patients with all 3 unfavorable genotypes, i.e., the ATIC G allele, the ITPA A allele, and 
the AMPD1 CC genotype. In patients with these genotypes, other DMARD therapy may be chosen 
rather than MTX, because their response rate at 6 months was only 10%. Thus, such pharmacoge-
netic testing could avoid ineffective treatment and, at the same time, indicate high potential for ef-
fective therapy in 14% of the RA population.  
Ideally, our findings regarding the effect of genetic variants in AMPD1, ITPA, and ATIC genes on 
MTX treatment outcome should be replicated and prospectively tested in a randomized controlled 
study comparing clinical response in 2 groups of patients (43,44). In such a study, patients in the 
first group would receive standard MTX treatment. In the second group, the pharmacogenetic test 
results would dictate whether patients receive standard MTX treatment (patients with the favorable 
genotypes) or other DMARDs (patients without the favorable genotypes).  
The polymorphisms tested were selected based on the hypothesis that the mechanism of action of 
MTX is related to adenosine release (Figure 1). The enzymes whose genetic polymorphisms were 
studied relate to adenosine and were chosen because in vitro studies showed that polymorphisms 
altered their enzyme function or expression. Moreover, other reports have indicated the clinical 
relevance of these SNPs in different complex traits (15,21–25). Although the effect of variant alleles 
in relation to cellular adenosine homeostasis has not yet been explored, several in vitro effects have 
been shown (32,33,45–48). 
Adenosine is thought to mediate the antirheumatic effects of MTX via adenosine receptor signaling 
(48–50). Binding of this compound to specific receptors enhances the antiinflammatory properties 
of MTX. The AMPD1 34C>T mutation generates an AMPD enzyme with lower activity (32). AMPD1 
catalyzes the conversion of AMP to inosine monophosphate (IMP). Alternatively, AMP is converted 
to adenosine. Thus, deficiency of AMPD1 could enhance adenosine release. In addition, both ITPA 
and ATIC may lead to formation of adenosine. ITPA polymorphisms have been shown to lead to 
ITPA deficiency. ITPA catalyzes the conversion of ITP to IMP, whereas ITP is formed by phosphory-
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lation of IMP. Deficiency of ITPA interrupts this cycle and possibly nfluences its balance with AMP 
and adenosine (33). Furthermore, MTX inhibits ATIC. This leads to cellular accumulation of AI-
CAR, a nucleoside precursor (18,24). AICAR inhibits adenosine deaminase, which results in reduced 
conversion of adenosine to inosine.  
Since understanding of these enzymes, their substrates, and interactions remains imprecise, no 
conclusions about the mechanism of action of MTX in relation to adenosine release can be drawn. 
Nevertheless, our results strongly indicate that MTX therapy works via the adenosine pathway. 
Moreover, we have confirmed that the genetic profile of RA patients is indeed a determinant of re-
sponse to MTX treatment (15,16,45).  
In summary, results of this analysis identify patients with adenosine genotypes who are most likely 
to achieve good clinical response with MTX. Findings of our pharmacogenetic analysis identified 
markers in the ATIC, ITPA, and AMPD1 genes that may assist the rheumatologist in making clinical 
treatment decisions for patients with recent-onset RA. 
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Clinical response to methotrexate (MTX) treatment differs among rheumatoid arthritis (RA) pa-
tients. Genetic variation, can at least partly, account for this phenomenon. In this study, functional 
polymorphisms in genes related to the mechanism of action of MTX or immunopathogenesis of RA 
were studied for association with treatment outcome in a Dutch cohort of patients with early RA.  
 
Methods 
Seven polymorphisms in seven genes were analyzed in 205 genotyped patients with active rheuma-
toid arthritis. All received standardized MTX treatment (up to 25 mg per week orally), combined 
with folic acid. MTX treatment outcome was evaluated by disease activity score criteria (DAS) and 
adverse drug events (ADE). The following genetic variants were analyzed and correlated: DHFR 
829C/T, ABCB1 3435C/T, ITPA IVS2 +21A/C, HLA-G (-/+14bp), IMPDH2 +787C/T, TGFB1 
+869T/C and TLR4 +896A/G. In case of significant differences, regression analyses were applied.  
 
Results 
No significant associations of these genetic variants with MTX efficacy were demonstrated. Regard-
ing toxicity, patients carrying the ABCB1 3435 T-allele and TLR4 G-allele were 2.5 times more likely 
to develop ADEs at 6 months (OR 2.6; 95%C.I. 1.1-6.2 and OR 2.5; 95%C.I. 1.1-6.1, respectively). 
Additionally, the chance of experiencing ADEs at 6 months increased almost 4 times in patients 
with the two unfavourable genotypes (OR 3.9; 95%C.I. 1.5-10.3). However, none of these associa-
tions remained significant after correction for multiple testing (p<0.004).  
 
Conclusion 
In conclusion, it is demonstrated that in RA patients treated with MTX toxicity was potentially asso-
ciated with ABCB1 3435C/T and TLR4 +896A/G. However, after correction, none of these associa-
tions remained significant. Further, no significant associations of these seven functional variants 
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Introduction 
 
The optimal strategy in treatment of early rheumatoid arthritis (RA) is to use effective disease mod-
ifying antirheumatic drugs (DMARDs) in an early stage of disease in order to reduce disease activity 
and to prevent destructive arthropathy. In clinical studies, this treatment goal is frequently achieved 
by methotrexate (MTX) (1;2). Accordingly, this drug developed as a mainstay in effective drug ther-
apy of RA (3;4). Still, a substantial part of patients (40-60%) , fail to achieve an efficacious clinical 
result and/or experience adverse drug events (15-30%) with MTX monotherapy (5;6).  
Interestingly, these differences in clinical response to MTX can at least partially be explained by 
pharmacogenetics (7). The ultimate aim of pharmacogenetics in RA is to use genetic profiles of RA 
patients for selecting the optimal antirheumatic drug treatment for the individual patient in an early 
phase of the disease. So far, most studied genetic variants were chosen based upon their hypotheti-
cal relation to the mechanism of MTX or inflammatory process in RA, such as genetic variants in the 
folate and adenosine pathway  (8;9). Ideally, functional genetic variants are selected because the 
alteration in protein function is thought to influence drug action and thus may explain interindivi-
dual differences in drug response (10;11). 
To date no genetic factors are proven and validated markers for predicting MTX therapy outcome. 
Specifically, several genetic markers such as MTHFR 677 C>T and RFC 80G>A have been corre-
lated with treatment outcome in RA patients over the last years (12;13) but have been found hard to 
replicate in large and independent cohorts of patients with valid clinical endpoints. Moreover, only a 
minority of the genetic variants have proven functional consequences, e.g. to impact gene expression 
and subsequent enzyme activity. Particularly, this lack of validation and replication limits the appli-
cation of pharmacogenetics of MTX in clinical decision making (11;14;15). 
Therefore, in this study we selected a series of functional genetic polymorphisms for association with 
MTX treatment outcome in early RA patients. The genetic polymorphisms included are DHFR 
829C>T, ABCB1 3435C>T, ITPA IVS2 +21A>C, HLA-G (->+14bp), IMPDH2 +787C>T, TGFB1 
+869T>C and TLR4 +896A>G. These variants are in genes, which are thought to be related with the 
mechanism of action of MTX and/or immunopathogenesis of RA (Table 1). 
 
 
Patients and methods 
 
Patients.  
The 205 patients enrolled in this study comprised a subcohort of the 508 patients who participated 
in the multicenter BeSt study. Inclusion criteria were a diagnosis of early RA as defined by the 
American College of Rheumatology (ACR) 1987 criteria for RA, age ≥18 years, and a symptom dura-
tion of <2 years. Patients were also required to have active RA, with ≥6 of 66 swollen joints and ≥6 
of 68 tender joints and either an erythrocyte sedimentation rate (ESR) ≥28 mm/hour or a global 
health score of ≥20 mm on 0 – 100 mm visual analogue scale (VAS) where 0= best and 100 = worst. 
Main exclusion criteria were previous treatment with DMARDs other than antimalarials and con-
comitant treatment with an experimental drug. Further details have been published elsewhere (16). 
The local ethics committee at each participating hospital approved the study protocol. All patients 
gave informed consent before enrolment into the study.  
Regarding ethnicity, our population consisted of 93.2% Caucasian (n= 191), 2.4% Asian (n= 5), 1.0% 
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Study design and treatment.  
Patients who were allocated to initial monotherapy with MTX (n=247) and for whom DNA samples 
were available (n= 205) were included in the current analysis. The primary goal, regarding efficacy 
of therapy in the BeSt study (16) groups was a clinical response as defined by the Disease Activity 
Score (DAS) of ≤2.4 at 6 months (17;18). The DAS is a validated composite outcome measure con-
sisting of the Ritchie articular index (RAI) (19), the swollen joint count (SJC), general well-being as 
indicated by the patient on a VAS and the ESR. A research nurse who was blinded to the allocated 
treatment group assessed the DAS.  
All patients included in this analysis began treatment with a regimen of oral MTX 7.5 mg weekly, 
with the dosage increasing to 15 mg weekly after 4 weeks, in combination with folic acid (1 mg daily). 
In the event of insufficient clinical response (DAS >2.4) at the 3-month follow up visit, the MTX 
dosage was increased stepwise from 5 mg every 2 weeks to 25 mg weekly. In case of intolerance, 
MTX could also be given by parenteral route of administration. In case of adverse drug events, MTX 
was continued at the highest tolerated dose. If MTX was not tolerated at all, the patient was treated 
with the next DMARD according to the BeSt protocol. Concomitant therapies with nonsteroidal 
anti-inflammatory drugs as well as intra-articular injections with corticosteroids were allowed for all 
treatment groups.  
 
Evaluation of clinical efficacy and toxicity 
Responders were defined as patients who were receiving MTX and had a DAS of ≤2.4 at 6 months 
(good clinical response). Nonresponders were defined as patients who were receiving MTX and had 
a DAS of >2.4. A total of 186 patients were available for the analysis of associations between selected 
SNPs and response to MTX at 6 months (16). Patients who experienced adverse events but contin-
ued to be treated with MTX at 6 months were included in the efficacy analysis. Baseline variables 
possibly influencing the patient’s disease state and MTX response were previously selected on the 
basis of literature (20). 
Toxicity was evaluated by counting each reported adverse drug event (ADE) and its consequences 
for the patient and treatment. Adverse drug events were spontaneously reported by the patients, or 
were reported as a result of non-specific questioning on patients' wellbeing by the investigator, by 
physical examination or laboratory measurements during follow up. In case of adverse drug events, 
MTX was continued at the lowest tolerated dose, or if MTX was not tolerated at all, the rheumatolo-
gists adjusted DMARD therapy according to the protocol. Of all reported ADEs, the following non-
infectious adverse drug events were evaluated explicitly: gastrointestinal adverse drug events de-
fined as patients' general wellbeing, nausea, vomiting, diarrhoea, and constipation; liver adverse 
drug events defined as all cases of elevated functional liverenzymes resulting in MTX dose adjust-
ment or discontinuation; pneumonitis; skin and mucosal disorders. Moreover, patients were eva-
luated for leucopenia (<4.109/L), ALAT 3 times upper limit of normal (>135 U/L) and for alkaline 
phosphatase (AF) 3 times the upper limit of normal (>360 U/L). The analyses of laboratory mea-
surements were performed for completers only.  
 
Selection of SNPs  
Seven nucleotide polymorphisms (SNPs) with proven functional consequences in seven candidate 
genes related to the mechanism of action of MTX and/or immunopathogenesis of RA were selected. 
Based on literature, the following criteria were taken into consideration: validated SNP, proven 
functional consequences of the variant (21-26) and indications for clinical relevance, as defined by 
previous associations with treatment outcome in RA (tables 1 and 3) (25;27-32).   
The genetic polymorphisms included were in genes coding for dihydrofolate reductase (DHFR), 
multi-drug resistance-1 (ABCB1), inosine triphosphate pyrophosphatase (ITPA), human leukocyte 
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antigen-G (HLA-G), transforming growth factor β1 (TGFB1), toll-like receptor 4 (TLR4), inosine 5’-
monophosphate dehydrogenase (IMPDH2). 
The following SNPs were analyzed: DHFR –829C>T (rs34764978), ABCB1 3435C>T (rs60023214), 
ITPA IVS2 +21A>C (rs7270101), HLA-G ->+ATTTGTTCATGCCT (->+14bp) (rs16375), TGFB1 
+869T>C (rs1982073), TLR4 +896A>G (rs4986790), IMPDH2 +787C>T. 
 
Genotyping  
DNA was isolated from peripheral white blood cells by the standard manual salting-out method. As 
a quality control, positive controls (Control DNA CEPH 347-02; Applied Biosystems) and negative 
controls (water) were used. In addition, 5-10% of samples were genotyped in duplicate and no in-
consistencies were observed. Real-time polymerase chain reaction (PCR) using Taqman technique, 
according to the protocol provided by the manufacturer (Applied Biosystems), was performed for 
genotyping SNPs in the genes ABCB1, ITPA, TLR4, TGFB1. Regarding HLA-G, the 14 bp deletion 
was determined with fragment length analysis on the ABI PRISM 3730xl Analyzer, according to 
standard procedures. 
Briefly, DNA was PCR-amplified using primers 5’-AAGGAATGCAGTTCAGCATG-3’ and 5’- 
CTCACGGCTTGTAAATGTGAC-3’ of which the forward primer was FAM-labeled.  PCR product 
was 20 times diluted and 1 µl was mixed with 9 µl formamide containing ROX dye. The fragments 
were analysed with peakscanner software (Applied Biosystems).IMPDH2 +787C/T was analysed by 
lightscanner (Idaho) using PCR primers 5’-CTGCTGTGTGGGGCAGCC-3’ and 5’-
TAGCAGCTCACCAAAACCAC3’ and as probe 5’-TGGACTTGCTCGCCCAGG-3’. DHFR 829C>T 
was detected using a multiplex pyrosequencing method. The sequence of DHFR 829C>T 
(rs34764978) appeared to be highly homologous with a sequence on chromosome 18. This specific 
gene has a T at position 829. To discriminate 829T of the DHFR gene with that on chromosome 18, 
allele-specific PCR primers were chosen in such a way that chromosome 18 will not be amplified. In 
addition, pyrosequencing was performed as a multiplex assay in which the second SNP discrimi-
nates another mismatch between both genes. PCR primers are 5’-CTTCTCCAAGACCCCAACTG-3’ 
and biotinylated revrese primer 5’- CTTCCAGGTTGTTTTCAATTTTT-3’. Sequence primers are 5’- 
AGTCCCCAGCACCTGCTA-3’ (sequence to analyze: C/TAGTGAGCTGCC) and 5’- AGTGGAAA-
TACCAAAA-3’ (sequence to analyze GC/ATTCCTACGT). Dispensation order was ACTCAG-
CAGTCTG. 
Success rates for these assays were as follows: for ABCB1 3435 C>T, 94.6%; for ITPA IV2 +21 A>C, 
98.5%; for HLA-G ->+14bp, 89%; for both TGFB1 +869T>C and TLR4 +896A>G, 95.6%; for 
DHFR 829C>T 96.0% and for IMPDH2 +787 C>T, 97.2%. 
Genotype distributions in percentages were for DHFR 829C>T, 100% CC, 0% CT, 0% TT; for 
ABCB1 3435C>T, 22% CC, 45% CT, 33% TT; for ITPA IVS2 +21A>C, 80% AA, 17% AC, 3% CC; for 
HLA-G ->+14bp, 31% -14bp/-14bp, 48% -14bp/+14bp, 21% +14bp/+14bp; for  TGFB1 +869T>C, 
37% TT, 49% TC, 14% CC; for  TLR4 +896A>G, 87% AA, 12% AG, 1% GG; for IMPDH2 +787C>T, 
100% CC, 0% CT, 0% TT. Notably, the variants within the DHFR gene (genotypes CT and TT) and 
IMPDH2 gene (genotypes CT and TT) were not observed during PCR sequence analysis in our pa-
tient cohort. 
Genotype frequencies for all genetic polymorphisms were in Hardy-Weinberg equilibrium, except 
for ITPA IVS2 +21 A>C (p=0.025). However, the genotype distribution of this SNP in our popula-
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Gene Role in relation with MTX and/or RA 
Genetic 
variant Hypothetical effect 
ABCB1 Efflux transporter; (hypothetically) efflux  
of MTX 
3435C>T Decrease of mRNA stability and enzyme 
expression; 
May increase intracellular MTX levels 
(36-38) 
DHFR Conversion DHF to THF; target of MTX -829C>T Increase of enzyme expression leading 
to increased enzyme production and 
MTX resistance 
(21;22) 
HLA-G Downregulation of inflammatory 
process; involved in immune tolerance 
->+14 bp Decrease of HLA-G mRNA stability; 




Catalyzation of conversion IMP to XMP; 
involved in the purine metabolism 
787C>T Decrease of enzyme activity (24) 
ITPA Conversion ITP to IMP; involved in the 
purine metabolism; indirect target MTX 
IVS2 +21A>C Alteration of enzyme structure and 
Decrease of enzyme activity (26) 
TGFB1 Involved in immunosuppression and 
inflammatory conditions 
869T>C May decrease or increase enzyme pro-
duction (59-62) 
TLR4 Mediation of secretion of inflammatory 
cytokines;  
896A>G Decrease of inflammatory cytokine; 
May associate with susceptibility to RA 
(53;55) 
 
Table 1. Characteristics of functional genetic polymorphisms 
 
Abbreviation(s): bp= basepair; DHFR= dihydrofolate reductase , ABCB1= multi-drug resistance-1; ITPA= inosine 
triphosphate pyrophosphatase; HLA-G= human leukocyte antigen-G; TGFB1= transforming growth factor β1; 
TLR4= toll-like receptor 4, IMPDH2=  inosine 5’-monophosphate dehydrogenase; MTX= methotrexate; N.A.= 
not available; RA= rheumatoid arthritis; mRNA= messenger ribonucleic acid; IMP= inosine monophosphate; 
XMP= xanthosine monophosphate; ITP= inosine triphosphate 
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Statistical analysis.  
Genotype distributions were related to efficacy and toxicity using 3 by 2 cross tabs for each genotype, 
and 2 by 2 cross tabs for carriers versus non-carriers analysis with the two-sided Chi-square test. 
Generally, if genotype distributions differed, defined as p-value of ≤0.1 between responders and 
nonresponders (or ADE versus non-ADEs) as tested in the Chi-square univariate analysis, the SNP 
was selected for the multiple regression analysis. Hereby, other factors related to MTX treatment 
outcome were used as covariates in all regression analyses, as previously reported (9;20). The p-
values that were considered significant were p<0.05 and corrected for multiple testing: 0.05 divided 
by 7 (SNPs) times two (efficacy and toxicity) = 0.004. All statistical analyses were performed using 
SPSS 16.0 software (SPSS Inc., Chicago, IL, USA). 
 
Power calculation 
With the appliance of a power calculation it was demonstrated that for our study population of 205 
patients, minimal allele frequencies ranging from 7% (TLR4 896A>G) to 45% (ABCB1 3435C>T), 
an exposure of 40% and a chosen type 1 error probability α=0.004 (because of multiple testing), a 







Baseline demographic and disease characteristics between responders and nonresponders of the 
205 genotyped patients were prevalent as earlier reported (34). After 6 months of treatment with 
MTX, 87 patients (47%) responded (DAS ≤2.4) to MTX monotherapy. Among these patients, 43% 
received MTX at a dosage of 15 mg weekly and 57% received MTX at a dosage of 25 mg weekly. All 
results remained similar when performed with and without inclusion of non-Caucasian patients 
(data not shown). 
 
Functional polymorphisms in relation with MTX efficacy 
Table 2 displays the comparison of wildtype and/or mutant allele carriers for successfully genotyped 
variants between responders and nonresponders. Generally, no significant differences in genotype 
frequency distribution between responders and nonresponders were seen in the univariate analysis 
for ABCB1 3435C>T, ITPA IVS2 +21 A>C, HLA-G ->14bp, TGFB1 +869T>C and TLR4 +896A>G 
(p>0.05). Notably, the SNPs DHFR 829 C>T and IMPDH2 +787C>T could not be used for correla-
tion analysis due to the presence of 100% homozygous wildtype genotype in the cohort of patients. 
Regarding subsequent analysis, only ABCB1 3435C>T was a candidate to include in the multivariate 
regression analysis (p=0.082). Patients with the ABCB1 3435TT genotype were more frequent in the 
group of nonresponders, as defined by to DAS >2.4, than in the group of responders (36% vs. 24%, 
respectively). However, in the multivariate regression analysis including the co-variates gender, 
rheumatoid factor  status, smoking status, DAS at baseline the SNP in the ABCB1 gene was no long-
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Genetic polymorphism 
Response 
in % (DAS ≤2.4) 
Nonresponse 
in % (DAS >2.4) 
P-
value 
ABCB1 3435C>T    
CC vs. T-allele carriers 25 75 23 77 0.769 
C-allele carriers vs. TT 76 24 64 36 0.082 
ITPA +21A>C    
AA vs. C-allele carriers 79 21 81 19 0.687 
A-allele carriers vs. CC 97 3 98 2 0.555 
HLA-G ->+14 bp     
-14bp/-14bp vs. +14bp car-
riers 
25 75 33 67 0.306 
-14bp carrier vs. 
+14bp/+14bp 
78 22 80 20 0.781 
TGFB1 +869T>C    
TT vs. C-allele carriers 39 61 38 62 0.709 
T-allele carriers vs. CC 88 12 85 15 0.541 
TLR4 +896A>G    
AA vs. G-allele carriers 88 12 88 12 0.967 
A-allele carriers vs. GG 99 1 100 0 0.289 
 
Table 2. Comparison of genetic polymorphisms between responders and nonresponders to MTX 
monotherapy at 6 monthsa,b 
 
a. Abbreviation(s): bp= basepair; ABCB1= multi-drug resistance-1; ITPA= inosine triphosphate pyrophospha-
tase; HLA-G= human leukocyte antigen-G; TGFB1= transforming growth factor β1; TLR4= toll-like receptor 4. 
b. The SNPs DHFR -829 C>T and IMPDH2 +787C>T could not be used for statistical analysis due to the pres-
ence of 100% homozygous wildtype genotype  
 
 
Functional polymorphisms in relation with toxicity 
MTX toxicity data at 6 months were present for 200 RA patients. Thirty percent of these patients 
(n= 60) experienced at least 1 ADE during 6 months of treatment (34). ADEs at 6 months were 
more frequent in patients carrying the mutant alleles of ABCB1 3435C>T and in those with TLR4 
896A>G in comparison with patients carrying homozygous wildtypes (34% vs. 16% and 50% vs. 
28%, respectively). For ITPA IVS2 21A>G, patients with the homozygous mutant genotype expe-
rienced more frequently ADEs in comparion with A-allele carriers (67% vs. 29%, respectively). 
In multivariate regression analyses, ABCB1 T-allele- and TLR4 G-allele carriers were approximately 
2.5 times more likely to experience toxicity at 6 months (OR 2.6; 95%C.I. 1.1-6.2 p=0.037 and OR 
2.5; 95%C.I. 1.1-6.1; p=0.037, respectively). Moreover, patients carrying both the ABCB1 T-allele and 
TLR4 G-allele (N=21) had an almost four times risk on a ADE (OR 3.9; 95%C.I. 1.5-10.3; p=0.005) 
(Figure 1). Additional multivariate analysis for the SNP in the ITPA gene revealed no significant 
association with developing toxicity at 6 months. However, none of these associations remained 
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Figure 1. Genetic variants and occurrence of adverse drug events during 6 months of MTX the-
rapya,b 
 
a. Abbreviation(s): ABCB1= multi-drug resistance-1; TLR4= toll-like receptor 4; OR= Odds ratio; CI95%= confi-
dence interval of 95% 
b. None of these genetic associations remained significant after correction for multiple testing (p<0.004) 
 
 
Finally, in order to assess whether the observed relationship of toxicity and ABCB1 T-allele and 
TLR4 G-allele carriership was attributable to achieving a response, toxicity regression analyses were 
performed at 6 months for the group of responders and nonresponders. No significance with ob-
taining response or nonresponse in developing ADEs was seen in patients genotyped for ABCB1 T-
allele (N=74). For carriers of both the TLR4 G-allele and ABCB1 T-allele and for carriers of the TLR4 
G-allele alone in patients, which achieved a DAS of >2.4 at 6 months (N=9 and N=11, respectively), a 
significantly higher percentage of toxicity and increased odds ratio was demonstrated (OR=8.2; 
95%C.I. 1.6-43.5; p=0.013 and OR= 4,0; 95%C.I. 1.0-15.4; p=0.043, respectively). Regarding ob-
taining response at 6 months in patients carrying both the TLR4 G-allele and ABCB1 T-allele and 
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Discussion 
 
In this study on the association between functional genetic variants and MTX treatment outcome in 
RA patients, it is shown that toxicity was potentially associated with ABCB1 3435C/T and TLR4 
+896A/G. However, none of these associations remained significant after correction for multiple 
testing. No significant associations of DHFR 829C/T, ABCB1 3435C/T, ITPA IVS2 +21A/C, HLA-G 
(-/+14bp), IMPDH2 +787C/T, TGFB1 +869T/C and TLR4 +896A/G with MTX efficacy were 
found. 
The genetic polymorphisms included in this study were selected based upon literature findings on 
their proven functional consequences of the variant.  
The ABCB1 (MDR-1) gene product P-glycoprotein (P-gp) is a member of the ATP-binding cassette 
(ABC) superfamily of membrane proteins which functions as an exporter of xenobiotics from cells. 
Despite the fact that it is yet unclear whether MTX is a substrate for P-gp, it was demonstrated in in-
vitro studies that the ABCB1 3435C>T variant alters the drug specificity of P-gp in general (35). Fur-
ther, it was shown that this genetic variant decreases the mRNA stability, expression and hence the 
activity of the efflux-transporter P-gp (36-38). In this way, hypothetically ABCB1 3435C>T could 
influence MTX treatment by a decreased MTX cellular efflux. However, studies have demonstrated 
conflicting results regarding a relation between P-gp expression and resistance of MTX therapy 
(39;40). Future research on this topic has to be performed. 
Interestingly, in one in-vitro study (23), an other functional change of ABCB1 3435C>T has been 
demonstrated: this SNP is (along with ABCB1 2677 G>T) of influence on the release of several in-
flammatory cytokines, from mononuclear cells treated with MTX and dexamethasone. Specifically, 
the release of IFN-γ, IL-2, IL-4 and TNF-alpha at cellular level in subjects with the haplotype pair 
3435TT-2677TT was significantly decreased in comparison with subjects with other haplotypes. It 
was hypothesized that this may lead to a reduced incidence and activity of RA and higher probability 
of remission of disease symptoms after treatment with MTX in patients with the 3435TT-2677TT 
haplotype. This would mean that patients with the ABCB1 3435TT before treatment of MTX, have a 
lower disease activity compared to patients genotyped for ABCB1 CC and ABCB1 CT. However, in 
our cohort no significant differences in baseline DAS between ABCB1 genotypes were seen.  
Previously, in clinical studies conflicting results have been found regarding the relationship of 
ABCB1 3435 C>T and MTX efficacy in RA patients (table 3). In our data, only a trend towards signi-
ficance was seen in the analysis of ABCB1 3435C>T and our primary efficacy parameter (DAS of 
≤2.4 at 6 months) (table 2). This result strengthens the insignificant results seen in the study of Bo-
hanec Grabar et al (27). However, an opposite result was reported by Drozdzik et al (28), which 
found that ABCB1 TT was related with an increased likelihood of response according to ACR20. 
However, in our study a higher dosage, 7.5-25mg MTX (compared with 7.5-15 mg in the study of 
Drozdzik et al (28)), was given. Hypothetically, intergenotype differences within the SNP ABCB1 
3435C>T will become apparent if lower dosage is prescribed. Specifically, in our cohort 77% of pa-
tients genotyped for ABCB1 TT (N=52) had a dosage of more than 15 mg MTX. In this way, dosage 
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Table 3. Replication of results earlier reported in pharmacogenetic studies concerning MTX in 
RA patientsa,b,c,d 
 
a. Abbreviation(s): bp= basepair; ABCB1= multi-drug resistance-1; HLA-G= human leukocyte antigen-G; 
TGFB1= transforming growth factor β1; TLR4= toll-like receptor 4; N.A.= not available; N.D.= not defined; 
HAQ= Health Assessment Questionnaire; ACR= American College of Rheumatology; EULAR criteria= Euro-
pean League Against Rheumatism-criteria; DAS= Disease activity score  
b. The SNPs DHFR -829 C>T and IMPDH2 +787C>T could not be used for analysis due to the presence of 100% 
homozygous wildtype genotype 
c. DMARDs: hydroxychloroquine, sulfasalazine, gold, or MTX 
d. In combination with sulfasalazine, methotrexate, hydroxychloroquine and prednisolone 
 
With regard to toxicity, experiencing ADEs at 6 months was more frequent in patients carrying the 
mutant allele of ABCB1 3435C>T in comparison with patients carrying homozygous wildtype. Pre-
viously, three studies concerning ABCB1 3435C>T and MTX toxicity have been performed 
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(27;32;41). Only, in the study of Bohanec Grabar et al (27), a comparable significant result was seen: 
patients with ABCB1 TT genotype experienced more frequently ADEs than C-allele carriers.  
HLA-G, represents the nonclassical major histocompatibility complex (MHC) class Ib molecules, 
and have demonstrated to play an important role as anti-inflammatory particles in autoimmune 
diseases (42). Since, it was reported that increased anti-inflammatory IL10 production was related 
with an improved clinical result to MTX (43;44) and that HLA-G and IL-10 are functionally corre-
lated (e.g. IL-10 modulates HLA-G expression) (45-47), a pharmacogenetic role of the SNP HLA-G -
/14bp in MTX treatment could be present. Indeed, it was demonstrated that a homozygous deletion 
of this SNP (-14bp/-14bp) within this gene was associated with HLA-G stability and regulation of 
sHLA-G production, induced by MTX (25;48).  
Two studies explored the relationship between HLA-G genotype and MTX efficacy in RA patients. 
In the study of Rizzo et al (25), HLA-G -14bp/-14bp was associated with clinical response according 
to ΔDAS >0.6. In contrast, in a smaller cohort of patients (N=133), Stamp et al (31) found no signifi-
cant relationship with response based upon obtaining low disease activity (absolute DAS28 ≤3.2). 
The intracellular conversion of MTX into its polyglutamated form (MTXPGs) is thought be essential 
for the inhibition of folate enzymes, like DHFR, which converts dihydrofolate to tetrahydrofolate for 
purine synthesis and, consequently, for cellular proliferation of inflammatory cytokines. Despite it is 
unclear whether MTXPGs is of influence in the response to MTX, hypothetically, a genetic polymor-
phism within the DHFR gene can account for a defect in polyglutamation of MTX leading to a de-
creased response. Previously, the genetic variant DHFR 829C>T was associated with an increased 
expression of DHFR (21) leading to enzyme overproduction and hypothetically MTX resistance 
(22). Besides our report, so far no pharmacogenetic studies have been performed on DHFR 829C>T 
and MTX treatment outcome in RA patients. 
Like DHFR, also both the enzymes IMPDH2 and ITPA are involved in the purine metabolism. 
IMPDH2, an isoform type 2 of IMPDH2, is involved in transformation of IMP (inosine 5' mono-
phosphate) to XMP (xanthosine 5' monophosphate) .Expression of this type, compared to type 1, is 
significantly up regulated in rapidly proliferating cells involved in the inflammatory process. In con-
trast, ITPA catalyzes the conversion of ITP (inosine triphosphate) to IMP, whereas ITP is formed by 
phosphorylation of IMP. Deficiency of ITPA interrupts this cycle and possibly influences its balance 
with AMP and the release of adenosine, a potential anti-inflammatory agent (49). IMPDH2 787 C>T 
and ITPA IVS2 +21A>C, have demonstrated a negative effect on their respective gene expression 
resulting in diminished enzyme activity. Besides our study, so far no studies have related IMPDH2 
787 C>T and ITPA IVS2 +21A>C with MTX treatment outcome in RA patients. 
As a first line defence mechanism against endogenous ligands, TLR, like TLR4, are potentially in-
volved in inflammatory conditions of RA (50). Specifically, TLR are highly expressed in RA syn-
ovium and higher inflammatory products upon TLR activation were demonstrated in RA pa-
tients(51;52). Polymorphisms within genes coding for TLR4, like TLR4 +896 A>G, have been re-
lated to several other diseases (53). TLR4 +896 A>G has been associated with the potency of me-
diating the magnitude of inflammatory response (53;54) and controversially of susceptibility to RA 
(55;56). Still, a relation with expression of TLR4 was not seen (54). Regarding an association of this 
SNP with MTX treatment outcome, only a pharmacogenetic effect of this SNP on sulphasalazine, 
not MTX, monotherapy outcome was seen (29).  
Like TLR4, the cytokine TGFB1 has been reported to be of influence in many inflammatory diseases 
(57;58). In RA, TGFB1 is thought to down regulate the inflammatory response. Conflicting result 
have been reported regarding the functionality of the SNP TGFB1 869T>C in decreasing or increas-
ing enzyme production (59-62). Regarding efficacy, overexpression of the TGFB1 gene has been 
related to TGFB1 869 C>T and decreased disease activity possibly resulting in enhanced MTX re-
sponse (30). Notably, a separate analysis of the association of this SNP with MTX monotherapy was 
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not reported. So far no studies have been performed, besides our report, which have analyzed a rela-
tion of TLR4 896A>G with toxicity in patients on MTX monotherapy. 
In an earlier study, performed in the same cohort of patients, we developed a clinical pharmacoge-
netic model, including four genetic polymorphisms, in order to predict the response to MTX (20). 
This predictive algorithm showed a positive predictive value of 95% and a negative predictive value 
of 86%. Potentially, the seven SNPs included in the current study could be useful to refine and im-
prove the model. However, since no significant results for association were found this study does not 
add novel parameters for the predicting MTX efficacy. Interestingly, the current study revealed two 
genetic polymorphisms potentially related with MTX toxicity and may therefore be useful in combi-
nation with our predictive model for MTX efficacy.   
In this study, Bonferroni correction for multiple testing is applied. By using this conservative me-
thod, the chance of missing a genuine effect (type 2 error) is increased. However, if this correction 
was not applied, the chance of finding false positive results (type 1 error) would have been substan-
tially large. 
The relatively large cohort used in this pharmacogenetic study comprises well characterized patients 
with recent-onset RA treated with MTX monotherapy without prior DMARD usage. A robust and 
widely accepted measure for efficacy (DAS of ≤2.4 at 6 months) and registration of ADEs was ap-
plied (16). Four of the seven included genetic polymorphisms (ABCB1 3435C/T, HLA-G (-/+14bp), 
TGFB1 +869T/C and TLR4 +896A/G) were studied before in relation to MTX efficacy in RA pa-
tients but with inconclusive results. Therefore, the current study can partly be considered as a repli-
cation study. Importantly, the original studies applied different clinical endpoints for efficacy such as 
American College of Rheumatology (ACR) (63) and Health Assessment Questionnaire (HAQ) (64) 
(Table 3). Since from our clinical study database all these efficacy measures could be retrieved, we 
were able to replicate the studies using the previously described clinical endpoints for efficacy. With 
these analyses in our cohort, no significant results were detected for efficacy. 
This analysis is important, as many replication studies use different endpoints as compared to the 
original studies which make them incomparable and leads to inconclusive results. However, beside 
endpoints, alternative factors such as population differences, dosage of MTX, co-medication (e.g. 
other DMARDs) and treatment- and disease duration may hamper the replication of explored asso-
ciations in pharmacogenetic studies. Concerning ethnic differences, our DHFR and IMPDH2 geno-
typing results demonstrate that remarkable differences are seen between populations, since no mu-
tant alleles were detected in our cohort.  Generally, differences in study design could be an explana-
tion for the findings in our cohort of patients. 
We are convinced that the publication of replication studies is important. The publication of nega-
tive replication studies is even more important as to prevent publication-bias (65). Indeed, associa-
tion studies for MTX treatment outcome have increasingly presented new genetic variants in the last 
decade, but replication of these variants could not be retained. Fortunately, growing evidence exists 
in acknowledging negative associations and replications (65). In this way, along with the perfor-
mance of genome wide association studies, false positive findings could be reduced and evidence of 
a genetic effect could be declared.  
Furthermore, analyses in our cohort revealed a lower effect size in experiencing ADEs in the ABCB1 
TT group compared with patients genotyped for ABCB1 TT in the study of Bohanec Grabar et al 
(27). In general, it is demonstrated that the initial reported effect size is overestimated of the true 
effect size in genetic association studies (66). Consequently, this could account for the different de-
gree of effect sizes in experiencing overall toxicity demonstrated within our replication cohort of 
patients and the cohort of Bohanec Grabar et al (27). Ideally, if multiple studies are performed on 
one specific genetic variant, a meta-analysis should be performed in order to calculate an effect size, 
which is close to a genuine effect size. Alternatively, but a more extensive approach is a pooled data 
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analysis, which overcomes heterogeneity between patient cohorts in order to clarify the role of the 
variant in drug response.  
In conclusion, in this study it is demonstrated that in RA patients treated with MTX toxicity was 
potentially associated with ABCB1 3435C/T and TLR4 +896A/G. However, none of these associa-
tions remained significant after correction for multiple testing. Further, no significant associations of 
DHFR 829C/T, ABCB1 3435C/T, ITPA IVS2 +21A/C, HLA-G (-/+14bp), IMPDH2 +787C/T, 
TGFB1 +869T/C and TLR4 +896A/G with efficacy were found.  
62
Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis
References 
 
(1) Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff 
MH, Smolen JS. Early referral recommendation for newly 
diagnosed rheumatoid arthritis: evidence based develop-
ment of a clinical guide. Ann Rheum Dis 2002 
Apr;61(4):290-7. 
 (2) Smolen JS, Aletaha D, Machold KP. Therapeutic 
strategies in early rheumatoid arthritis. Best Pract Res Clin 
Rheumatol 2005 Feb;19(1):163-77. 
 (3) Cronstein BN. Low-dose methotrexate: a mainstay in 
the treatment of rheumatoid arthritis. Pharmacol Rev 2005 
Jun;57(2):163-72. 
 (4) Aletaha D, Smolen JS. The rheumatoid arthritis patient 
in the clinic: comparing more than 1,300 consecutive 
DMARD courses. Rheumatology (Oxford) 2002 
Dec;41(12):1367-74. 
 (5) Klareskog L, van der Heijde D., de Jager JP, Gough A, 
Kalden J, Malaise M, et al. Therapeutic effect of the combi-
nation of etanercept and methotrexate compared with each 
treatment alone in patients with rheumatoid arthritis: 
double-blind randomised controlled trial. Lancet 2004 Feb 
28;363(9410):675-81. 
 (6) Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, 
Kautiainen H, Korpela M, et al. Comparison of combina-
tion therapy with single-drug therapy in early rheumatoid 
arthritis: a randomised trial. FIN-RACo trial group. Lancet 
1999 May 8;353(9164):1568-73. 
 (7) Eichelbaum M, Ingelman-Sundberg M, Evans WE. 
Pharmacogenomics and Individualized Drug Therapy. 
Annu Rev Med 2006;57:119-37 
 (8) Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh 
M, et al. Polyglutamation of methotrexate with common 
polymorphisms in reduced folate carrier, aminoimidazole 
carboxamide ribonucleotide transformylase, and thymidy-
late synthase are associated with methotrexate effects in 
rheumatoid arthritis. Arthritis Rheum 2004 
Sep;50(9):2766-74. 
 (9) Wessels JA, Kooloos WM, De Jonge R., de Vries-
Bouwstra JK, Allaart CF, Linssen A, et al. Relationship 
between genetic variants in the adenosine pathway and 
outcome of methotrexate treatment in patients with recent-
onset rheumatoid arthritis. Arthritis Rheum 2006 
Sep;54(9):2830-9. 
 (10) Evans WE, Relling MV. Pharmacogenomics: 
translating functional genomics into rational therapeutics. 
Science 1999 Oct 15;286(5439):487-91. 
 (11) Hattersley AT, McCarthy MI. What makes a good 
genetic association study? Lancet 2005 Oct 
8;366(9493):1315-23. 
 (12) Hider SL, Bruce IN, Thomson W. The pharmacogenet-
ics of methotrexate. Rheumatology (Oxford) 2007 
Oct;46(10):1520-4. 
 (13) Wesoly J, Wessels JA, Guchelaar HJ, Huizinga TW. 
Genetic markers of treatment response in rheumatoid 
arthritis. Curr Rheumatol Rep 2006 Oct;8(5):369-77. 
 (14) Colhoun HM, McKeigue PM, Davey SG. Problems of 
reporting genetic associations with complex outcomes. 
Lancet 2003 Mar 8;361(9360):865-72. 
 (15) Rebbeck TR, Spitz M, Wu X. Assessing the function of 
genetic variants in candidate gene association studies. Nat 
Rev Genet 2004 Aug;5(8):589-97. 
 (16) Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart 
CF, van Zeben D., Kerstens PJ, Hazes JM, et al. Clinical and 
radiographic outcomes of four different treatment strate-
gies in patients with early rheumatoid arthritis (the BeSt 
study): a randomized, controlled trial. Arthritis Rheum 
2005 Nov;52(11):3381-90. 
 (17) van der Heijde DM, van ’t Hof M, van Riel PL, van de 
Putte LB. Development of a disease activity score based on 
judgment in clinical practice by rheumatologists. J Rheu-
matol 1993 Mar;20(3):579-81. 
 (18) van Gestel AM, Prevoo ML, van 't Hof MA, van 
Rijswijk MH, van de Putte LB, van Riel PL. Development 
and validation of the European League Against Rheumat-
ism response criteria for rheumatoid arthritis. Comparison 
with the preliminary American College of Rheumatology 
and the World Health Organization/International League 
Against Rheumatism Criteria. Arthritis Rheum 1996 
Jan;39(1):34-40. 
 (19) Ritchie DM, Boyle JA, McInnes JM, Jasani MK, 
Dalakos TG, Grieveson P, et al. Clinical studies with an 
articular index for the assessment of joint tenderness in 
patients with rheumatoid arthritis. Q J Med 1968 
Jul;37(147):393-406. 
 (20) Wessels JA, van der Kooij SM, le Cessie S., Kievit W, 
Barerra P, Allaart CF, et al. A clinical pharmacogenetic 
model to predict the efficacy of methotrexate monotherapy 
in recent-onset rheumatoid arthritis. Arthritis Rheum 2007 
Jun;56(6):1765-75. 
 (21) Goto Y, Yue L, Yokoi A, Nishimura R, Uehara T, 
Koizumi S, et al. A novel single-nucleotide polymorphism 
in the 3'-untranslated region of the human dihydrofolate 
63
Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis
reductase gene with enhanced expression. Clin Cancer Res 
2001 Jul;7(7):1952-6. 
 (22) Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello 
GS, Banerjee D, Bertino JR. A miR-24 microRNA binding-
site polymorphism in dihydrofolate reductase gene leads to 
methotrexate resistance. Proc Natl Acad Sci U S A 2007 
Aug 14;104(33):13513-8. 
 (23) Pawlik A, Baskiewicz-Masiuk M, Machalinski B, 
Kurzawski M, Gawronska-Szklarz B. Involvement of 
C3435T and G2677T multidrug resistance gene polymor-
phisms in release of cytokines from peripheral blood mo-
nonuclear cells treated with methotrexate and dexametha-
sone. Eur J Pharmacol 2005 Dec 28;528(1-3):27-36. 
 (24) Wang J, Zeevi A, Webber S, Girnita DM, Addonizio L, 
Selby R, et al. A novel variant L263F in human inosine 5'-
monophosphate dehydrogenase 2 is associated with dimi-
nished enzyme activity. Pharmacogenet Genomics 2007 
Apr;17(4):283-90. 
 (25) Rizzo R, Rubini M, Govoni M, Padovan M, Melchiorri 
L, Stignani M, et al. HLA-G 14-bp polymorphism regulates 
the methotrexate response in rheumatoid arthritis. Phar-
macogenet Genomics 2006 Sep;16(9):615-23. 
 (26) von Ahsen N., Oellerich M, Armstrong VW. 
Characterization of the inosine triphosphatase (ITPA) gene: 
haplotype structure, haplotype-phenotype correlation and 
promoter function. Ther Drug Monit 2008 Feb;30(1):16-
22. 
 (27) Bohanec Grabar P., Logar D, Lestan B, Dolzan V. 
Genetic determinants of methotrexate toxicity in rheuma-
toid arthritis patients: a study of polymorphisms affecting 
methotrexate transport and folate metabolism. Eur J Clin 
Pharmacol 2008 Nov;64(11):1057-68. 
 (28) Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny 
B, Gornik W, et al. The effect of 3435C>T MDR1 gene 
polymorphism on rheumatoid arthritis treatment with 
disease-modifying antirheumatic drugs. Eur J Clin Phar-
macol 2006 Nov;62(11):933-7. 
 (29) Kuuliala K, Orpana A, Leirisalo-Repo M, Kautiainen 
H, Hurme M, Hannonen P, et al. Polymorphism at position 
+896 of the toll-like receptor 4 gene interferes with rapid 
response to treatment in rheumatoid arthritis. Ann Rheum 
Dis 2006 Sep;65(9):1241-3. 
 (30) Mattey DL, Nixon N, Dawes PT, Kerr J. Association of 
polymorphism in the transforming growth factor {beta}1 
gene with disease outcome and mortality in rheumatoid 
arthritis. Ann Rheum Dis 2005 Aug;64(8):1190-4. 
 (31) Stamp LK, O'Donnell JL, Chapman PT, Barclay ML, 
Kennedy MA, Frampton CM, et al. Lack of association 
between HLA-G 14 bp insertion/deletion polymorphism 
and response to long-term therapy with methotrexate 
response in rheumatoid arthritis. Ann Rheum Dis 2009 
Jan;68(1):154-5. 
 (32) Takatori R, Takahashi KA, Tokunaga D, Hojo T, 
Fujioka M, Asano T, et al. ABCB1 C3435T polymorphism 
influences methotrexate sensitivity in rheumatoid arthritis 
patients. Clin Exp Rheumatol 2006 Sep;24(5):546-54. 
 (33) Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, 
Smigielski EM, et al. dbSNP: the NCBI database of genetic 
variation. Nucleic Acids Res 2001 Jan 1;29(1):308-11. 
 (34) Wessels JA, de Vries-Bouwstra JK, Heijmans BT, 
Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, et al. 
Efficacy and toxicity of methotrexate in early rheumatoid 
arthritis are associated with single-nucleotide polymor-
phisms in genes coding for folate pathway enzymes. Arthri-
tis Rheum 2006 Apr;54(4):1087-95. 
 (35) Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, 
Calcagno AM, Ambudkar SV, et al. A "silent" polymor-
phism in the MDR1 gene changes substrate specificity. 
Science 2007 Jan 26;315(5811):525-8. 
 (36) Drescher S, Schaeffeler E, Hitzl M, Hofmann U, 
Schwab M, Brinkmann U, et al. MDR1 gene polymor-
phisms and disposition of the P-glycoprotein substrate 
fexofenadine. Br J Clin Pharmacol 2002 May;53(5):526-
34. 
 (37) Hoffmeyer S, Burk O, von RO, Arnold HP, 
Brockmoller J, Johne A, et al. Functional polymorphisms 
of the human multidrug-resistance gene: multiple se-
quence variations and correlation of one allele with P-
glycoprotein expression and activity in vivo. Proc Natl Acad 
Sci U S A 2000 Mar 28;97(7):3473-8. 
 (38) Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. 
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 
3435C>T affects mRNA stability. Pharmacogenet Genom-
ics 2005 Oct;15(10):693-704. 
 (39) Hider SL, Owen A, Hartkoorn R, Khoo S, Back D, 
Silman AJ, et al. Down regulation of multidrug resistance 
protein-1 expression in patients with early rheumatoid 
arthritis exposed to methotrexate as a first disease-
modifying antirheumatic drug. Ann Rheum Dis 2006 
Oct;65(10):1390-3. 
 (40) Norris MD, De GD, Haber M, Kavallaris M, 
Madafiglio J, Gilbert J, et al. Involvement of MDR1 P-
glycoprotein in multifactorial resistance to methotrexate. 
Int J Cancer 1996 Mar 1;65(5):613-9. 
 (41) Ranganathan P, Culverhouse R, Marsh S, Mody A, 
Scott-Horton TJ, Brasington R, et al. Methotrexate (MTX) 
pathway gene polymorphisms and their effects on MTX 
64
Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis
toxicity in Caucasian and African American patients with 
rheumatoid arthritis. J Rheumatol 2008 Apr;35(4):572-9. 
 (42) Baricordi OR, Stignani M, Melchiorri L, Rizzo R. HLA-
G and inflammatory diseases. Inflamm Allergy Drug Tar-
gets 2008 Jun;7(2):67-74. 
 (43) Rudwaleit M, Yin Z, Siegert S, Grolms M, Radbruch A, 
Braun J, et al. Response to methotrexate in early rheuma-
toid arthritis is associated with a decrease of T cell derived 
tumour necrosis factor alpha, increase of interleukin 10, 
and predicted by the initial concentration of interleukin 4. 
Ann Rheum Dis 2000 Apr;59(4):311-4. 
 (44) Seitz M, Zwicker M, Wider B. Enhanced in vitro 
induced production of interleukin 10 by peripheral blood 
mononuclear cells in rheumatoid arthritis is associated 
with clinical response to methotrexate treatment. J Rheu-
matol 2001 Mar;28(3):496-501. 
 (45) Hviid TV, Rizzo R, Christiansen OB, Melchiorri L, 
Lindhard A, Baricordi OR. HLA-G and IL-10 in serum in 
relation to HLA-G genotype and polymorphisms. Immu-
nogenetics 2004 Jun;56(3):135-41. 
 (46) Rizzo R, Hviid TV, Stignani M, Balboni A, Grappa MT, 
Melchiorri L, et al. The HLA-G genotype is associated with 
IL-10 levels in activated PBMCs. Immunogenetics 2005 
May;57(3-4):172-81. 
 (47) Moreau P, drian-Cabestre F, Menier C, Guiard V, 
Gourand L, Dausset J, et al. IL-10 selectively induces HLA-
G expression in human trophoblasts and monocytes. Int 
Immunol 1999 May;11(5):803-11. 
 (48) Rousseau P, Le DM, Mouillot G, Marcou C, Carosella 
ED, Moreau P. The 14 bp deletion-insertion polymorphism 
in the 3' UT region of the HLA-G gene influences HLA-G 
mRNA stability. Hum Immunol 2003 Nov;64(11):1005-10. 
 (49) Cao H, Hegele RA. DNA polymorphisms in ITPA 
including basis of inosine triphosphatase deficiency. J Hum 
Genet 2002;47(11):620-2. 
 (50) Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu 
Rev Immunol 2003;21:335-76. 
 (51) Huang Q, Ma Y, Adebayo A, Pope RM. Increased 
macrophage activation mediated through toll-like receptors 
in rheumatoid arthritis. Arthritis Rheum 2007 
Jul;56(7):2192-201. 
 (52) Radstake TR, Roelofs MF, Jenniskens YM, Oppers-
Walgreen B, van Riel PL, Barrera P, et al. Expression of toll-
like receptors 2 and 4 in rheumatoid synovial tissue and 
regulation by proinflammatory cytokines interleukin-12 
and interleukin-18 via interferon-gamma. Arthritis Rheum 
2004 Dec;50(12):3856-65. 
 (53) Schroder NW, Schumann RR. Single nucleotide 
polymorphisms of Toll-like receptors and susceptibility to 
infectious disease. Lancet Infect Dis 2005 Mar;5(3):156-64. 
 (54) Roelofs MF, Wenink MH, Toonen EJ, Coenen MJ, 
Joosten LA, van den Berg WB, et al. The functional variant 
(Asp299gly) of toll-like receptor 4 (TLR4) influences TLR4-
mediated cytokine production in rheumatoid arthritis. J 
Rheumatol 2008 Apr;35(4):558-61. 
 (55) Radstake TR, Franke B, Hanssen S, Netea MG, 
Welsing P, Barrera P, et al. The Toll-like receptor 4 
Asp299Gly functional variant is associated with decreased 
rheumatoid arthritis disease susceptibility but does not 
influence disease severity and/or outcome. Arthritis 
Rheum 2004 Mar;50(3):999-1001. 
 (56) Sanchez E, Orozco G, Lopez-Nevot MA, Jimenez-
Alonso J, Martin J. Polymorphisms of toll-like receptor 2 
and 4 genes in rheumatoid arthritis and systemic lupus 
erythematosus. Tissue Antigens 2004 Jan;63(1):54-7. 
 (57) Crilly A, Hamilton J, Clark CJ, Jardine A, Madhok R. 
Analysis of transforming growth factor beta1 gene poly-
morphisms in patients with systemic sclerosis. Ann Rheum 
Dis 2002 Aug;61(8):678-81. 
 (58) Taketazu F, Kato M, Gobl A, Ichijo H, ten DP, Itoh J, et 
al. Enhanced expression of transforming growth factor-
beta s and transforming growth factor-beta type II receptor 
in the synovial tissues of patients with rheumatoid arthritis. 
Lab Invest 1994 May;70(5):620-30. 
 (59) Arkwright PD, Laurie S, Super M, Pravica V, Schwarz 
MJ, Webb AK, et al. TGF-beta(1) genotype and accelerated 
decline in lung function of patients with cystic fibrosis. 
Thorax 2000 Jun;55(6):459-62. 
 (60) Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, 
Healey CS, Kemp PR, et al. A transforming growth factor-
beta1 signal peptide variant increases secretion in vitro and 
is associated with increased incidence of invasive breast 
cancer. Cancer Res 2003 May 15;63(10):2610-5. 
 (61) Hinke V, Seck T, Clanget C, Scheidt-Nave C, Ziegler R, 
Pfeilschifter J. Association of transforming growth factor-
beta1 (TGFbeta1) T29 --> C gene polymorphism with bone 
mineral density (BMD), changes in BMD, and serum 
concentrations of TGF-beta1 in a population-based sample 
of postmenopausal german women. Calcif Tissue Int 2001 
Dec;69(6):315-20. 
 (62) Yamada Y, Miyauchi A, Goto J, Takagi Y, Okuizumi H, 
Kanematsu M, et al. Association of a polymorphism of the 
transforming growth factor-beta1 gene with genetic suscep-
tibility to osteoporosis in postmenopausal Japanese wom-
en. J Bone Miner Res 1998 Oct;13(10):1569-76. 
65
Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis
 (63) Felson DT, Anderson JJ, Boers M, Bombardier C, 
Furst D, Goldsmith C, et al. American College of Rheuma-
tology. Preliminary definition of improvement in rheuma-
toid arthritis. Arthritis Rheum 1995 Jun;38(6):727-35. 
 (64) Fries JF, Spitz P, Kraines RG, Holman HR. 
Measurement of patient outcome in arthritis. Arthritis 
Rheum 1980 Feb;23(2):137-45. 
 (65) Little J, Bradley L, Bray MS, Clyne M, Dorman J, 
Ellsworth DL, et al. Reporting, appraising, and integrating 
data on genotype prevalence and gene-disease associations. 
Am J Epidemiol 2002 Aug 15;156(4):300-10. 
 (66) Lohmueller KE, Pearce CL, Pike M, Lander ES, 
Hirschhorn JN. Meta-analysis of genetic association stu-
dies supports a contribution of common variants to suscep-





















Cross-validation of a clinical pharmacogenetic model 





Jaap Fransen1, Wouter M. Kooloos2, Judith AM Wessels2, Tom WJ Huizinga3, Henk-Jan Guche-
laar2, Piet LCM van Riel1 and Pilar Barrera1 
 
1 Rheumatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.  
2 Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands. 





















To cross-validate a clinical pharmacogenetic model to predict the efficacy of methotrexate (MTX) 
monotherapy in patients with established rheumatoid arthritis and previous failure of disease mod-
ifying antirheumatic drugs (DMARDs). 
 
Methods 
A clinical pharmacogenetic model developed in DMARD naive recent-onset RA patients, was ap-
plied in MTX naive RA patients and failure of other DMARDs. Patients from an RA inception co-
hort (N=593) were eligible if they fulfilled the ACR classification criteria for RA, received MTX mo-
notherapy for at least 6 months and failed on at least one DMARD before MTX. Concomitant oral 
prednisone was allowed if the dose did not exceed 10 mg. Hundred-and-eighteen patients fulfilled 
these inclusion criteria, DNA and clinical data were available for 75 of those patients, and 71 patients 
were genotyped successfully. Risk scores for non-response as defined by DAS>2.4 at 6 months, 
were calculated using the pharmacogenetic model utilising eight baseline factors: gender, rheuma-




The mean (SD) DAS at baseline was 3.55 (1.11). The time-averaged dose of MTX was 13.9 mg/week 
(range 5-25 mg/week); 48% of the patients used folic acid suppletion and 16% used prednisone. At 
6 months, the DAS decreased with a mean (SD) of -0.72 (1.13) points (p<0.0001), resulting in 33% 
responders (n=25) and 67% non-responders (n=50). At baseline, risk scores ranged from 0 to 10.5. 
Seventy-five percent (56/75) of the patients could be categorized into predicted responders (risk 
score ≤ 3.5) and predicted non-responders (risk score ≥ 6) using the eight baseline variables. Com-
parison of the observed and predicted response at 6 months showed that the true positive response 
ratio was 47% (14/30) and the true negative response ratio was 81% (21/26). 
 
Conclusion 
The pharmacogenetic model predicts the efficacy of MTX monotherapy better in DMARD naive 
recent-onset RA patients than in patients with preceding DMARD failure. Updating the model is 









Early treatment response in newly diagnosed rheumatoid arthritis (RA) patients is effective in de-
creasing functional disability and bone destruction (1,2). In addition, combination strategies of Dis-
ease Modifying Anti–Rheumatic Drugs (DMARDs), with or without anti-tumor necrosis factor (an-
ti-TNF) agents, show higher response rates compared to monotherapy strategies in treating RA and 
considerably improve the prognosis (3,4).   
Although combination strategies are more efficacious, such intensive approach is probably not ne-
cessary for all newly diagnosed RA patients since ~30 to 40% of the patients will experience a sus-
tained good clinical response to methotrexate (MTX) monotherapy (5,6). To avoid unnecessary 
combination treatment, it is important to determine whether patients have a high probability of 
response to MTX monotherapy.  
Recently a clinical pharmacogenetic model to predict response to MTX monotherapy has been de-
veloped in DMARD-naive patients with early onset RA (Table 1) (7). This model includes disease 
activity, gender, smoking and rheumatoid factor status next to four polymorphisms in genes related 
to the MTX mechanism of action and correctly predicts the response to MTX in early RA (7).  
Next to MTX, other DMARDs such as sulphasalazine (SSZ) are still frequently used as a first 
DMARD for treating RA in daily clinical practice. Of note, the number of previous DMARDs and 
disease duration have been associated with reduced response to MTX (8,9). It is unclear whether 
the clinical pharmacogenetic model is still informative if MTX is intended after failure of another 
DMARD. In order to tailor treatment choices in RA, there is a need for prediction of response to 
MTX therapy in patients with established RA patients with previous DMARD failure.  
The objective of this study was to cross-validate the clinical pharmacogenetic model with clinical 
and genetic factors to predict the efficacy of MTX monotherapy in established RA patients with 






Eligible patients were selected from the database of the inception cohort of early RA patients at the 
Department of Rheumatology of the Radboud University Nijmegen (10). Inclusion criteria of the 
cohort are: fulfillment of the ACR criteria for RA (ACR 1978), no use of DMARDs, a symptom dura-
tion < 1 year. Additional inclusion criteria for the present study were: use of MTX mono-therapy for 
at least 6 months, no use of oral prednisone > 10mg/day during the first 6 months of the MTX 
course, treatment with at least one other DMARD previously, availability of clinical data at start of 
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   Premenopausal 1 
   Postmenopausal 1 
Male gender 0 
DAS at baseline  
   ≤3.8 0 
   >3.8 and ≤5.1 3 
   >5.1 3.5 
RF-negative nonsmoker 0 
RF-negative smoker 1 
RF-positive nonsmoker 1 
RF-positive smoker 2 
MTHFD1 1958 AA genotype 1 
AMPD1 34 CC genotype 1 
ITPA 94 A-allele carrier 2 
ATIC 347G-allele carrier 1 
Other genotype 0 
 
Table 1. The original clinical pharmacogenetic model to predict response to MTX 
monotherapy 
 
Abbreviation(s): RF = Rheumatoid Factor; DAS = Disease Activity Score; AMPD1= adenosine 
monophosphate deaminase; ATIC= aminoimidazole, carboxamide ribonucleotide transformylase; 





Patients in the Nijmegen RA inception cohort were regularly assessed regarding disease activity and 
medication use (10). Medication and clinical information was registered in a computerized data-
base. DNA had been collected in an unselected subsample of patients. At the time of patient selec-
tion for the present study in 2007, there were N=593 patients included in the database. N=352 pa-
tients had used MTX at any time point; MTX was the first DMARD used in n=36 patients, and a 
total of n=151 patients had switched to MTX monotherapy after one or more previous DMARDs, 
most often SSZ. Out of those 151 patients on MTX monotherapy, 118 had used MTX for at least 6 
months. For 76 of them, DNA and DAS values were available. One patient used oral prednisone > 
10mg/day and was excluded. Consequently, genotyping was performed in 75 patients, and was 
complete in 71 patients. The dates of start of MTX of the included patients ranged uniformly from 
1988 to 2006. There were no significant differences between patients that were included (n=75) and 
patients that were not included (n=76) regarding age, gender, rheumatoid factor, smoking, DAS at 
diagnosis and MTX dose. 
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Variables 
Age and disease duration at the time of MTX initiation (baseline) were calculated. As menopausal 
status was unavailable, age categories of ≤55 and 55< were used as proxy. For Rheumatoid Factor 
(RF) positivity, the most recent value before baseline was used. Smoking status was defined as cur-
rent smoker and nonsmoker at the time of diagnosis. Joint counts were assessed by trained research 
nurses, Visual Analogue Scales (VAS, 0-100 mm.) for general health and pain were filled in by the 
patient. ESR was determined using the Westergren method. The DAS was calculated using the Rit-
chie Articular Index (RAI), the 44 swollen joint count (SJC), ESR and general health, according to 
the original formula (11). 
 
Treatment 
All treatment decisions were to the discretion of the treating rheumatologist and the patient. Con-
comitant use of methylprednisolone and Non-steroidal Anti-inflammatory Drugs (NSAIDs) was 
allowed. Patients receiving oral prednisone > 10mg/day during the first 6 months of the MTX 
course were not included. 
 
MTX response evaluation 
For the purpose of the present study, the same response definition as in the previous study form 
Wessels et al. was used (7). Responders were defined as patients who were treated with MTX for 6 
months and had a DAS≤2.4 at 6 months, nonresponders were defined as patients who were treated 
with MTX for 6 months but had a DAS>2.4 at 6 months (12). 
 
Prediction rule 
The variables of the prediction rule for the probability of non-response (DAS>2.4) after 6 months of 
MTX use were: gender, menopausal status, RF status, smoking status, DAS at baseline, and 4 poly-
morphisms in AMPD1, ATIC, ITPA, MTHFD1 (7). To arrive at a clinical useful prediction rule, 
weighted scores had been assigned by rounding the regression coefficients in the final prediction 




Genomic DNA was extracted from peripheral venous blood (10 ml/sample) according to standard 
protocols. All included patients were genotyped for SNPs in genes coding for adenosine monophos-
phate deaminase (AMPD1; rs17602729), aminoimidazole carboxamide ribonucleotide transformy-
lase (ATIC; rs2372536), inosine triphosphate pyrophosphatase (ITPA; rs1127354) methylenetetra-
hydrofolate dehydrogenase (MTHFD1; rs17850560). Genotype frequencies of AMPD1 (p=0.068), 
ATIC (p=0.22), ITPA (p=0.23), and MTHFD1 (p=0.065) were not significantly different to the distri-
butions as expected based on the HapMap-CEU sample (http://www.ncbi.nlm.nih.gov/sites/entrez). 
Genotype distributions were as follows: for AMPD1 34C>T, 68% CC, 31% CT, 1% TT; for ATIC 
347C>G, 49% CC, 41% CG, 9% GG; for ITPA 94C>A, 80% CC, 20% CA; and for MTHFD 1958G>A, 
23% GG, 59% GA, 18% AA. Hardy-Weinberg equilibrium was not calculated because of the small 
sample. Genotyping was performed using real-time polymerase chain reaction with TaqMan®, 
according to the protocol provided by the manufacturer (Applied Biosystems, Nieuwerkerk aan den 
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Statistical analysis 
Responders and non-responders were compared at baseline regarding the clinical and genetic va-
riables in the prediction model and regarding former medication use, using Student’s t-test, Wilcox-
ons’ test, Chi-square test or Fisher-Exact test, as appropriate. 
No variable selection procedure was attempted for model building. The variables of the existing 
prediction formula were applied in a logistic regression model with MTX response (yes/no) as de-
pendent variable, and the clinical variables (nongenetic model) and the clinical and genetic variables 
combined (pharmacogenetic model) as independent variables. The exponential of the regression 
coefficient, eβ is an estimate of the adjusted Odds Ratio. In congruence with the original publication 
(7), the probability of a non-response was modeled. Of both the nongenetic model and the pharma-
cogenetic model, discrimination was evaluated using the area-under-the-receiver-operating-
characteristic-curve (c-statistic) and the variance explained (Nagelkerke R2). The clinical prediction 
rule and the cut-points for nonresponse, intermediate, and response were applied as delineated in 
the original publication (7). The resulting clinical prediction scores were compared between res-
ponders and nonresponders using Student’s t-test. Using observed and predicted responses the true 
positive and true negative response ratios were calculated. It was attempted to update the nongenet-
ic and pharmacogenetic models by addition of the predefined variables: number of previous 
DMARDs and disease duration (8), and SSZ as previous DMARD. 





Description of the cohort 
The starting dose of MTX of the included patients was in median 15 mg/week, ranging from 2.5-
22.5 mg/week. After 6 months the median MTX dose was also 15 mg/week, with a range of 5-25 
mg/week. The median time-averaged dose of MTX was 13.9 mg/week (range 5-25 mg/week). Of 
the included patients 36/75 (48%) used folic acid suppletion and 12/75 (16%) used concomitant oral 
prednisone in the allowed dose of ≤10 mg/day. The mean (SD) DAS at baseline was 3.55 (1.11). After 
6 months, the DAS had significantly decreased with mean (SD) -0.72 (1.13) points (p<0.0001), re-
sulting in 33% responders (n=25) with a DAS≤2.4 and 67% non-responders (n=50) with a 
DAS>2.4.  
In table 2, baseline values of responders and nonresponders are compared. The prespecified va-
riables for the pharmacogenetic model were: gender, menopausal status, Rheumatoid Factor posi-
tivity, smoking status, DAS at baseline, and 4 polymorphisms in AMPD1, ATIC, ITPA, MTHFD1 
genes. Of these variables, only baseline DAS was significant at a level of p<0.05. Notably, none of 
the 4 genetic factors were statistically significant at that p-level. Moreover, of all variables tested, 
only RF positivity, the baseline DAS, the tender joint counts, pain, ESR and the number of previous 




















Age 55 (13) 58 (14) 0.33 
Age > 55 12 (48%) 30 (60%) 0.32 
Female gender 15 (60%) 35 (70%) 0.39 
RF positivity 41 (82%) 16 (64%) 0.09 
Disease duration (months) 19 (7-49) 19 (5-43) 0.99 
Current smoker 8 (32%) 15 (30%) 0.86 
DAS baseline 3.1 (1.3) 3.8 (0.9) 0.01 
SJC44 12 (5-18) 14 (10-18) 0.31 
TJC53 4 (2-9) 11 (7-19) 0.002 
RAI 5 (2-7) 8 (5-12) 0.0005 
Pain VAS 37 (25) 48 (22) 0.07 
General Health VAS 46 (25) 50 (24) 0.47 
ESR 14 (7-36) 24 (13-44) 0.14 
Folic acid use 10 (40%) 26 (52%) 0.33 
Oral prednisone use 3 (12%) 9 (18%) 0.74 
Number of previous 
DMARDs 
1 (1-3)* 1 (1-4)* 0.15 
Previous DMARDs>1 6 (24%) 20 (40%) 0.17 
Previous DMARD was SSZ 21 (84%) 36 (72%) 0.25 
MTHFD1 1985 AA genotype 4 (17%) 9 (18%) 0.99 
AMPD1 34 CC genotype 14 (58%) 35 (73%) 0.21 
ITPA 94 A-allele carrier 4 (16%) 11 (22%) 0.54 
ATIC 347 G-allele carrier 13 (52%) 25 (50%) 0.87 
 
Table 2. Baseline variables of responders and nonresponders 
 
Abbreviation(s): RF = Rheumatoid Factor; DAS = Disease Activity Score; SJC44 = 44 swollen joint count; TJC53 
= 53 tender joint count; RAI = Ritchie Articular Index, SJC44 and TJC53 both are based on the joints assessed in 
the RAI; VAS = visual analogue scale; SSZ=Sulphasalazine; AMPD1= adenosine monophosphate deaminase; 
ATIC= aminoimidazole, carboxamide ribonucleotide transformylase; ITPA= inosine triphosphate pyrophospha-
tase; MTHFD1= methylenetetrahydrofolate dehydrogenase. 
 
 
Cross-validation of the clinical pharmacogenetic model 
The variables entered in the logistic regression model to predict non-response to MTX at 6 months 
according to a DAS≤2.4 were prespecified by the existing prediction model (Table 3). 
First, the nongenetic variables were simultaneously entered in a logistic regression model; next the 
genetic variables were added. The sample was too small for including interaction terms. According 
to the odds ratio’s it is seen that the contribution of gender was small (OR near 1) and that smoking 
was inversely associated with non-response (OR below 1). Age, RF positivity and DAS at baseline 
were all predictive for non-response. 
The genetic factors were not statistically significant, three of the genetic factors had a sign (‘-‘) re-
versed to the expectation, the sign for AMPD1 was in agreement with the expectation according to 
the publication of Wessels et al. (7). 
When the original clinical prediction rule was applied on the baseline variables, the resulting risk 
scores ranged from 0 to 10.5. The mean (SD) risk score was 5.1 (2.3) and 3.8 (2.7) for non-
responders and responders, respectively. The difference between these scores was significant 
(p=0.03). Accordingly, 75% (56/75) of the patients could be correctly categorized into predicted 
responders (risk score ≤ 3.5) and predicted non-responders (risk score ≥ 6) using the eight baseline 
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variables of the pharmacogenetic model (Table 4). Comparison of the observed and predicted re-
sponse at 6 months showed that the true positive response ratio was 47% (14/30) and the true nega-




 Nongenetic model Pharmacogenetic model 
Variable β OR (95% CI) β OR (95% CI) 
Female gender 0.028 1.1 (0.3-3.3) -0.12 0.8 (0.2-2.7) 
Age ≥55 0.78 2.2 (0.7-6.7) 0.89 2.4 (0.7-8.0) 
DAS at baseline 0.70 2.0 (1.2-3.5) 0.77 2.2 (1.2-4.0) 
RF-positive 1.13 3.1 (0.8-11.5) 0.98 2.7 (0.7-11.0) 
Smoking -0.47 (0.6 (0.2-2.0) -0.47 0.6 (0.2-2.2) 
MTHFD1 1958 AA genotype -- -- -0.31 0.7 (0.2-3.2) 
AMPD1 34 CC genotype -- -- 0.34 1.4 (0.4-4.9) 
ITPA 94 A-allele carrier -- -- -0.21 0.8 (0.2-3.6) 
ATIC 347G-allele carrier -- -- -0.23 0.8 (0.3-2.4) 
 
Table 3. Regression coefficients and odds ratio’s of the logistic regression models to predict non-
response to MTX 
 
Abbreviation(s): RF = Rheumatoid Factor; DAS = Disease Activity Score; AMPD1= adenosine monophosphate 
deaminase; ATIC= aminoimidazole, carboxamide ribonucleotide transformylase; ITPA= inosine triphosphate 





 Predicted response 
Observed response Nonresponder Intermediate Responder 
Pharmacogenetic model    
   Nonresponder 21 11 16 
   Responder 5 4 14 
Nongenetic model    
   Nonresponder 4 16 28 
   Responder 1 3 19 
 
Table 4. Observed and predicted response after 6 months of MTX, using the original pharmaco-
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Discriminatory performance of the nongenetic model and the pharmacogenetic model was studied 
using the area-under-the-ROC curve (Figure 1). The area-under-the-curve was 0.73 for the nonge-
netic model and 0.77 for the pharmacogenetic model. The variance explained (R2) was 0.22 and 
0.28 for the nongenetic and pharmacogenetics models, respectively. To assess the relative contribu-
tion of both models in predicting (DAS-) response in comparison to a very reduced model, a model 





Figure 1. ROC curves for predicting the response to  MTX using the original pharmacogenetic 




Updating the clinical and pharmacogenetics models by removing the interactions of age and gender, 
and smoking and RF positivity, and adding the variables ‘number of previous DMARDs’ and ‘SSZ as 
previous DMARD’ did not improve the discriminatory performance (not shown). Disease duration 
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Discussion 
 
This study shows that the previously published clinical pharmacogenetic model to predict MTX 
mono-therapy efficacy in patients with established RA does not perform as good as in DMARD 
naïve patients with recent-onset RA. Previously it was found that the clinical pharmacogenetic 
model had a true positive and negative response rate of 95% and 86% respectively, whereas in the 
current cross-validation positive and negative response rates of only 47% and 81% were found. 
There are several possible explanations for these findings.  
Clinical prediction rules developed in relatively small patient samples, which is not uncommon in 
medicine, generally perform less well in replication studies using independent samples. Therefore, 
cross-validation is necessary to assess the performance of clinical prediction rules in future patients 
(13). The original clinical pharmacogenetic model was developed in early RA patients who were 
DMARD naïve (7). In that same study, the model was validated in a small sample of early-onset 
DMARD-naïve RA patients from another hospital. In the current study, the model was applied in 
RA patients with established disease and a history of DMARD use, notably SSZ. By taking a differ-
ent population, it was tested whether the model would be applicable for predicting MTX non-
response in patients for whom MTX is not the first DMARD. 
The MTX response in the present study was less in comparison with the MTX response in the study 
in which the clinical pharmacogenetic model was derived (7). Only one-third of the patients reached 
a response as defined by a DAS>2.4 at 6 months after start of MTX mono-therapy. These patients 
therefore appear to be more therapy-resistant, but also MTX dosages were lower than in the original 
study. Since MTX dosage was increased according to the discretion of the treating rheumatologist, 
the median MTX dosage of 15 mg/week at 6 months after initiation was less in comparison with 
recent tight control strategies in treating RA (2,14). Previously, it has been shown that tight disease 
control with increased MTX dosages, up to 30 mg/week, will lead to increased response rates even 
after re-employment after previous MTX failure (15-17). The clinical pharmacogenetic model was 
also based on a tight control strategy with increased dosages MTX, including folic acid suppletion 
(7). Therefore, it might be that MTX non-responders in our inception cohort would have been res-
ponders if treated with tight-control strategies instead of daily practice. 
Yet, it also has been shown that RA patients failing previous DMARD monotherapy have an in-
creased likelihood to fail on the next DMARD after switching (18,19). In this context, RA patients 
with longer disease duration do not respond as well to treatment compared with patients with early 
disease (9). Further, patients with DMARD failure are a subset of all patients. As a consequence, 
predictive factors for response may differ as well. In contrast with the original study, in the present 
study gender appeared to have no predictive value, and smoking appeared to be associated with 
response instead of non-response. The latter may have been caused by the fact that in the current 
study, smoking was only assessed at diagnosis, not at start of MTX which was in median 19 months 
later. Also, menopausal status was not assessed, but menopausal state is not of influence in calculat-
ing the risk score (7). 
Interestingly, our results suggest that the clinical prediction model is capable to predict non-
response to MTX also in patients with previous DMARD failure. This is despite the fact that the 
variables ‘disease duration’, ‘number of previous DMARDs’, and ‘previous SSZ use’ did not improve 
the clinical (nongenetic) model. The pharmacogenetic model showed no substantial improvement 
over the clinical model in this study. Failure on previous DMARDs, notably SSZ, could select pa-
tients into a subsample for which the proposed genetic factors are not discriminative. However, in 
our study there appeared to be no selection in direction of the less favorable genotypes, as the gene 
frequencies in this study were similar to the frequencies as expected based on the HapMap-CEU 
sample and similar to the frequencies as found by Wessels et al. earlier (7,20). Therefore, it remains 
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yet unclear whether the four selected genetic variants are true markers for MTX response (21,22). 
Fine mapping of these and other genes related to MTX treatment outcome is necessary in order to 
probably detect better pharmacogenetic factors for MTX response. Large collaborations between 
groups and continued collection of patients and data on MTX pharmacogenetics in RA are still 
needed in order to validate the pharmacogenetic model, in DMARD naïve early-onset RA treated 
with MTX according to a tight control strategy. In addition, the robustness of the pharmacogenetic 
model could also be tested by cross-validation in a larger population of patients again with estab-
lished RA and previous DMARD failure, treated according to a tight control strategy. 
In conclusion, the pharmacogenetic model predicts the efficacy of MTX monotherapy better in 
DMARD naive recent-onset RA patients than in patients with preceding DMARD failure. Updating 
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Previously, comparison of genetic, demographic and other clinical factors between methotrexate 
(MTX) responders and nonresponders has led to a clinical pharmacogenetic model including 4 ge-
netic polymorphisms and 4 nongenetic factors to predict MTX therapy outcome. The aim of this 
study is to validate this predictive model in Swedish patients with recent-onset RA. 
 
Methods  
Genetic and nongenetic factors were collected in 355 patients participating in the Swefot clinical 
trial. All patients received up to 20 mg MTX monotherapy weekly for 3 to 4 months. After this 
treatment period, efficacy was evaluated by Disease Activity Score (DAS28). Based on individual 
scores calculated by factors compromising the prediction model, patients were classified as pre-
dicted responders, nonresponders and intermediate responders. Hereby, predicted response and 
observed response on MTX were compared by calculating accuracy, true negative and true positive 
predictive values (TNPV and TPPV) and by constructing receiver operating curves (ROC). Further-
more, predictive values of the original BeSt cohort, in which the predictive model was derived, and 
the validation cohort were compared. 
 
Results  
At baseline, no significant differences in frequencies of genetic and nongenetic factors compromis-
ing the predictive model were observed between this validation cohort and the BeSt cohort. With 
application of the model, the TNPV and TPPV observed in patients of the validation cohort, were 
significantly lower compared to the values observed in the original cohort (for TPPV 70% vs. 95%; 
for TNPV 68% vs. 86% respectively; all p<0.05). Regarding the number of classifiable patients, the 




In this study, a pharmacogenetic model for predicting efficacy of MTX in patients with RA was vali-
dated. Our data imply that response prediction with this model is feasible in a substantial part of the 
patients. In order to implement this model in rheumatology clinical practice, additional replication 
and (ideally) performance of prospectively designed studies is eligible. 
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Introduction 
 
Over the last two decades, several genetic risk factors for RA like HLA-DRB1 (shared epitope) and 
PTPN22 have been introduced (1;2). Besides the diagnostic ability of genetics, it has been demon-
strated, although to a lesser extent, that genetics could also influence treatment outcome in RA pa-
tients (3-5). Intelligibly, a pharmacogenetic effect could be an explanation for the high variability of 
effective drug responses, up to 30-40%, between RA patients in large clinical trials (6;7).  
Most genetic factors in relation to RA treatment outcome have been studied with MTX as the drug 
under study. Specifically, increasing knowledge about the hypothetical mechanism of  MTX action 
and its role in the inflammatory pathway in RA has led to a substantial number of candidate genetic 
variants, mostly single nucleotide polymorphisms (SNPs), potentially influencing its efficacy in RA 
patients (8). However, genetics can not solely account for variability of effective drug response. Clin-
ical and demographic factors, like disease activity- and rheumatoid factor (RF) status, have been 
shown to be related with treatment outcome (9-11). Still, only a part of the reported pharmacogenet-
ic studies have also included nongenetic factors for the association with treatment outcome. Howev-
er, in order to detect an individual or a synergystic effect of biomarkers on MTX response, genetic- 
and nongenetic factors should be analyzed collectively.  
In a previous study of our group, comparison of genetic, demographic and other clinical factors be-
tween MTX responders and nonresponders led to a clinical pharmacogenetic model to predict MTX 
therapy outcome in a Dutch cohort of patients with early RA (12). This model demonstrated a true 
positive (predictive) rate of 95% and a true negative (predictive) rate of 86% and was able to categor-
ize 60% of the patients into responders or non-responders defined as achieving DAS >2.4 and DAS 
≤2.4 at 6 months, respectively. Despite the potential ability of the model to predict MTX efficacy, 
validation in larger cohorts is required before this pharmacogenetic model can assist rheumatolo-
gists in treatment-decision making. Therefore, the aim of this study is to validate the performance of 
this previously designed predictive model in an independent Swedish cohort of patients with recent-
onset rheumatoid arthritis treated with MTX monotherapy (Swefot). 
 
 
Patients and methods 
 
RA patients 
The 355 patients enrolled in this study are originated from a cohort participating in the “Swedish 
Pharmacotherapy” (Swefot) randomized clinical trial (13). In this trial, the addition of conventional 
DMARDs was compared with the addition of anti-TNFα drugs in patients with early rheumatoid 
arthritis (RA), who had failed initial treatment with MTX at 3 to 4 months.  
Patients were recruited by rheumatologists in fifteen rheumatology units in Sweden, which collabo-
rated in this study. Inclusion criteria contained a diagnosis of RA according to the revised ACR 
(formerly ARA) criteria; RA symptom duration of less than 1 year; no prior disease modifying anti-
rheumatic drug (DMARD) therapy; no oral glucocorticoid therapy or stable glucocorticoid therapy 
for at least 4 weeks of at most 10 mg daily prednisolone (or equivalent); Disease Activity Score 
(DAS) based on 28-joint count of more than 3.2. Exclusion criteria were contraindications to any of 
the trial medications, and prior treatment with any DMARD. All patients gave written informed 
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Study design  
In the Swefot trial, all patients (n=487) started with MTX monotherapy at an initial dose of 10 mg 
weekly. This dosage was increased biweekly by 5 mg increasing to a maximum of 20 mg weekly. 
Next to MTX, folic acid suppletion was prescribed in tablets of 5 mg to be taken 1-6 times weekly. In 
this study, monitoring of liver enzymes and blood counts was performed and abnormalities could 
lead to dose adjustments based on well-established clinical routines.  
At a follow-up visit at least 3 and at most 4 months after the baseline visit, disease activity scores 
(DAS28) (14) were estimated. If patients were responders on MTX therapy (defined in the protocol 
as DAS28 <3.2), MTX was continued and patients were followed in usual care. If patients did not 
obtain response (defined as DAS28 >3.2), patients were randomized to either arm A (the addition of 
sulphasalazine plus hydroxychloroquine) or arm B (the addition of infliximab) according to the 
study protocol (REF Swefot study).  
Patients who received MTX monotherapy and were evaluated at the follow-up visit at least 3 and at 
most 4 months after the baseline visit and for whom DNA samples were available (N=355) were 
included in the current analysis.  
 
Clinical evaluation 
The clinical pharmacogenetic predictive model was based on obtaining good clinical response as 
defined by DAS44 (12). Specifically, responders were defined as patients who were receiving MTX 
and had a DAS of ≤2.4 (good clinical response). Nonresponders were defined as patients who were 
receiving MTX and had a DAS of >2.4.  
Notably, the original model is based on the DAS44 which includes a 44-joint count. In order to vali-
date the predictive model in the SWEFOT data, main clinical endpoint for each patient in the Swefot 
cohort was converted: patient’s DAS28 scores (based on 28 joints) were recalculated to DAS scores 
based on a 44-joint count (DAS44) using the transformation formula: DAS28= (1,072 X DAS44) + 
0,938 (15).  
Of the 355 patients included for the efficacy analysis, patients were unavailable for efficacy analysis 
due to lack of information about RF status (N=3), missing DAS at baseline and/or after 3-4 months 
(N=4) or due to incomplete genotype data (N=15). Consequently, remaining patients (N=333) were 
included for validation of the predictive model. 
 
Genotyping 
The standard method used for DNA extraction is modified salting-out method. SNPs for analysis in 
this study were selected according to the genetic polymorphisms previously included in the pharma-
cogenetic model (12). The selected SNPs were in genes coding for adenosine monophosphate dea-
minase (AMPD1), aminoimidazole, carboxamide ribonucleotide transformylase (ATIC), inosine 
triphosphate pyrophosphatase (ITPA) and methylenetetrahydrofolate dehydrogenase (MTHFD1). 
Specifically, these SNPs were analyzed: AMPD1 34C>T (rs17602729), ITPA 94A>C (rs1127354), 
ATIC 347C>G (rs2372536) and MTHFD1 1958G>A (rs17850560).  
The method used for genotyping was TaqMan allelic Discrimination (Applied Biosystems, Foster 
City, U.S.A.). 5’ Nuclease assay was performed according to a standard protocol in a 384-well format 
with 10 ng of DNA per sample. Detection of the final fluorescent signals from probes, which targeted 
alleles for each SNP, was performed at 7900 Sequence Detector (Applied Biosystems, Foster City, 
U.S.A.). 
During the genotyping the following frequency distributions of these SNPs were observed: for 
AMPD1 34C>T, 74% CC, 24% CT, 2% TT; for ITPA 94A>C, 1% AA, 14% AC, 85% CC; for ATIC 
347C>G, 47% CC, 42% CG, 11% GG and for MTHFD1 1958G>A, 27% GG, 49% GA, 24% AA. Geno-
type frequencies for all 4 SNPs were in Hardy-Weinberg equilibrium in this cohort (p>0.05). The 
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success rates for each SNP were as follows: for AMPD1 34C>T 99%; for ITPA 94A>C 98%, for ATIC 
347C>G 99% and for MTHFD1 1958G>A 98%. 
 
Statistical analysis 
Swefot data were analysed for validation of the previously designed predictive model for MTX effi-
cacy in the BeSt cohort (12). Briefly, reciprocal comparison in multivariate regression analyses of 17 
polymorphisms and 24 nongenetic factors in the BeSt cohort led to a predictive model for MTX 
efficacy. This model consisted of gender, RF and smoking status, the DAS at baseline, and 4 SNPs in 
the AMPD1, ATIC, ITPA, and MTHFD1 genes. Each patient was scored based on the regression 
coefficients of the independent variables and categorized in three groups: patient with scores of ≤3.5 
(predicted response), patients with scores between 3.5 and 6 (predicted intermediate response) and 
patients with scores of ≥6 (predicted non-response). Additionally, a nongenetic model was devel-
oped based on gender, RF and smoking status, the DAS at baseline, which led to a subdivision of 
patients based on achieving a score of ≤2 (predicted responder), a score of >2 but <5.5 (intermediate 
predicted responder) and a score of ≥5.5 (predicted nonresponder).  
For initial analysis in this study, baseline factors (included the prediction model) between patients in 
the BeSt cohort and the validation cohort were compared using chi-square test. Next, Swefot pa-
tients were individually scored based on the sum of points obtained by each baseline factor included 
in the original predictive model. Based on these calculated scores, patients were classified in one of 
the three groups of predicted response according to the original pharmacogenetic- and nongenetic 
model. Predicted response and observed response on were compared by calculating true negative 
and true positive predictive values (TNPV and TPPV) and levels of accuracy. Specifically, accuracy 
was calculated by the proportion of true results (the number of true positives en negatives) in the 
patient population.  
Additionally, receiver operating characteristic (ROC) curves were constructed to evaluate the dis-
criminative performance of the pharmacogenetic model in comparison with the nongenetic model 
in the SWEFOT cohort. Finally, levels of accuracy, ROC curves and TNPV and TPPV between the 
BeSt cohort and the validation cohort were compared using a chi-square test.  
Notably, due to the absence of information on smoking status in the Swefot cohort, smoking status 
per individual could not be applied in the pharmacogenetic model. In this way, the maximum num-
ber of points which could be obtained was 10.5 (Table 1). Also, due to this absence  the nongenetic 
model could not be optimally tested in the Swedish validation cohort and was therefore left out of 
the analysis.  






The response of the included RA patients (N=333) at 3-4 months after start with treatment of MTX 
monotherapy was 41% according to DAS44 ≤2.4. This was not significantly different in comparison 
with obtained good clinical response of patients in the original BeSt cohort at 6 months (41% vs. 
47%; p>0.05) (12). In addition, no significant differences in baseline factors included the prediction 
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Table 1. Comparison of baseline factors between patients in the original (BeSt) cohort and pa-
tients in the validation (Swefot) cohorta,b 
 
a. Abbreviations: AMPD1= adenosine monophosphate deaminase; ATIC= aminoimidazole, carboxamide ribo-
nucleotide transformylase; ITPA= inosine triphosphate pyrophosphatase; MTHFD1= methylenetetrahydrofolate 
dehydrogenase; DAS= Disease activity score  
b. No significant differences between the validation cohort and the   population were observed for gender, DAS at 
baseline (based on quartiles), RF status and MTHFD1, ATIC, AMPD1, and ITPA genotype frequencies (p>0.05) 
 
 
Variable Score Original cohort in % (N=186) 
Validation co-
hort in %  
(N=333)b 
   
Gender   
Male 0 30 28 
Female 1 70 72 
DAS at baseline   
≤3.8 0 25 26 
>3.8 and ≤5.1   
2nd quartile 3 25 22 
3rd quartile 3 26 30 
>5.1 3.5 26 23 
Rheumatoid factor   
Negativity 0 32 30 
Positivity 1 68 70 
    
MTHFD1 1958 AA 1 21 23 
AMPD1 34 CC genotype 1 74 75 
ITPA 94 A-allele carrier 2 15 15 
ATIC 347 G-allele carrier 1 53 53 
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Validation of the pharmacogenetic model in the Swedish cohort  
Assigned scores as defined by the pharmacogenetic model for the Swedish cohort ranged from 1 to 
10.5. Application of the pharmacogenetic model cut off values for predicted (non)response to MTX 
monotherapy resulted in a TPPV rate of 70% (38 of 54 patients) and a TNPV rate of 68% (122 of 179 
patients). In total, 233 patients (70%) in the Swefot cohort were classified as either predicted res-
ponder or nonresponder, whereas 100 patients (30%) were classified as predicted intermediate 
responders (Table 2). Hereby, the accuracy of the model in this cohort of patients was 48%, which 
represents the proportion of true results (TP+TN/All patients= 33+122/333). 
In figure 1, a ROC of the pharmacogenetic model is demonstrated. Hereby, the discriminative ability 










Observed response    
    
Pharmacogenetic model    
Responder (DAS ≤2.4) 38 42 57 
Nonresponder (DAS >2.4) 16 58 122 
Total 54 100 179 
 
Table 2. Comparison of the number of observed and predicted response to MTX therapy at 3-4 
months for patients in the validation (Swefot) cohorta,b 
 
a. Predicted response = DAS ≤3.5, Predicted intermediate response = DAS >3.5 & DAS <6.0, Predicted nonres-
ponse = DAS ≥6.0 
b. Abbreviations: DAS= Disease activity score. 
 
 
Comparison performance original cohort and validation cohort  
TPPV and TNPV demonstrated in this analysis, were significantly lower in the validation cohort 
compared to the predictive values observed in the original cohort (for TPPV 70% vs. 95%: p<0.0001 
and for TNPV 68% vs. 86%: p=0.004, respectively) (12). Regarding the number of patients classi-
fied, level of accuracy of the model and AUC no significant differences were found between the Swe-
fot cohort and BeSt cohort (for number of patients classified 70% vs 60%: p=0.182; for accuracy 
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Figure 1. Receiver operating characteristic curve for predicting response to methotrexate in the 




 Original Cohort in % 
(N=186) 
Validation cohort in % 
(N=333)b 
P-valueb 
Predictive values    
N of patients classified (%) 60 70 0.182 
TPPV (%) 95 70 0.0001 
TNPV (%) 86 68 0.0040 
Accuracy (%) 53 48 0.572 
AUC (%) (95% C.I.) 86 (80-91) 75 (70-81) 0.111 
 
Table 3. Comparison of predictive values for response to MTX therapy at 3-4 months for patients 
in the validation (Swefot) cohorta and patients in the original (BeSt) cohorta,b 
 
a. Abbreviations: AUC= area under the curve; TPPV= true positive predictive values; TNPV= true negative predic-
tive values 
b. Tested by chi-square test 
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Discussion 
 
In this study, a model for predicting the efficacy of MTX monotherapy was validated in a cohort of 
Swedish RA patients (Swefot). Importantly, no significant differences in frequencies of genetic and 
nongenetic factors compromising the predictive model were observed between this validation co-
hort and the BeSt cohort at baseline. Application of this pharmacogenetic model resulted in a TPPV 
rate of 70% and a TNPV rate of 68%. In total, 233 patients (70%) were classified as either predictive 
responder or nonresponder. With application of the model, the TPPV and TNPV observed in pa-
tients of the validation cohort were significantly lower compared to the values found in the original 
cohort. However, for the predictive values accuracy, number of patients classified and AUC the re-
sults were comparable. Overall, these validation data imply that efficacy of a substantial part of early 
RA patients treated with MTX could be predicted by this clinical pharmacogenetic model.  
Interestingly, the performance of the pharmacogenetic model was already found to be comparable 
at initial validation in a separate, but much smaller, group of Dutch RA patients (N=38) in the origi-
nal manuscript (12). In this Dutch group TPPV rate was 70 % and TNPV rate was 68%, whereas 
68% of the patients could be categorized as either predictive responder or nonresponder. However, 
in comparison with the original BeSt cohort significant differences were observed concerning TPPV 
and TNPV. Several explanations are possible to declare these differences. 
Firstly, differences in the performance of the model may partially be due to the lower response rate 
achieved (DAS ≤2.4) in the validation cohort with a smaller period of time on MTX therapy before 
evaluation of response compared with the original cohort (41% at 3 months vs. 47% at 6 months, 
respectively).  
Next, no significant associations of the four individual SNPs included in this model and treatment 
response were found in the validation cohort (p>0.05). In the analyses of the original BeSt cohort, 
the four genetic variants increased the AUC of the pharmacogenetic model with 9% compared with 
the nongenetic model (85% vs. 76%, respectively) (12). However, in the validation cohort, a clear 
difference between AUCs of the pharmacogenetic- and nongenetic models could not be analyzed 
due to absence of smoking status. Conclusively, it remains unclear, if the four variants are true 
markers for MTX response, if other variants in the four genes are responsible for the effect on 
treatment outcome, ór whether the extent of genes or the effect of other genes involved in the me-
chanism of action of MTX is more important than the current genes. Since the MTX responsive 
phenotype may be considered polygenetic, selecting SNPs according to a candidate gene (mono- or 
oligogenetic) approach will repeatedly lead to only a limited explanation of variance in MTX re-
sponse. Hereby, other genes could be more involved in MTX’s mechanism of action than MTHFD1, 
ATIC, AMPD1, and ITPA. Future research on the mechanism of action of MTX is therefore required.  
Finally, in this study the DAS28 of each patient was converted to the original DAS based on a 44 
joint count. However, since cut-off criteria for response are applied to these scores, different re-
sponse rates could be observed. Specifically, in the Swefot trial, patients were defined as responder if 
a DAS28 of less than or equal to 3.2 was achieved. Responders in the BeSt study were defined as 
achieving an original DAS of less than or equal to 2.4. Comparison of these response rates revealed 
that 18 patients were defined responder according to DAS, but nonresponder according to DAS28. 
These patients account for almost 13% of the patients in the DAS responder group. Hypothetically, 
due to a different observed response distribution in the validation cohort, different predictive values 
could be the result. Therefore additional analyses were performed considering responders according 
to DAS, but were nonresponder according to DAS28 (n=18), as nonresponders. Regarding the 
number of patients classified, TPPV, TNPV, accuracy and AUC, no significant differences compared 
with the results in table 3 were found (data not shown).    
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The additional recommendation for classification of patients in the intermediate group at baseline, 
as reported in our previously study (achieving a decrease of >1.2 or ≤1.2 in DAS at 3 months) (12), 
was left out of the validation analyses. Notably, no data was present due to alternative study design 
of the Swefot clinical trial. 
In general, lower values for the Swefot cohort of patients found in this study (except for the number 
of patients classified) were anticipated. Namely, effect sizes found by association studies could ap-
pear to be smaller, but closer to a genuine effect size, than the first reported effect size (16). A well-
designed meta-analysis of comparing the effect size (e.g. TPPV) with this predictive model in more 
cohorts of patients could provide the most optimal legitimate effect size. 
Screening for markers in serum of patients with arthritis is a helpful tool and common practice in 
rheumatology diagnostics. For example, in a meta-analysis by Nishimura et al it was demonstrated 
that the sensitivity and specificity of testing for RF status within RA patients was 69% and 85% (17). 
Notably, this meta-analysis included studies that evaluated patients for the utility of RF for diagnosis 
or suspected RA. The sensitivity and specificity could be recalculated to a TPPV of 82% and a TNPV 
of 72% for the diagnosis of RA by testing for RF positivity. Interestingly, these predictive values, 
explained by RF-status, are comparable with the values regarding the predictive model’s TPPV and 
TNPV found in our study. In this way, testing for response to MTX monotherapy in recent-onset RA 
patients prior to treatment appears to be qualitatively equivalent to testing for RF status to diagnose 
RA in clinical practice. 
In this study, a pharmacogenetic model for predicting the efficacy of MTX in patients with RA was 
validated. Notably, the exact role as predictive markers of response for the four genetic polymor-
phisms included in this model remains to be determined by future studies. Still, our results demon-
strate that predicting treatment response is feasible in RA. Additional replication and (ideally) per-
formance of prospectively designed study with this model in large cohorts is warranted to demon-
strate the legitimate predictive value in rheumatology practice.  
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Two nonsynonymous genetic variants within the methylenetetrahydrofolate reductase (MTHFR) 
gene, MTHFR 677C>T (rs1801133) and MTHFR 1298A>C (rs1801131), have been extensively stu-
died over the last decade. It has been demonstrated that these single nucleotide polymorphisms 
(SNPs) cause an amino acid replacement at codon 222 (Ala222Val) and at codon 429 (Glu429Ala), 
respectively (1;2). Additional haplotype analyses have revealed that these polymorphisms are in 
linkage disequilibrium (LD), meaning that a combination of C and A alleles of the two SNPs occur 
more frequently in a population than would be expected on a random basis (3).  
MTHFR is a key enzyme in the folate pathway, which catalyzes the conversion of homocysteine to 
methionine for a variety of metabolic reactions (4). In vitro studies have demonstrated that MTHFR 
677C>T and MTHFR 1298A>C, are associated with diminished enzyme activity of MTHFR leading 
to homocysteinemia and a disturbed folate balance (1;2;5). Moreover, a functional interaction be-
tween these two SNPs have been observed, which resulted in a synergistic effect on MTHFR enzyme 
activity (6).  
Alteration of enzymatic function related to these SNPs might modulate disease susceptibility, but 
studies also have proposed MTHFR 677C>T and MTHFR 1298A>C as genetic determinants of clin-
ical therapy outcome. These studies have mainly been performed with MTX (7-10). Notably, MTX 
functions as a folate antagonist, which inhibits indirectly MTHFR. Recently, a meta-analysis re-
ported that the MTHFR 677C>T polymorphism was significantly associated with increased toxicity 
in rheumatoid arthritis (RA) patients on MTX treatment (11). Regarding efficacy, opposing results 
have been found for MTHFR 677C>T and MTHFR 1298A>C, whereas most of the performed stu-
dies did not find any association (12-17). Notably, a substantial part of the studies did not take lin-
kage disequilibrium between these two MTHFR SNPs into account. Only a few studies have ex-
amined associations between haplotypes of MTHFR 1298A>C and MTHFR 677C>T and MTX effi-
cacy in RA patients. In the reports of Urano et al and Taniguchi et al no significant associations of 
response defined as lower MTX dosages and the haplotype MTHFR 1298A-677C were found 
(16;18). In addition, in the study of Urano et al, carriers of the MTHFR 1298C-677C haplotype did 
show a relation with lower MTX dosage (18). Furthermore, Hughes et al reported no significant 
associations with MTX treatment outcome with any of the haplotypes comprising MTHFR 
1298A>C and MTHFR 677C>T (14). In the study of Kurzawski et al a lower probability of remission 
was seen in patients genotyped for MTHFR 1298AA and 677CC in comparison with patients with 1 
or 0 copies of 677C-1298A. Moreover, the presence of both 677T and 1298C alleles was associated 
with an increased frequency of remission (8).  
We have reported that MTX treated RA patients genotyped for MTHFR 1298AA and 677CC were 
associated with efficacy (19). Additional analyses demonstrated that the number copies of the haplo-
type as determined by the 1298A-677C SNPs importantly strengthened the association with good 
clinical improvement (achieving an improvement of DAS >1.2) at 6 months. 
Previously, we developed a pharmacogenetic model in combination with clinical factors to predict 
MTX efficacy in recent-onset RA. In this study it was reported that the clinical factors gender, rheu-
matoid factor combined with smoking status and disease activity at baseline together with genetic 
factors were predictive for MTX response. The included genetic factors were the SNPs AMPD1 
34C>T, ATIC 347C>G, ITPA 94 A>C and MTHFD1 1958G>A. The prediction resulted in the classi-
fication of 60% of the RA patients into MTX responders and nonresponders (defined as achieving 
DAS >2.4 or DAS ≤2.4, respectively), with a 95% and 86% true positive and negative response rate, 
respectively. Thus 40% of the patients (n=74) could not be classified resulting in a group with a pre-
dicted intermediate probability of response to MTX (a score between 3.5 and 6 points). For these 
patients an evaluation was added using good clinical improvement at 3 months as an intermediate 
94
The influence of the number of haplotypes of MTHFR 1298A-677C alleles on the predicted probability 
to respond to methotrexate in early RA patients
endpoint. This would enable clinicians to decide on continuation or alteration of MTX therapy at an 
early stage of treatment and could possibly prevent treatment delay of three months (unnecessary 
MTX exposure due to inefficacy). Still, with the addition of this interim evaluation, categorization 
into responders and nonresponders at 6 months remained suboptimal. Regarding the influence of 
MTHFR 1298A>C and MTHFR 677C>T and particularly their haplotypes on achieving good clinical 
improvement, addition of these genotypes to the pharmacogenetic model to improve categorization 
of patients in the predicted intermediate response group could be beneficial.  
In this paper, it is aimed to assess the discriminative performance of the pharmacogenetic predictive 
model by the addition of the number of copies of the MTHFR 1298A-677C haplotype. Also, it is 
aimed to increase the percentage of patients for which the pharmacogenetic model predicts re-






Characteristics of the patients enrolled in this study are similar to characteristics earlier described by 
our group (19;20). Briefly, the 205 patients enrolled in this study comprised a subcohort of the pa-
tients participating in the BeSt study. Main inclusion criteria were a diagnosis of early RA as defined 
by the American College of Rheumatology (ACR) 1987 criteria for RA (21), age ≥18 years, symptom 
duration of <2 years and active RA according to the BeSt study protocol (22). Main exclusion criteria 
were previous treatment with DMARDs other than antimalarials and concomitant treatment with 
an experimental drug. Further details have been published elsewhere (22). The local ethics commit-
tee at each participating hospital approved the study protocol. All patients gave informed consent 
before enrolment into the study.  
 
Study design and evaluation of clinical efficacy 
The discriminative performance of the pharmacogenetic model was defined as the difference in area 
under the curves (AUCs), obtained by plotting receiver operating curves (ROCs), between curves 
with and without inclusion of two copies of the haplotype into the model. Notably, AMPD1 34C>T, 
ITPA 94C>A, ATIC 347C>G and MTHFD1 1958G>A have been related with good response at 6 
months (defined as obtaining a DAS ≤2.4) (23). Therefore, the discriminative performance of carry-
ing 1 or 2 and 2 copies alone of the MTHFR haplotype in comparison with these four good response-
related SNPs were presented according to the endpoint good response at 6 months. For this analysis 
205 patients were included in the study. Of these,  74 patients were predicted having an interme-
diate probability of response to MTX  (20) and this cohort was analysed for increasing the percen-
tage of patients for which the pharmacogenetic model predicts  response or nonresponse by incor-
porating the number of copies of the haplotype. Hereby, the primary goal was good clinical im-
provement (achieving an improvement of DAS >1.2) at 3 months.  
 
Genotyping 
DNA isolation, genotyping techniques and success rates of the SNPs MTHFR 1298A>C, MTHFR 
677C>T, AMPD1 34C>T, ATIC 347C>G, ITPA 94 A>C and MTHFD1 1958G>A were as previously 
described (19;23).  
 
Statistical analysis 
Frequencies of the number of copies of the MTHFR haplotypes were calculated using chi-square 
tests. Additionally, the estimated probability for achieving good response was calculated for each 
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individual patient by adding the number of MTHFR haplotype to the prediction model. Next, re-
ceiver operating characteristic (ROCs) were derived to demonstrate the discriminative performance 
of the model with and without 1 or 2 and 2 copies alone of the MTHFR haplotype. In the predicted 
intermediate responders, associations of genotypes and haplotypes with treatment outcome were 
analyzed using chi-square tests and/or Fisher exact tests.   





Assessment of the discriminative performance of the pharmacogenetic predictive 
model by the addition of the number of copies of the MTHFR 1298A-677C haplotype. 
In the cohort (N=205) the following haplotype distributions were present: for 2 copies 677C-1298A 
13% (n=27); for 1 copy 677C-1298A 40% (n=82); for 0 copies 677C-1298A 46% (n=94) (Table 1).  
No differences in predicted probability with the addition of number of copies of the haplotypes as 
predictors for good response were found (p>0.05). Specifically, similar AUCs were observed for all 
three ROC curves, as depicted in figure 1 (AUC=86% and 95% C.I.= 81-91%). Furthermore, compar-
ison of ROC curves showed that the AUCs of the MTHFR 1 or 2 and 2 copies genotypes were smaller 
compared to the AUCs of other SNPs included in the model (table 2- ROCs not displayed). Specifi-
cally, the discriminative ability (AUC) of both number carriers of the MTHFR haplotype was 50% 
(95%C.I. 40-59%) in comparison with an AUC of 61% of the single SNP ATIC 347 C>G. Also, when 
the AUC of the MTHFR 2 copies genotype was compared with the AUC of AMPD1 34C>T, ITPA 
94C>A, ATIC 347C>G and MTHFD1 1958G>A combined a significant difference was observed 




MTHFR 1298 A>C 
AA AC CC Total 
MTHFR 677C>T CC 27 43 22 92 
CT 39 53 1 93 
TT 18 0 0 18 
Total 84 96 23 203 
 
Table 1. MTHFR 1298A>C and MTHFR 677C>T genotype distribution to demonstrate the num-
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Figure 1. Receiver operating characteristic curve for predicting the response to methotrexate 
with and without the number of copies of the MTHFR 1298A-677C haplotype   
 
Abbreviation(s): MTHFR= methylenetetrahydrofolate reductase. 
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SNPs AUC in % (95% C.I.) 
MTHFR 2 copies vs. 0 or 1 50% (42-59%) 
MTHFR 1 or 2 copies vs. 0 50% (42-59%) 
ITPA 94 CC vs. CA or AA 56% (47-64%) 
MTHFD1 1958 GG or GA vs. AA 56% (47-64%) 
AMPD1 34 CC vs. CT or TT 57% (49-66%) 
ATIC 347 CC vs. CG or GG 61% (53-70%) 
 
Table 2. AUCs (95%C.I.) for predicting the response to methotrexate of the number of copies of 
the haplotype MTHFR 1298A-677C, ITPA 94C>A, MTHFD1 1958G>A, AMPD1 34C>T, ATIC 
347C>G 
 
Abbreviation(s): AUC= area under the curve; MTHFR= methylenetetrahydrofolate reductase, 
AMPD1=adenosine monophosphate deaminase, ATIC= aminoimidazole, carboxamide ribonucleotide transfor-
mylase, ITPA= inosine triphosphate pyrophosphatase; MTHFD1= methylenetetrahydrofolate dehydrogenase and 
SNP= single nucleotide polymorphism 
 
 
Optimalization of the clinical pharmacogenetic model to predict methotrexate 
treatment response: the influence of the number of haplotypes of MTHFR 1298A-
677C alleles on probability to respond. 
In the group of patients with a predicted intermediate response to MTX (n=74), the number of hap-
lotypes of the MTHFR 1298A>C and 677C>T SNPs was assessed. The genotypes of the two single 
SNPs were not significantly associated with good clinical improvement at 3 months (data not 
shown). Subsequently, diplotype analyses demonstrated that none of these diplotypes in this specific 
group of patients appeared able to significantly enhance prediction of achieving good clinical im-
provement at 3 months (data not shown). Additionally, trend analyses were performed to explore 
differences in carrying the number of alleles of the 1298A and 677C haplotype (0, 1 and 2). The data 
revealed no significant differences between the number of MTHFR haplotype and good clinical im-
provement at 3 months (table 3).  
 
 
Table 3. Number analysis of the MTHFR 1298A and 677C haplotype between responders and 
nonresponders in patients predicted with an intermediate probability of response to MTX 
(N=74)a 
 
a) Fisher’s Exact Test (One-sided) 
 







2 vs. 0 or 1 4 vs 36 5 vs 29 0.395 
2 or 1 vs. 0 21 vs 19 22 vs 12 0.205 
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Discussion 
 
In this study, it is concluded that the predictive performance of the pharmacogenetic model to pre-
dict the efficacy of MTX therapy in this group of early RA patients is not improved when the 
MTHFR haplotype is included in the model. Moreover, the discriminative effect for the prediction of 
MTX efficacy including 1 or 2 or (solely) 2 copies of the 1298A and 677C haplotype was significantly 
smaller compared with the four SNPs AMPD1 34C>T, ITPA 94C>A, ATIC 347C>G and MTHFD1 
1958G>A. 
Furthermore, it is observed that incorporation of the number of alleles of the favorable MTHFR 
1298A en 677C haplotype (0, 1 or 2) into the predictive model does not lead to improvement of the 
number of classifiable patients in those with an intermediate probability of response to MTX. How-
ever, some remarks have to be made concerning the analysis of the MTHFR haplotype.  
Notably, current analyses were performed in Caucasian patients. In this way, our results can not 
easily be compared with studies representing other ethnicities. This is demonstrated in the study of 
Hughes et al (14), which revealed significant differences in haplotype distribution between Cauca-
sians and African-Americans. Namely, alternative distributions in haplotypes between ethnic groups 
are caused by differences in allele frequencies of the two SNPs in these groups resulting in different 
values for D’ (D-prime), a value ascribing LD. Specifically, Hughes et al (14) reported that the D’ 
value for the two SNPs was 0.955, indicating strong LD. However, in African-Americans the D’ value 
is much lower (0.408), indicating less linkage disequilibrium (www.hapmap.org). Alternative values 
of linkage disequilibrium could therefore explain the different results seen in the reports of Urano et 
al (18) and Taniguchi et al (16), which studied the influence of the haplotype on response in patients 
with Asian backgrounds. Furthermore, the degree of LD could be biased by the number of patients 
under study, since small numbers of included patients may lead to differences in haplotype distribu-
tion. 
Also, to elucidate an additive effect of the number of risk haplotypes on treatment outcome, a gene 
dose effect is informative. Hereby, a gene dose effect compromises a linear relationship between the 
number of haplotypes and clinical response. In a part of above described studies, this specific trend 
is not seen. For example in study of Kurzawski et al (8), patients carrying 1 haplotype MTHFR 
1298A-677C showed increased response when compared with patients carrying 0 or 2 haplotypes 
meaning that a gene dose effect was lacking. In this way, a clear biological explanation for involve-
ment in MTX efficacy remains difficult to acquire. 
Finally, it has been demonstrated that the pathophysiological consequences of MTHFR genetic va-
riants (especially the C677T polymorphism) are significantly affected by demographic and environ-
mental factors such as nutritional (folate) status age, smoking and alcohol intake, parameters that 
may bias genetic associations with therapy outcome to MTX (24-26). Therefore, multivariate analy-
sis including these confounding factors is inevitable. Regarding our analyses, no significant changes 
in results are expected.  
In conclusion, incorporation of the number of alleles of the MTHFR 1298A and 677C haplotype (0, 1 
or 2) into the pharmacogenetic model did not lead to improvement of the model, since no associa-
tions with achieving good clinical improvement at 3 months (ΔDAS>1.2) were seen in patients with 
an intermediate probability of response to MTX. Moreover, the results presented in this paper sug-
gest that a (leading) role for the MTHFR 1298A and 677C haplotype with regard to predicting effica-
cy of MTX monotherapy in early RA patients seems unlikely. Future research is necessary to eluci-
date the exact pharmacogenetic and biological role of MTHFR 1298A>C and MTHFR 677C>T and 
their haplotypes in the efficacy of MTX in RA. 
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Etanercept, infliximab and adalimumab have shown clinical benefit in immune-mediated 
inflammatory diseases; however, the outcome of treatment with these tumour-necrosis factor inhi-
bitors remains insufficient in 40–60% of individuals with rheumatoid arthritis. Moreover, their use 
is accompanied by adverse events and unintentional immune suppression. Pharmacogenetics has 
the potential to increase efficacy and ameliorate adverse events and immune suppression, and its 
application might be of clinical benefit for patients with rheumatoid arthritis. Pharmacogenetic stu-
dies have shown associations between single nucleotide polymorphisms in genes encoding enzymes 
related to the pharmacodynamics and pharmacokinetics of these drugs and treatment outcome. As 
we discuss here, replication and prospective validation are warranted before pharmacogenetics can 
be used in clinical practice. 
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Introduction 
 
Although the pathogenesis of many autoimmune diseases including rheumatoid arthritis remains 
unknown, studies have shown that tumour-necrosis factor-a (TNFα) has a key role in the inflamma-
tory process of these immune-mediated disorders. TNFα is known to play a leading role in stimulat-
ing cytokine (including its own) and chemokine production, in enhancing neutrophil, chondrocyte 
and osteoclast activation, expression of adhesion molecules. Also, it facilitates also as a co-stimulator 
of T-cell activation and antibody production by B cells (1;2). 
Consequently, TNFα has emerged as an important target in novel therapeutic strategies used to treat 
rheumatoid arthritis. The anti-TNF targeting drugs currently used in daily clinical practice are eta-
nercept (Enbrel®), infliximab (Remicade®) and adalimumab (Humira®). Etanercept is a human, 
soluble, dimeric TNF type II receptor linked to an IgG1 Fc half that binds to and inactivates TNFα. 
The chimaeric IgG1 monoclonal antibody infliximab and the complete humanized IgG1 monoclonal 
antibody adalimumab bind to TNFα with high affinity and 
thereby inactivate it. The therapeutic effect of these biological agents is achieved by blocking the 
potential interaction of TNFα with the accessory TNF cell-surface receptors (3;4). In vivo and (more 
in) in vitro studies have demonstrated that this effects in neutralization and blockage (5;6); interac-
tion with Fc receptor (cross-linkage) (7); initiation of reverse signalling, leading to blockage, in-
creased apoptosis or growth arrest (8;9); reduction of inflammatory cytokine production and angi-
ogenic factor expression (6;10-12); Mediation of complement-dependent cytotoxicity and antibody-
dependent cytotoxicity (5;9); down-regulation or discontinuation of bone and cartilage destruction 
(13;14). In this manner, an expanding array of drug therapy options for the treatment of rheumatoid 
arthritis in the clinic has been established over the past decade (15;16).  
However, high costs, adverse drug events and unintentional concomitant immune suppression, 
leading to serious (opportunistic) infections, present limitations that might prevent the prescription 
of these biological drugs (17;18). For example, Bongartz et al. (19) have provided evidence for a high-
er risk of serious infections (odds ratio (OR) 2.0) and a dose-dependent, increased risk of malignan-
cies (OR 3.3) in patients with rheumatoid arthritis who are treated with anti-TNF antibody therapy. 
Another limitation is that the treatment outcome of the TNF inhibitors remains insufficient in 40–
60% of patients with rheumatoid arthritis (20-22). 
Pharmacogenetics has the potential to increase drug efficacy and to ameliorate adverse events and 
immune suppression. Its application might be of great clinical benefit for individuals affected with 
rheumatoid arthritis. Studies have shown associations between single nucleotide polymorphisms in 
genes encoding enzymes related to the pharmacodynamics of the anti-TNF drugs used to treat this 
disease and treatment outcome. The ultimate aim of using pharmacogenetic markers is to predict 
the probability of a wanted or unwanted drug response 
in individual patients (23). Replication and prospective validation are warranted before pharmaco-
genetics can be used in clinical practice (24). 
Here, we review the potential of pharmacogenetics and its impact on anti-TNF therapy outcome in 
individuals with rheumatoid arthritis.  
 
 
Diagnostics and therapeutics of rheumatoid arthritis 
 
Treatment of rheumatoid arthritis usually follows a stepwise approach that is based on the evalua-
tion of disease activity and radiological progression of joint damage (21). The most commonly used 
measure to evaluate disease activity is the ‘28-joint disease activity score’ (DAS28), which includes 
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an assessment of 28 joints for swelling and tenderness, the erythrocyte sedimentation rate and a 
general health assessment using a visual analogue scale (25). To assess disease activity in clinical 
trials, specific improvement and response criteria have been developed (26). These American Col-
lege of Rheumatology (ACR) improvement criteria are based on a perceptual improvement (20, 50, 
70 and 90%) in disease symptoms (termed ACR20, ACR50, ACR70 and ACR90, respectively). The 
ACR criteria measure only change (dichotomous outcome), whereas the DAS28 measures both 
change and the extent of rheumatoid arthritis (continuous outcome). The validity of both methods 
for describing the results of randomized clinical trials is comparable (25;27). In this way, data inte-
gration is being performed by presenting both criteria in clinical trials. Radiological damage is eva-
luated using the Sharp–van der Heijde score, which assesses erosions and joint space narrowing of 
joints of hands and feet in rheumatoid arthritis (28).  
In daily clinical practice, the design of a therapy plan would ideally be based on monitoring disease 
activity and strict treatment scheduling to prevent functional disability (29). First, patients would be 
treated with disease-modifying antirheumatic drugs (DMARDs), of which methotrexate is the first 
drug of choice (30;31). Should there be an unfavourable response, side-effects and/or drug toxicity, 
therapy would then be escalated to include biological agents, such as TNF inhibitors, either alone or 
in combination with DMARDs, and modifications of the dosing regimen (20;22;32). After the onset 
of disease, tightly scheduled management of treatment is required to maintain efficacy (33). Because 
high and variable disease activity results in joint damage, effective intervention with TNF inhibitors, 
either as a monotherapy or in combination with DMARDs, can halt the progression of radiological 
damage, which consequently translates into a slowing or cessation of functional decline (34;35). 
 
 
Pharmacogenetics of TNF inhibitors 
 
Pharmacogenetics holds the promise not only to explain interindividual variability in drug response, 
but also to predict efficacy and adverse drug events in different patients (23). Importantly, several 
studies have revealed that failure to respond to TNF blocking drugs is not a class effect, but instead 
is related to the individual drug. For example, the response rates to adalimumab have been eva-
luated in patients who were unresponsive to etanercept or infliximab (36). Remarkably, the re-
sponse rates measured were similar to those in patients not previously exposed to TNF blocking 
agents, which makes a class effect of these agents unlikely (20). The results of several studies in 
which anti-TNF treatment has been switched underline the pharmacogenomic independency of 
these drugs (37;38). Therefore, pharmacogenetic results are presented in this review with annota-
tion of the specific TNF inhibitor.  
Studies have gathered considerable information on drug interaction with, and mediation of, the 
cytokine TNFα (2). The fact that these drugs target TNFα has led to interest in TNFα itself as a can-
didate gene for pharmacogenetic association studies. In recent years, many polymorphisms in genes 
encoding proteins related to TNFα have been identified that might be associated with treatment 
outcome. Such candidate gene polymorphisms have been investigated for their ability to predict 
treatment outcome in patients with rheumatoid arthritis receiving anti-TNF drugs.  
The polymorphism in the promoter region of TNF SNP –308A>G is one of the most studied varia-
tion in TNF gene (Table 1). However, results considering an association of infliximab, etanercept or 
adalimumab efficacy with this polymorphism are inconsistent.  For etanercept, six studies reported 
an association with this SNP (39-44) with half of these studies finding an association with clinical 
response. Specifically, patients genotyped for TNF -308 GG were likely to obtain a better response 
compared to patients with an A-allele genotype (40;42;44). This was further elucidated by a meta-
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analysis performed by Lee et al in order to compare the results concerning the TNF –308A>G. After 
inclusion and analysis of six studies, it was seen that patients carrying an A allele have a poorer re-
sponse to anti-TNF therapy than those with the G allele (45). This TNF –308A>G polymorphism 
was also studied in relation with treatment outcome and infliximab. The majority of thee studies 
also found a positive association of the GG genotype with infliximab efficacy (42;44;46-49).  
However, regarding treatment with adalimumab, an association was found with the G-allele, as part 
of a single TNF haplotype (238G/-308G/-857C) and inefficacy (50). Additionally for the SNP -857 
C>T in the TNF gene it was reported that T-allele carriers were associated with a positive response 
to etanercept therapy (41). 
Interestingly, it is hypothesized that altered binding capacities of the two TNFα receptors 
(TNFRSF1A and TNFRSF1B) for TNFα is due to genetic variation in these receptors (51). Therefore, 
SNPs in genes encoding these receptors are linked to treatment outcome in several reports. Initially 
in one study, three SNPs within the TNFRSF1A gene were explored (at positions -609, -580, -383), 
but no associations with response to etanercept was seen (39).  
More data are available about the SNP +676 T>G in the TNFRSF1B gene. Specifically, three reports 
demonstrated a link with the G-allele and inefficacy to infliximab and etanercept, whereas other 
studies reported no effect of this SNP on treatment outcome to all three TNF inhibitors (39;52-55). 
Besides anti-TNFα neutralizing properties, TNF inhibitors may involve in effects via their IgG1 Fc 
fragments, for example by complement activation and binding to cellular Fc-gamma receptors (Fc-
R) (56). Hypothetically, ligation of the low-affinity FcR type IIIA can induce apoptosis in synovial 
macrophages. However, significant effects of FcR IIIA -158V>F on the efficacy of infliximab and 
etanercept were not found  (39;54;56). In contrast, increased efficacy was found with the -158 FF 
genotype in two smaller cohorts of patients treated with either of the three TNF inhibitors (57;58). 
Regarding the SNP -131R>H within FcGR IIA gene, an association was found with a positive clinical 
response and patients with the homozygous wild-type genotype (58).However the whole genetic 
region of the Fc-gamma receptors is characterized by extensive gene duplication and the presence of 
insertions and deletion. This all lead to a highly polymorphic locus and no studies have been pub-
lished that that the full variability of the locus into account. 
It is thought that the pro-inflammatory cytokine IL-1 enhances the inflammatory response in RA 
(2). This is also seen in clinical trials, in which RA patients were successfully treated with the IL1-
receptor antagonist anakinra (59). Therefore, genetic variation within genes coding for IL1 or its 
receptor could potentially influence treatment outcome to TNF inhibitors. In three studies, SNPs 
within the genes IL-1B and ILRN were assessed (43;60;61). Only one association was found in a 
small cohort of patients: carriage of the number of tandem repeats within the IL1RN gene was asso-
ciated with obtaining a better clinical response to infliximab therapy (61).   
Notably, anti-inflammatory cytokines, such as IL-10, could also influence TNF-inhibitor therapy 
outcome. Indeed, it is demonstrated that the SNP IL-10 -1087G>A is associated with an increased 
IL10 production and hereby anti-inflammatory response (62). However, this result was not detected 
in an association study with a clinical endpoint to measure efficacy in etanercept treatment (43). 
One other study focused on two IL-10 promoter microsatellite polymorphisms, IL10.R and IL10.G, 
which have been shown to be related with IL-10 secretion (63). A positive response was associated 
with carriage of the R3 allele or R3-G9 haplotype, whereas the allele G13 and the haplotype R2-G13 
were present in patients with moderate or no response (64).  
For many years it is known that HLA-DRB1 shared epitope (SE) is associated with susceptibility to 
RA. More recently, other SNPs, for example in the PTPN22 gene, have been associated with suscep-
tibility to RA. Patients with mutations in these genes are likely to have a more severe disease activity 
state and at baseline compared with patients not having mutations in these disease-susceptibility 
genes. In contrast,  
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an association between HLA-DRB1 (SE) and treatment outcome was only reported in one of seven 
studies (39;41;50;60;65-67). In this study, two HLA-DRB1 alleles encoding the SE were related to a 
positive clinical response to etanercept treatment (39).  
Only recently, a genome-wide association study using a 300K-SNP array was performed to analyze 
response in anti-TNF treatment (etanercept, infliximab and adalimumab). Four SNPs were signifi-
cantly associated with treatment outcome in this genome-wide analysis in loci MAFB, IFNk, PON1 
and IL10 genes. However, replications of these SNPs in independent and larger data sets are re-
quired due to the small sample size used in this study (68) (not displayed in table 1).   
Beside its potential to reduce disease activity leading to the reduction of inflammation and joint 
damage, the use of biologic DMARDs in RA has raised concern about the risk of serious and oppor-
tunistic infections. Specifically, Bongartz et al. (19) have provided evidence for a higher risk of e.g. 
serious infections (odds ratio of 2.0) in patients with RA who are treated with anti-TNF antibody 
therapy. Yet, common infections, such as upper respiratory infections and urinary tract infections, 
have not been studied in large prospective clinical trials. Only, one group performed an association 
study concerning this last topic (69). In this study, the SNPs TNF -238G>A, LTA +365G>C and 
FCGR3A +176F/V were significantly associated with experiencing a urinary tract infection during 
MTX and etanercept treatment. Additionally, the number of risk alleles (TNF -238 A-allele, LTA 
+365 C-allele and FCGR3A +176 F-allele) was correlated with an increased risk to this type of infec-
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Gene Function Genetic poly-
morphism(s) 
Clinical effect on: 
Toxicity Efficacy 
TNF TNFα production and regulation 
-308 G>A  
A-allele associated with increased 
TNFα levels after INF  (49); No 
association with toxicity ETN (69) 
GG associated with 
efficacy ETN and INF 
(40,42,44,47,48); In hp 
G-allele effect on ineffi-
cacy ADA (50); A-allele 
associated with inefficacy 
(45); No association with 
efficacy ETN, INF and 
ADA (39,41-43,53,60) 
-857C>T * 
T-allele associated with 
efficacy ETA (41); In hp 
C-allele effect on ineffi-
cacy ADA (50)   
-238G>A A-allele effect on toxicity ETA (69) 
G-allele associated with 
inefficact INF (42); In hp 
G-allele effect on ineffi-
cacy ADA (50); No 
association with efficacy 
INF (60) 
-1031T>C, -863 C>A, 
+488, +2018 





Linked to TNFα  -308 A>G poly-
morphism 
a,b,c,d,e * 
TNF α11 and β4 haplo-
type associated with 
efficacy INF (67) 
TNFRSF1
A 
TNFα soluble receptor type 1 -609, -580, -383 * No effect on efficacy ETA (39) 
TNFRSF1
B 
TNFα soluble receptor type 2 676T>G * 
No effect on efficacy 
ETA, INF and ADA 
(39,55); GG associated 
with inefficacy ETA and 
INF (73)  
G-allele associate with 




Mediation of inflammatory actions  
 
+319C>A, +177A>G,  
+249, +720 No effect on efficacy or toxicity  ETA (39,41,69) 







Antigen presenting molecules See references * 
No effect on efficacy 
ETA, INF ADA 
(41,50,60,65-67); HLA-
DBRB1 associated with 
efficacy ETA (39);   
PTPN22 
Involved in T-cell receptor signaling 
pathway 1858 C>T * 
No effect on efficacy 
ETA, INF and ADA (65)  
FCGR 
(I,II,III) 
Influence cell activation, apoptosis. 
Indirect target anti-TNF 
131H/R, NA1/NA2, 
212V/F 
No effect on efficacy or toxicity ETA and INF  (39,54,69) 
131 RR associated with efficacy INF (58) 
-158V/F * 
No effect on efficacy ETA 
and INF (56); 
FF associated with 
efficacy ETN, INF, ADA 
(57,58) 
176F/V F-allele effect on toxicity ETA (69) 






-1087G>A * No effect on efficacy ETA 
(43) 
Several microsatel-
lites, see reference * 
IL-10- R3 and haplotype 
IL-10 R3-R9 associated 




Pro-inflammatory cytokine IL-1β +3954C>T * No effect on efficacy INF 
(60,61) 
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Table 1. Pharmacogenetic association studies of TNF inhibitors with treatment outcome in 
rheumatoid arthritis 
 
* = No information on association(s) with specific efficacy or toxicity was present regarding this SNP under study. 







Inhibits action of interleukine 1 
IL-1 RN +2018 T>C * 
C-allele associated with 
inefficacy INF (60) 
IL-1 RN VNTR intron 
2 * 
IL1RN*2 allele asso-
ciated with efficacy INF  
(61) 
MIF Pro-inflammatory cytokine, Modulation of macrophage and T-cell function 
-173 C>C, CATT (7) 
repeat * 
No effect on efficacy INF 
(74) 
112
Pharmacogenetics of TNF inhibitors in rheumatoid arthritis
Conclusion 
 
TNF inhibitors have been demonstrated to be effective in the treatment of rheumatoid arthritis. 
Nevertheless, several patients fail to achieve a good response, develop serious side-effects and/or 
experience drug toxicity, which precludes further treatment with the drug. Unfortunately, interindi-
vidual differences in drug response cannot be predicted in patients and (genetic) markers are war-
ranted to individualize and optimize drug treatment. Here, we have discussed mainly reports of 
associations between genetic polymorphisms in candidate genes and drug efficacy of TNF inhibitor 
treatment in rheumatoid arthritis, because clear data on associations between toxicity and TNF-
inhibiting therapy and associations between genetic characteristics and discontinuation of TNF-
inhibiting treatment are limited. 
Most pharmacogenetic studies performed so far have an insufficient sample size (power) to detect 
expected differences in genotype frequencies between responders and non-responders. 
Replication and validation in larger comparable cohorts are required before definitive conclusions 
can be drawn (70). From the studies that have been published, no conclusions can be made on the 
potential utility of genotyping for TNF -308 A/G, the HLA-DRB1 shared epitope or TNF microsatel-
lite haplotypes to predict treatment outcome in rheumatoid arthritis patients who are treated with 
infliximab. Similarly, on the basis of the levels of significance, the clinical use of genotyping rheuma-
toid arthritis patients who are treated with etanercept cannot be implemented as yet.  
Several difficulties exist in interpreting and comparing the results in pharmacogenetic studies. For 
example, difficulties arise when genetic variations are known to be disease related, such as the HLA-
DRB1 shared epitope gene in rheumatoid arthritis (71). Patients with mutations in these genes are 
likely to have a more severe disease and thus a higher state of disease activity at baseline, as com-
pared with patients lacking such mutations. Owing to regression to the mean, patients with high 
disease activity, in contrast to those with low disease activity, might show a higher response. Predict-
ing a positive or negative treatment outcome is thus hampered by higher disease activity at baseline, 
rather than referring to an effect of variance in genotype.  
In addition, owing to their mechanism of action, the dose of anti-TNF drugs should be considered 
when interpreting and comparing treatment outcome in pharmacogenetic studies. In theory, the 
cellular amount of TNFα and, thus, the amount available for inhibition by anti-TNF drugs, might 
depend on the genotype. The clinical consequence of the genotype might thus be dependent on drug 
dose, because increasing or decreasing dosage could have a similar net effect. In pharmacogenetic 
studies, therefore, it is important that baseline characteristics (disease activity state) and drug do-
sages between cohorts are kept at similar level to estimate adequately associations between genetic 
polymorphisms and treatment outcome. To avoid genetic variation in a population itself as a predic-
tor for clinical response, the prevalence of a candidate gene in responders and non-responders and 
in controls must be compared in pharmacogenetic studies. In this way, a genuine gene–dose effect 
becomes visible (24). 
Furthermore, the problem of potential functionality of a candidate gene, tested in vitro, remains 
because any functionality determined can have no relevance to the in vivo mechanism of 
drug action. Such genes can be in linkage with other loci, which have a true influence on the phar-
macology of the drug (72). Lastly, the location of SNPs on chromosomes and the frequency of SNPs 
vary to a great extent between different populations; in the interpretation of any associations pre-
sented, the genetic variation between racial and ethnic groups has to be considered.  
We conclude that pharmacogenetics of anti-TNF drugs in the treatment of patients with rheumatoid 
arthritis has the potential to optimize therapy and clinical outcome. In general, however, the current 
studies are too small and subsequent findings in larger studies often fail to replicate the original 
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data. Continued large-scale studies are essential before a pharmacogenetic approach will be applica-




Pharmacogenetics of TNF inhibitors in rheumatoid arthritis
References 
 
(1) Brennan FM, McInnes IB. Evidence that cytokines play 
a role in rheumatoid arthritis. J Clin Invest 2008 Novem-
ber;118(11):3537-45. 
(2) Choy EH, Panayi GS. Cytokine pathways and joint 
inflammation in rheumatoid arthritis. N Engl J Med 2001 
March 22;344(12):907-16. 
(3) O'dell JR. Therapeutic strategies for rheumatoid arthri-
tis. N Engl J Med 2004 June 17;350(25):2591-602. 
(4) Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. 
Tumor necrosis factor antagonist mechanisms of action: a 
comprehensive review. Pharmacol Ther 2008 Febru-
ary;117(2):244-79. 
(5) Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, 
Foulkes R et al. Mechanism of action of certolizumab pegol 
(CDP870): in vitro comparison with other anti-tumor 
necrosis factor alpha agents. Inflamm Bowel Dis 2007 
November;13(11):1323-32. 
(6) Paleolog EM, Young S, Stark AC, McCloskey RV, Feld-
mann M, Maini RN. Modulation of angiogenic vascular 
endothelial growth factor by tumor necrosis factor alpha 
and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 
1998 July;41(7):1258-65. 
(7) Kohno T, Tam LT, Stevens SR, Louie JS. Binding cha-
racteristics of tumor necrosis factor receptor-Fc fusion 
proteins vs anti-tumor necrosis factor mAbs. J Investig 
Dermatol Symp Proc 2007 May;12(1):5-8. 
(8) Mitoma H, Horiuchi T, Tsukamoto H. Binding activities 
of infliximab and etanercept to transmembrane tumor 
necrosis factor-alpha. Gastroenterology 2004 
March;126(3):934-5. 
(9) Van den Brande JM, Braat H, van den Brink GR, Vers-
teeg HH, Bauer CA, Hoedemaeker I et al. Infliximab but 
not etanercept induces apoptosis in lamina propria T-
lymphocytes from patients with Crohn's disease. Gastroen-
terology 2003 June;124(7):1774-85. 
(10) Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, 
Antoni C et al. Regulation of cytokines, cytokine inhibitors, 
and acute-phase proteins following anti-TNF-alpha thera-
py in rheumatoid arthritis. J Immunol 1999 August 
1;163(3):1521-8. 
(11) Klimiuk PA, Sierakowski S, Domyslawska I, Fiedorczyk 
M, Chwiecko J. Reduction of soluble adhesion molecules 
(sICAM-1, sVCAM-1, and sE-selectin) and vascular endo-
thelial growth factor levels in serum of rheumatoid arthritis 
patients following multiple intravenous infusions of inflix-
imab. Arch Immunol Ther Exp (Warsz ) 2004 Janu-
ary;52(1):36-42. 
(12) Ulfgren AK, Andersson U, Engstrom M, Klareskog L, 
Maini RN, Taylor PC. Systemic anti-tumor necrosis factor 
alpha therapy in rheumatoid arthritis down-regulates 
synovial tumor necrosis factor alpha synthesis. Arthritis 
Rheum 2000 November;43(11):2391-6. 
(13) Kubota A, Hasegawa K, Suguro T, Koshihara Y. Tumor 
necrosis factor-alpha promotes the expression of osteopro-
tegerin in rheumatoid synovial fibroblasts. J Rheumatol 
2004 March;31(3):426-35. 
(14) Lee CK, Lee EY, Chung SM, Mun SH, Yoo B, Moon 
HB. Effects of disease-modifying antirheumatic drugs and 
antiinflammatory cytokines on human osteoclastogenesis 
through interaction with receptor activator of nuclear factor 
kappaB, osteoprotegerin, and receptor activator of nuclear 
factor kappaB ligand. Arthritis Rheum 2004 Decem-
ber;50(12):3831-43. 
(15) O'dell JR. Therapeutic strategies for rheumatoid arth-
ritis. N Engl J Med 2004 June 17;350(25):2591-602. 
(16) Panaccione R, Ferraz JG, Beck P. Advances in medical 
therapy of inflammatory bowel disease. Curr Opin Phar-
macol 2005 December;5(6):566-72. 
(17) Olsen NJ, Stein CM. New drugs for rheumatoid arthri-
tis. N Engl J Med 2004 May 20;350(21):2167-79. 
(18) Welsing PM, Severens JL, Hartman M, van Riel PL, 
Laan RF. Modeling the 5-year cost effectiveness of treat-
ment strategies including tumor necrosis factor-blocking 
agents and leflunomide for treating rheumatoid arthritis in 
the Netherlands. Arthritis Rheum 2004 December 
15;51(6):964-73. 
(19) Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matte-
son EL, Montori V. Anti-TNF antibody therapy in rheuma-
toid arthritis and the risk of serious infections and malig-
nancies: systematic review and meta-analysis of rare harm-
ful effects in randomized controlled trials. JAMA 2006 May 
17;295(19):2275-85. 
(20) Breedveld FC, Weisman MH, Kavanaugh AF, Cohen 
SB, Pavelka K, van VR et al. The PREMIER study: A multi-
center, randomized, double-blind clinical trial of combina-
tion therapy with adalimumab plus methotrexate versus 
methotrexate alone or adalimumab alone in patients with 
early, aggressive rheumatoid arthritis who had not had 
previous methotrexate treatment. Arthritis Rheum 2006 
January;54(1):26-37. 
115
Pharmacogenetics of TNF inhibitors in rheumatoid arthritis
(21) Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart 
CF, van ZD, Kerstens PJ, Hazes JM et al. Clinical and 
radiographic outcomes of four different treatment strate-
gies in patients with early rheumatoid arthritis (the BeSt 
study): a randomized, controlled trial. Arthritis Rheum 
2005 November;52(11):3381-90. 
(22) Klareskog L, van der HD, de Jager JP, Gough A, Kal-
den J, Malaise M et al. Therapeutic effect of the combina-
tion of etanercept and methotrexate compared with each 
treatment alone in patients with rheumatoid arthritis: 
double-blind randomised controlled trial. Lancet 2004 
February 28;363(9410):675-81. 
(23) Eichelbaum M, Ingelman-Sundberg M, Evans WE. 
Pharmacogenomics and Individualized Drug Therapy. 
Annu Rev Med 2006;57:119-37. 
(24) Huizinga TW, Pisetsky DS, Kimberly RP. Associations, 
populations, and the truth: recommendations for genetic 
association studies in Arthritis & Rheumatism. Arthritis 
Rheum 2004 July;50(7):2066-71. 
(25) van Gestel AM, Prevoo ML, 't Hof MA, van Rijswijk 
MH, van de Putte LB, van Riel PL. Development and 
validation of the European League Against Rheumatism 
response criteria for rheumatoid arthritis. Comparison with 
the preliminary American College of Rheumatology and 
the World Health Organization/International League 
Against Rheumatism Criteria. Arthritis Rheum 1996 Janu-
ary;39(1):34-40. 
(26) Aletaha D, Ward MM, Machold KP, Nell VP, Stamm 
T, Smolen JS. Remission and active disease in rheumatoid 
arthritis: defining criteria for disease activity states. Arthri-
tis Rheum 2005 September;52(9):2625-36. 
(27) van der Heijde D., Klareskog L, Rodriguez-Valverde V, 
Codreanu C, Bolosiu H, Melo-Gomes J et al. Comparison of 
etanercept and methotrexate, alone and combined, in the 
treatment of rheumatoid arthritis: two-year clinical and 
radiographic results from the TEMPO study, a double-
blind, randomized trial. Arthritis Rheum 2006 
April;54(4):1063-74. 
(28) van der Heijde D. How to read radiographs according 
to the Sharp/van der Heijde method. J Rheumatol 2000 
January;27(1):261-3. 
(29) Vencovsky J, Huizinga TW. Rheumatoid arthritis: the 
goal rather than the health-care provider is key. Lancet 
2006 February 11;367(9509):450-2. 
(30) Cronstein BN. Low-dose methotrexate: a mainstay in 
the treatment of rheumatoid arthritis. Pharmacol Rev 2005 
June;57(2):163-72. 
(31) Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. 
Methotrexate as the "anchor drug" for the treatment of 
early rheumatoid arthritis. Clin Exp Rheumatol 2003 
September;21(5 Suppl 31):S179-S185. 
(32) Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst 
D, Weisman MH et al. Sustained improvement over two 
years in physical function, structural damage, and signs 
and symptoms among patients with rheumatoid arthritis 
treated with infliximab and methotrexate. Arthritis Rheum 
2004 April;50(4):1051-65. 
(33) Smolen JS, Aletaha D, Machold KP. Therapeutic 
strategies in early rheumatoid arthritis. Best Pract Res Clin 
Rheumatol 2005 February;19(1):163-77. 
(34) O'dell JR. Treating rheumatoid arthritis early: a win-
dow of opportunity? Arthritis Rheum 2002 Febru-
ary;46(2):283-5. 
(35) Welsing PM, Landewe RB, van Riel PL, Boers M, van 
Gestel AM, van der LS et al. The relationship between 
disease activity and radiologic progression in patients with 
rheumatoid arthritis: a longitudinal analysis. Arthritis 
Rheum 2004 July;50(7):2082-93. 
(36) Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog 
L, van Vollenhoven RF. Adalimumab (Humira) restores 
clinical response in patients with secondary loss of efficacy 
from infliximab (Remicade) or etanercept (Enbrel): results 
from the STURE registry at Karolinska University Hospital. 
Scand J Rheumatol 2005 September;34(5):353-8. 
(37) Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, 
Combe B. The efficiency of switching from infliximab to 
etanercept and vice-versa in patients with rheumatoid 
arthritis. Clin Exp Rheumatol 2005 November;23(6):795-
800. 
(38) Sidiropoulos PI, Boumpas DT. Differential drug resis-
tance to anti-tumour necrosis factor agents in rheumatoid 
arthritis. Ann Rheum Dis 2006 June;65(6):701-3. 
(39) Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, 
Wang J et al. The influence of genetic variation in the HLA-
DRB1 and LTA-TNF regions on the response to treatment 
of early rheumatoid arthritis with methotrexate or etaner-
cept. Arthritis Rheum 2004 September;50(9):2750-6. 
(40) Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot 
E, Wendling D et al. Influence of -308 A/G polymorphism 
in the tumor necrosis factor alpha gene on etanercept 
treatment in rheumatoid arthritis. Arthritis Rheum 2007 
December 15;57(8):1426-30. 
(41) Kang CP, Lee KW, Yoo DH, Kang C, Bae SC. The 
influence of a polymorphism at position -857 of the tumour 
necrosis factor alpha gene on clinical response to etaner-
cept therapy in rheumatoid arthritis. Rheumatology (Ox-
ford) 2005 April;44(4):547-52. 
116
Pharmacogenetics of TNF inhibitors in rheumatoid arthritis
(42) Maxwell JR, Potter C, Hyrich KL, Barton A, Worthing-
ton J, Isaacs JD et al. Association of the tumour necrosis 
factor-308 variant with differential response to anti-TNF 
agents in the treatment of rheumatoid arthritis. Hum Mol 
Genet 2008 November 15;17(22):3532-8. 
(43) Padyukov L, Lampa J, Heimburger M, Ernestam S, 
Cederholm T, Lundkvist I et al. Genetic markers for the 
efficacy of tumour necrosis factor blocking therapy in 
rheumatoid arthritis. Ann Rheum Dis 2003 
June;62(6):526-9. 
(44) Seitz M, Wirthmuller U, Moller B, Villiger PM. The -
308 tumour necrosis factor-alpha gene polymorphism 
predicts therapeutic response to TNFαlpha-blockers in 
rheumatoid arthritis and spondyloarthritis patients. 
Rheumatology (Oxford) 2007 January;46(1):93-6. 
(45) Lee YH, Rho YH, Choi SJ, Ji JD, Song GG. Association 
of TNF-alpha -308 G/A polymorphism with responsive-
ness to TNF-alpha-blockers in rheumatoid arthritis: a 
meta-analysis. Rheumatol Int 2006 December;27(2):157-
61. 
(46) Cuchacovich M, Ferreira L, Aliste M, Soto L, Cuenca J, 
Cruzat A et al. Tumour necrosis factor-alpha (TNF-alpha) 
levels and influence of -308 TNF- 
alpha promoter polymorphism on the responsiveness to 
infliximab in patients with rheumatoid arthritis. Scand J 
Rheumatol 2004;33(4):228-32. 
(47) Fonseca JE, Carvalho T, Cruz M, Nero P, Sobral M, 
Mourao AF et al. Polymorphism at position -308 of the 
tumour necrosis factor alpha gene and rheumatoid arthritis 
pharmacogenetics. Ann Rheum Dis 2005 May;64(5):793-
4. 
(48) Mugnier B, Balandraud N, Darque A, Roudier C, 
Roudier J, Reviron D. Polymorphism at position -308 of 
the tumor necrosis factor alpha gene influences outcome of 
infliximab therapy in rheumatoid arthritis. Arthritis 
Rheum 2003 July;48(7):1849-52. 
(49) Marotte H, Arnaud B, Diasparra J, Zrioual S, Miossec 
P. Association between the level of circulating bioactive 
tumor necrosis factor alpha and the tumor necrosis factor 
alpha gene polymorphism at -308 in patients with rheuma-
toid arthritis treated with a tumor necrosis factor alpha 
inhibitor. Arthritis Rheum 2008 May;58(5):1258-63. 
(50) Miceli-Richard C, Comets E, Verstuyft C, Tamouza R, 
Loiseau P, Ravaud P et al. A single tumour necrosis factor 
haplotype influences the response to adalimumab in rheu-
matoid arthritis. Ann Rheum Dis 2008 April;67(4):478-84. 
(51) Chen PC, DuBois GC, Chen MJ. Mapping the do-
main(s) critical for the binding of human tumor necrosis 
factor-alpha to its two receptors. J Biol Chem 1995 Febru-
ary 10;270(6):2874-8. 
(52) Chatzikyriakidou A, Georgiou I, Voulgari PV, Venetsa-
nopoulou AI, Drosos AA. Combined tumour necrosis 
factor-alpha and tumour necrosis factor receptor genotypes 
could predict rheumatoid arthritis patients' response to 
anti-TNF-alpha therapy and explain controversies of stu-
dies based on a single polymorphism. Rheumatology 
(Oxford) 2007 June;46(6):1034-5. 
(53) Ongaro A, De MM, Pellati A, Caruso A, Ferretti S, 
Masieri FF et al. Can tumor necrosis factor receptor II gene 
676T>G polymorphism predict the response grading to 
anti-TNFαlpha therapy in rheumatoid arthritis? Rheuma-
tol Int 2008 July;28(9):901-8. 
(54) Rooryck C, Barnetche T, Richez C, Laleye A, Arveiler B, 
Schaeverbeke T. Influence of FCGR3A-V212F and 
TNFRSF1B-M196R genotypes in patients with rheumatoid 
arthritis treated with infliximab therapy. Clin Exp Rheuma-
tol 2008 March;26(2):340-2. 
(55) Toonen EJ, Coenen MJ, Kievit W, Fransen J, Eijsbouts 
AM, Scheffer H et al. The tumour necrosis factor receptor 
superfamily member 1b 676T>G polymorphism in relation 
to response to infliximab and adalimumab treatment and 
disease severity in rheumatoid arthritis. Ann Rheum Dis 
2008 August;67(8):1174-7. 
(56) Kastbom A, Bratt J, Ernestam S, Lampa J, Padyukov 
L, Soderkvist P et al. Fcgamma receptor type IIIA genotype 
and response to tumor necrosis factor alpha-blocking 
agents in patients with rheumatoid arthritis. Arthritis 
Rheum 2007 February;56(2):448-52. 
(57) Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch 
R, Boyle D. Fcgamma receptor type IIIA polymorphisms 
influence treatment outcomes in patients with inflammato-
ry arthritis treated with tumor necrosis factor alpha-
blocking agents. Arthritis Rheum 2005 Septem-
ber;52(9):2693-6. 
(58) Canete JD, Suarez B, Hernandez MV, Sanmarti R, 
Rego I, Celis R et al. Influence of variants of 
Fc{gamma}receptors IIA and IIIA on the ACR and EULAR 
responses to anti-TNF{alpha} therapy in rheumatoid 
arthritis. Ann Rheum Dis. 2009 Oct;68(10):1547-52  
(59) Cohen SB, Moreland LW, Cush JJ, Greenwald MW, 
Block S, Shergy WJ et al. A multicentre, double blind, 
randomised, placebo controlled trial of anakinra (Kineret), 
a recombinant interleukin 1 receptor antagonist, in patients 
with rheumatoid arthritis treated with background metho-
trexate. Ann Rheum Dis 2004 September;63(9):1062-8. 
(60) Marotte H, Pallot-Prades B, Grange L, Tebib J, Gau-
din P, Alexandre C et al. The shared epitope is a marker of 
severity associated with selection for, but not with response 
117
Pharmacogenetics of TNF inhibitors in rheumatoid arthritis
to, infliximab in a large rheumatoid arthritis population. 
Ann Rheum Dis 2006 March;65(3):342-7. 
(61) Tolusso B, Pietrapertosa D, Morelli A, De SM, Gremese 
E, Farina G et al. IL-1B and IL-1RN gene polymorphisms in 
rheumatoid arthritis: relationship with protein plasma 
levels and response to therapy. Pharmacogenomics 2006 
July;7(5):683-95. 
(62) Turner DM, Williams DM, Sankaran D, Lazarus M, 
Sinnott PJ, Hutchinson IV. An investigation of polymor-
phism in the interleukin-10 gene promoter. Eur J Immu-
nogenet 1997 February;24(1):1-8. 
(63) Eskdale J, Gallagher G, Verweij CL, Keijsers V, Wes-
tendorp RG, Huizinga TW. Interleukin 10 secretion in 
relation to human IL-10 locus haplotypes. Proc Natl Acad 
Sci U S A 1998 August 4;95(16):9465-70. 
(64) Schotte H, Schluter B, Drynda S, Willeke P, Tidow N, 
Assmann G et al. Interleukin 10 promoter microsatellite 
polymorphisms are associated with response to long term 
treatment with etanercept in patients with rheumatoid 
arthritis. Ann Rheum Dis 2005 April;64(4):575-81. 
(65) Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Sym-
mons DP et al. Association of RF and anti-CCP positivity, 
but not carriage of shared epitope or PTPN22 susceptibility 
variants, with anti-TNF response in RA. Ann Rheum Dis. 
2009 Jan;68(1):69-74 
(66) Pinto JA, Rego I, Rodriguez-Gomez M, Canete JD, 
Fernandez-Lopez C, Freire M et al. Polymorphisms in 
genes encoding tumor necrosis factor-alpha and HLA-
DRB1 are not associated with response to infliximab in 
patients with rheumatoid arthritis. J Rheumatol 2008 
January;35(1):177-8. 
(67) Martinez A, Salido M, Bonilla G, Pascual-Salcedo D, 
Fernandez-Arquero M, de MS et al. Association of the 
major histocompatibility complex with response to inflix-
imab therapy in rheumatoid arthritis patients. Arthritis 
Rheum 2004 April;50(4):1077-82. 
(68) Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, Beck-
man E et al. Genome-wide association scan identifies 
candidate polymorphisms associated with differential 
response to anti-TNF treatment in rheumatoid arthritis. 
Mol Med 2008 September;14(9-10):575-81. 
(69) Hughes LB, Criswell LA, Beasley TM, Edberg JC, 
Kimberly RP, Moreland LW et al. Genetic risk factors for 
infection in patients with early rheumatoid arthritis. Genes 
Immun 2004 December;5(8):641-7. 
(70) Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-
Ioannidis DG. Replication validity of genetic association 
studies. Nat Genet 2001 November;29(3):306-9. 
(71) Lanchbury JS. The HLA association with rheumatoid 
arthritis. Clin Exp Rheumatol 1992 May;10(3):301-4. 
(72) Halapi E, Hakonarson H. Advances in the develop-
ment of genetic markers for the diagnosis of disease and 
drug response. Expert Rev Mol Diagn 2002 Septem-
ber;2(5):411-21. 
 
(73) Fabris M, Tolusso B, Di PE, Assaloni R, Sinigaglia L, 
Ferraccioli G. Tumor necrosis factor-alpha receptor II 
polymorphism in patients from southern Europe with 
mild-moderate and severe rheumatoid arthritis. J Rheu-
matol 2002 September;29(9):1847-50.  
 
(74) Radstake TR, Fransen J, Toonen EJ, Coenen MJ, 
Eijsbouts AE, Donn R et al. Macrophage migration inhibi-
tory factor polymorphisms do not predict therapeutic 
response to glucocorticoids or to tumour necrosis factor 
alpha-neutralising treatments in rheumatoid arthritis. Ann 
Rheum Dis 2007 November;66(11):1525-30.  
118








Criteria for the selection of single nucleotide poly-
morphisms in pathway pharmacogenetics: TNF inhi-




Wouter M. Kooloos1, Judith A.M Wessels1, Tahar van der Straaten1, Tom W.J. Huizinga2 and Henk-
Jan Guchelaar1 
 
1 Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands. 






















Pharmacogenetics aims to identify genetic variation to predict drug response or to establish an 
individual optimal dose. Classically, explorative pharmacogenetic studies are performed concerning 
a limited number of SNPs in genes encoding enzymes involved in the drug’s metabolic route. Alter-
natively, potential markers across the genome are elucidated by the performance of the hypothesis-
free genome-wide method. Besides their successful use, both methods provide substantial disadvan-
tages. A solution toward these difficulties is the pathway pharmacogenetic approach, which consid-
ers variability in the entire pathway without restricting the analysis to only one gene. In this article, 
we present selection criteria for this approach to effectively explore potential associating SNPs. As an 
illustration, the method is applied to the biological adalimumab as a case study. 
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Introduction 
 
The concept of pharmacogenetics is that germline genetic variability causes variable drug response 
among individual patients. Knowledge about related genetic variants, mostly single nucleotide po-
lymorphisms (SNPs), may help to predict drug response or optimal dose in the individual patient 
(1). Classically, explorative pharmacogenetic association studies are aimed at finding potential pre-
dictive SNPs. These concern a limited number of SNPs in genes encoding enzymes or proteins 
representing the drug’s major metabolic route or target. For example, to explain variable drug re-
sponse of the anticoagulant warfarin, association studies showed that bleeding time (INR) was asso-
ciated with cytochrome P450 2C9 (the major metabolic route of warfarin) genotype and VKORC1 
genotype (the pharmacodynamic target of warfarin) (2,3). Obviously, the selection of SNPs within 
the candidate gene is essential, because only some of them may be related to drug response whereas 
others are not.  
This approach has its limitations, however, because of an incomplete knowledge of the pharmacolo-
gy of a substantial number of drugs and the wide variety of SNPs in the human genome. Thus it may 
not be surprising that the candidate gene approach has led to poor reproducibility with regard to 
potential predictors of drug response. Therefore, systematic selection remains a challenge to scien-
tists in obtaining 
a potentially successful set of SNPs for predicting drug response.  
In this article, SNP selection for pharmacogenetic association studies is discussed. Additionally, a 
pharmacogenetic pathway approach is presented, together with proposed criteria for systematic 
selection of SNPs. We have applied this method for the selection of potential interesting SNPs within 
genes related to the mechanism of action of TNF inhibiting drug adalimumab. This drug has been 
effective in the treatment of progressive rheumatoid arthritis (RA) by reducing inflammation and 
joint destruction (4). Approximately 40–60% of individuals with RA, however, do not respond ade-
quately to this drug (5,6). Moreover, the use of TNF inhibitors is accompanied by adverse events and 
unintentional immune suppression. Pharmacogenetics has the potential to increase efficacy and 




Candidate gene method 
Selection of SNPs in hypothesis driven pharmacogenetic association studies is based on their func-
tionality, in which the genetic variant leads (or is predicted to lead) to alteration in protein 
function and hence differences in drug response. This approach has led to the discovery of a sub-
stantial number of relevant SNPs in pharmacogenetics [3,8,9]. This approach, however, also dem-
onstrated associations that could not be replicated by other investigators [10,11] and thus could re-
sult in possibly false-positive findings. Moreover, in a substantial number of studies, SNP selection is 
not systematically performed but seems to be arbitrary or extensions of previous findings. Also, 
because complex traits are mostly considered not to be monogenetic, selecting SNPs according to 
this hypothetical approach will repeatedly lead to a limited explanation of variance in drug response. 
 
Genome-wide method 
A more comprehensive, and more expensive, approach is the genome-wide method using SNP ar-
rays (WGA). A clear advantage of this method is that it is hypothesis-free and that this may reveal 
unexpected SNPs related to drug response. Hence this method does not rely on current knowledge 
with regard to the metabolism and mechanism of action of the drug. Indeed, in the past two years 
genome-wide association studies have presented novel associations of SNPs with drug response 
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[12–14]. Moreover, novel information about the pathogenesis and progression of complex diseases, 
like RA and Crohn’s disease, could be revealed using the genome-wide SNP approach [15–17]. An 
advantage of this approach is that complex traits can be explored, accommodating polygenetic var-
iation. Yet, various remarks can be placed regarding clinical overvaluation of the results from this 
approach because of the overall limited effect sizes found [18]. Additional problems arise regarding 
the discrepancy between type I errors (false-positive results) and subsequently adjusted type II er-
rors (false negative results) in detecting an associated SNP [19,20]. Specifically, the appliance of 
rigorous criteria for significance (owing to multiple testing) to oppose type I errors can eventually 
lead to type II errors (missing a real effect). 
 
Pathway gene method 
A third method is the pathway gene approach that combines the advantages of the candidate gene 
approach and the genomewide approach. Moreover, with this method fewer disadvantages are ex-
perienced. Namely, by applying the pathway gene approach fewer false-positive results will be found 
than with the genome-wide method owing to the limitation of multiple testing. A characteristic of 
the pathway gene method is that a set of SNPs is selected based on a description of pathways regard-
ing the mechanism of action and pharmacokinetics of the drug under study. In this systems phar-
macology approach, one considers variability in the entire pathway without restricting the analysis 
to a single gene, of which the impact on the drug’s mechanism of action is unknown. With the can-
didate gene method, SNPs that are responsible for the rate limiting or extending step in mechanism 
of action are easily missed. For example, if SNPs in the signal transduction routes of the beta-
adrenergic receptor are explored, a complex quandary of proteins come across which are involved in 
the signal transduction route. Assumably, for most drugs pharmacogenetics has the greatest poten-
tial to be clinically useful if information on multiple genes is used. In this context, the pharmacoge-
netics of most drugs is likely to be comparable to the genetics of complex diseases. In both cases 
numerous proteins are involved, and genetic variability in each might contribute to the overall va-
riability observed clinically [21]. 
 
 
Before SNP selection in pathway pharmacogenetics 
 
Exploration of the pathway and gene selection 
Before SNP selection, an extensive literature search regarding the hypothetical mechanism of action 
of TNF inhibitors was performed to select candidate genes coding for involved proteins. 
Pubmed/National Center for Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov) was 
searched for original research concerning in vivo and in vitro studies, published in the past five 
years, regarding this subject. This search was performed using the Mesh terms RA, TNF-alpha, 
pharmacology, monoclonal antibodies, etanercept, adalimumab and infliximab.  
The anti-TNF drug adalimumab is a complete humanized IgG1 monoclonal antibody which binds to 
and neutralizes both soluble and transmembrane forms of TNF-alpha. Generally, a summary of 
seven groups can be created (table 1): neutralization and blockage [22,23]; interaction with Fc re-
ceptor (crosslinkage) [24]; initiation of reverse signaling, leading to blockage, increased apoptosis or 
growth arrest [25,26]; reduction of inflammatory cytokine production and angiogenic factor expres-
sion [23,27–29]; restoration of immune regulation (Treg cell) [30]; mediation of complement-
dependent cytotoxicity (CDC) and antibodydependent cytotoxicity (ADCC) [22,26]; downregulation 
or discontinuation of bone and cartilage destruction [31,32]. These mechanisms of action have 
mainly been demonstrated in vitro and, to a lesser extent, in vivo [33,34]. In the defined pathway 
124 genes related to the mechanism of action of TNF inhibitors were explored. 
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SNP sources 
After candidate genes had been selected, a SNP search within these genes was performed. SNPs 
were assessed using the database of the NCBI (http://www.ncbi.nlm.nih.gov/SNP). The NCBI has 
compiled a dataset of over 10 million SNPs throughout the entire human genome resulting from 
publicly and privately funded genome sequencing projects in the dbSNP [35,36]. Other databases of 
SNPper/CHIP-Bioinformatics (http://snpper.chip.org/bio) and Snap/SNP Annotation platform 
(http://snap.humgen.au.dk/views/index.cgi), mainly related to the NCBI, were consulted. A total of 
51,793 SNPs in 124 genes were available for the SNP selection procedure. 
 
 
Criteria for the selection of SNPs 
 
Primary selection aims to obtain SNPs, with a high probability to detect, as a result of reported hete-
rozygosity frequencies and the number of previous genotyping techniques applied. When these two 
primary criteria are applied, fewer SNPs are included for the secondary selection with more exten-
sive parameters. Because of this time-effective aspect, namely not analyzing each SNP in each gene, 




The primary selection of SNPs is based on the criteria:  
 
 Genetic region and heterozygosity: introns with a heterozygosity between 0.400 and 
0.480 and all exons with a heterozygosity of more than 0.095. 
 Validation status: only SNPs with a validation status of 2 or more measurements as re-
ported in the NCBI. 
 
When these criteria were applied, 2629 SNPs out of the total of 51,793 SNPs in 124 genes were se-
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Mechanism of action Selected genes N of genes Refer-
ences 
   
Neutralization and blockage TNF, LTA, TNFRSF1A, TNFRSF1B, ADAM17, IL1A 
IL1B, IL1R1, IL1R2, IL1RAP, IL1RN 
11 (22,23) 
Interaction with Fc receptor 
(cross-linkage)  
FCGR2A, FCGR2B, FCGR3A, FCGR3B 4 (24) 
Initiation of reverse signaling, 
leading to blockage or increased 
apoptosis or growth arrest 
TRADD, FADD, RIPK1, TRAF2, TANK, TNFAIP3, 
MAP3K7IP1, MAP3K7IP2, MAP3K7, IKBKG, 
CHUK, IKBKB, NFKB1, NFKB2, NFKB3, MAPK8, 
TP53, BAX, BAK1, CASP3, CASP7, CASP8, MAPK14, 
BCL2L1, BIRC2, BIRC3, XIAP, CFLAR 
28 (25,26) 
Reduction of inflammatory cyto-
kine production and angiogenic 
factor expression 
IL6, IL6R, CSF2, CSF2RA, CSF2RB, CSF1, CSF1R, 
CSF3, CSF3R, LIF, LIFR, OSM, OSMR, IL2, IL2RA, 
IL3, IL3R, IL7, IL7R, IL8, IL8RA, IL8RB, IL9, IL9R, 
IL12A, IL12B, IL12RB1, IL12RB2, IL18, IL18R1, 
IFNA1, IFNB, IFNG, IFNGR1, IFNGR2, IL15, 
IL15RA, CD11, CD28, CD40, CD40L, CD69, APOA1, 
IL4, IL4R, IL10, IL10RA, IL10RB, IL11, IL11RA, 
IL13, IL13RA1, IL13RA2, TGFB1, VEGFA, VEGFB, 
VEGFC, FIGF, KDR, FLT1, FLT4, SELE, ICAM1, 
VCAM1, vWF, PECAM1  
66 (23,27-29) 
Restoration of immune regula-
tion (Treg cell) 
FOXP3 1 (30) 
Mediation of complement-
dependent cytotoxicity (CDC) 
and antibody-dependent cytotox-
icity (ADCC)  




tion of bone and cartilage de-
struction  
TNFRSF11A, TNFSF11, TNFRSF11B, TRAF6 4 (31,32) 
 
Total number of genes 124  
 
Table 1. Candidate gene selection 
 
Abbreviations and accessory full names of formal genes can be relocated in the NCBI gene database 
(http://www.ncbi.nlm.nih.gov) 
 
Figure 1. Design stepwise SNP selection 
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Genetic region 
In the NCBI SNP database, a subdivision is made between different regions of genes: 3’ and 5’ near a 
gene, introns and exons. Additionally, functional characteristics in these regions are: noncoding, 
nonsynonymous, frameshift, synonymous, promoter or untranslated. Important for SNP selection, 
on the basis of alteration of a gene product and in this way protein function, is the presence of SNPs 
in exons. Still, noncoding SNPs, like introns, which maybe, for example transcribed to noncoding 
RNA, could have functions in transcriptional interference and promoter inactivation, as well as indi-
rect effects on transcription regulatory proteins and in genomic imprinting [37].  
In the NCBI database, specific regions within each gene were examined. A subdivision was made 
into different regions: unknown, 3’ and 5’ near gene, introns and exons. Additionally, exons were 
subdivided into synonymous, nonsynonymous, 3’UTR and 5’UTR subgroups. 
 
Heterozygosity 
True associations in case–control studies depend on the precise definition of response criterion, 
power and sample size of the study. For the detection of small differences in allele frequencies, 
a study has to be sufficiently powered. Additionally, selecting SNPs with a low minor allele frequen-
cy (MAF) will require very large sample size cohorts to achieve an association which is statistically 
sufficiently powered [38]. Figure 2 presents examples of number of cases needed to detect signifi-
cant differences in variable allele frequencies in a case–control (1:2) study design. Paired lines 
represent number of cases required to detect differences with significance level of 1.10-4 and 1.10-6 
with 80% power depending on the MAF in controls and hypothetical odds ratios for obtaining good 
response in cases relative to controls. For example, to detect a significant difference with a MAF in 
controls of 0.3 with a hypothetical odds ratio of 2.0 for obtaining good response in cases relative to 
controls, at least 147 cases and 294 controls are needed. 
A constructive tool in selection based on frequency is the usage of a SNP’s heterozygosity, which is 
the frequency of the occurrence of heterozygous individuals for a particular SNP. To use a specific 
range of heterozygosity as a criterion, the heterozygosity can be calculated from a preferred MAF 
within a sample size regarding the power for an association study. 
In this case study, SNPs were included on the basis of a total sample size of 400–500. In this way, 
for all SNPs, except exons, cutoff values regarding heterozygosity were chosen between 0.400 and 
0.480. If heterozygosity was lower than 0.400 and higher than 0.480, SNPs were excluded, except 
for SNPs with a significant predicted functional change of protein (defined below). Because SNPs in 
exons are less abundant, cut-off values regarding heterozygosity were lowered. In this way, SNPs in 
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Figure 2. Schematic representation of the number of cases needed to detect significant differ-
ences in a case-control (1:2) study designa,b 
 
a) Lines represent number of cases required to detect differences with significance level of 1.10-4 (lower light line of 
pair of hypothetical odds ratio- OR) and 1.10-6 (upper dark line of pair of hypothetical OR) with 80% power de-
pending on the MAF in controls and hypothetical odds ratios for obtaining good response in cases relative to 
controls. 
b) Abbreviation(s): MAF= minimal allele frequency, OR= odds ratio 
 
Validation 
The NCBI has created several descriptions of validation status for SNPs, which have been observed 
in individual experiments and accepted in this database without validation evidence. These descrip-
tions are important in distinguishing high-quality validated data from unconfirmed data. Subse-
quently, this will lead to an increase in certainty of selecting a genuine polymorphic SNP. Validation 
status was assembled in six groups depending on the number of validation measurements:  
- by multiple, independent submissions to the refSNP cluster, 
- by frequency or genotype data: minor alleles observed in at least two chromosomes, 
- by submitter confirmation regarding the SNP, 
- all alleles have been observed in at least two chromosomes a piece, 
- the SNP was genotyped by the HapMap project. 
In this way, a validation score system (number of measurements) was created to distinguish high-
quality validated data from unconfirmed data. 
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Secondary selection 
The secondary selection of SNPs is based on three criteria: 
 
 Predicted functionality 
 Tag SNPs and linkage disequilibrium (LD) 
 Ethnicity 
 
When these criteria were applied, 223 SNPs out of 111 genes of the total remaining 2629 SNPs in 124 
genes were selected. 
 
Functionality 
SNPs that affect gene expression occur in all regions of the genome. SNPs causing amino acid altera-
tions (nonsynonymous SNPs) have been extensively studied. Less examined are variants located 
within the noncoding regions of the genome because mechanistic roles of noncoding genome se-
quences remain poorly defined. Moreover, the analysis of their functional consequences is complex 
[39]. While mostly regarded as nonfunctional, these variants can impact gene regulatory sequences, 
like promotors, to change gene expression and enzyme activity. 
Another important feature is the exploration of possible functionally important regions in candidate 
genes within different species, which are identified within evolutionarily conserved sequences [40]. 
Several web software tools have been developed to assess these regions but this aspect is not further 
discussed in this article [41]. 
Functional change of a SNP was qualified and estimated using the Internet tools SNPs3D 
(http://www.snps3d.org/) [42] and/or PMut (http://mmb2.pcb.ub.es:8080/PMut) [43]. These 
resources provide a method of identifying those nonsynonymous SNPs that are likely to have a dele-
terious impact on molecular function in vivo.  
For each SNP in the second step of the selection, predicted functionality according to the above re-
sources was examined. If a predicted significant effect of a SNP was demonstrated, according to 
SNPs3D, this SNP was favorable to include in comparison with other SNPs with the same validation 
score, same heterozygosity for Caucasians and location within a gene region. 
 
Tag SNPs and linkage disequilibrium 
Tag SNPs usually occur in haploblocks or subregions. SNPs in different haploblocks or from differ-
ent genes may, however, also be in LD. It is useful to search for both in association studies [44]. The 
degree of LD between alleles at two loci can be described with the correlation coefficient (r2). This 
coefficient is informative in association analyses because it is inversely proportional to the sample 
size that is required for detecting a pharmacogenetic association given a fixed genetic risk [45]. An r2 
of 1 indicates full linkage, which means that there is no loss of power when using a marker Tag SNP 
instead of directly genotyping the disease causal variant. LD blocks (including tagged SNPs) can be 
relocated using the metric D0, which is closely related to r2, and provides information about the 
recombination breakpoints of chromosomes. These parameters are required for the search of Tag 
SNPs in the HapMap database (http://www.hapmap.org). To limit the effort and costs of associa-
tion studies, taking account of Tag SNPs is important [45].  
Tag SNPs were explored in the database provided by the International HapMap Project [46]. Addi-
tional criteria were ethnicity (Caucasian, discussed below), r2 > 0.8, MAF > 0.20 and maximum 
segment size of 250 basepairs. 
Additionally, available software for the exploration of LD, are the HapMap database and WGAview-
er (http://www.genome.duke.edu/centers/pg2/downloads/wgaviewer.php) [47]. This last tool 
provides an interface to automatically annotate, visualize and interpret the set of P-values emerging 
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from a whole genome association study [17]. HapMap data are used to identify nongenotyped poly-
morphisms that associate with the phenotype of interest through LD with genotyped variants. Re-
garding LD, SNPs with r2 > 0.7 andD0 = 1 were regarded as SNPs in LD. Within a demonstrated LD, 
the most favorable SNP based on validation status and heterozygosity was selected. This was also 
the case for Tag SNPs: regarding SNPs in LD only the most favorable SNPs, based on validation 
status and heterozygosity, were included in the final selection. 
 
Ethnicity 
During a first exploration of frequency in SNPs the mean heterozygosity was assessed. Yet, it is also 
important to be aware of the differences in frequency mutation among ethnic populations 
[48,49]. In the NCBI, the MAF for each ethnic group is presented. Hereby, the consistency of the 
patient population under study should be examined, before accomplishing a SNP selection. For 
our case study we used the heterozygosity of each SNP for Caucasian population. 
 
 
Characteristics of the selected SNPs 
 
After applying these criteria, 186 SNPs were finally selected to analyze in RA patients treated with 
the TNF inhibitor adalimumab. Percentages of SNP selection according to mechanism of action are 
displayed in figure 3. The largest group of genes, 58% of all SNPs (N = 107), are located in genes 
involved in the reduction of inflammatory cytokine production and angiogenic factor expression. 
None of the SNPs within the gene coding for proteins related to immune regulation (Table 1) was 






Figure 3. Percentages of selected SNPs according to mechanism of action. 
 
 
In table 2, characteristics of the finally selected SNPs are presented. The majority of the selected 
SNPs are located in an intron or exon region (N = 170; 91.4%). In the exon region, 32 SNPs are 
thought to influence amino acid replacement, while 20 SNPs are substitutions that are synonymous. 
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More than half of the SNPs have a heterozygosity between 0.400 and 0.480. Of all available criteria 
scores, derived from the NCBI validation criteria, SNPs with several four criteria were abundant. 
Less effective criterion was the functionality of the finally selected SNPs using SNP3D. In 11 SNPs, a 
subdivision could be made based on deleterious (N = 3) and nondeleterious (N = 8). Additionally, 
93 Tag SNPs were included for SNPs in a region of the genome with high LD, which facilitate a re-
duction of genotyping 467 SNPs, earlier selected in our primary selection. Finally, the number of 
SNPs selected with the capacity of representing a LD block was 20. Within our selection, these SNPs 
represent a total of 55 SNPs. During this selection, a large percentage within the criterion functional-




Criteria N of SNPs selected (%) 
Gene region: 
- Unknown/N.A. 
- 3’ near gene 













































Tag SNPs 93 (50.0) 
SNPs representative for LD  20 (10.8) 
 
 
Table 2. Characteristics of finally selected SNPs according to defined criteria 
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Discussion 
 
We present a rational approach for the selection of SNPs for pathway pharmacogenetic association 
studies. This method was applied in the presented case study by describing the pathways regarding 
the mechanism of action and pharmacokinetics of the TNF inhibitor adalimumab. This approach 
has several advantages over either the candidate gene approach or the genome-wide SNP analysis. 
First, because the rate-limiting step in the described pathway is unknown, this systems pharmacolo-
gy approach provides a solution: variability in the entire pathway is explored. In fact, the relative 
contribution of the different SNPs in the pathway to the explanation of variability to drug response 
can be assessed. Second, this approach has an important statistical advantage: the chance of false-
positive results is lower compared to the genomewide method, because of decreased multiple test-
ing. 
The next step would be to bring this pathway pharmacogenetic approach into practice. Namely, a 
pharmacogenetic study may be considered to validate the functionality of the selected SNPs in the 
pathway with respect to the therapeutic outcome to TNF inhibitors. Interestingly, an association 
study is projected by our group in the near future. Hereby, the efficacy of treatment with adalimu-
mab in RA patients is linked with genetic variants systematically selected by this approach. Gene 
ontology analysis software may be useful in identifying novel pathways associated with mechanism 
of action of TNF inhibitors. One free-available software program is the Gene Ontology project, 
which is a large bioinformatics initiative to unify genomic databases and to increase convenient 
usage for biological scientists [50]. This software tool, however, was not used in our exploration of 
genes involved in the mechanism of action of adalimumab. 
With the application of proposed criteria, objective selection of SNPs can be achieved. Defined steps 
were made to include 186 SNPs in 111 genes out of 51,793 SNPs in 124 genes in our case study. How-
ever, several crucial remarks can be placed.  
Because the SNP selection is performed based on in vivo and in vitro studies concerning assumed 
pathways and targets in the mechanism of action of TNF inhibitors, there could be issues owing to 
limited understanding or changing opinion about the mechanism of action of the drug. For example, 
scientists thought that the drug imatinib was an inhibitor of several tyrosine kinases (TKs), like the 
BCR-Abl and platelet-derived growth factor (PDGF) receptor. Reports of inhibition of the c-kit sig-
nal transduction pathway by imatinib mesylate gave new insights into the mechanism of action of 
this drug [51,52]. Irrespective of whether or not the mechanism of action of the group of TNF inhibi-
tors, such as infliximab, etanercept and adalimumab, is similar, clinical trials have demonstrated 
that the patient response differs within and between RA patients, as seen in results of several studies 
in which anti-TNF treatment has been switched [53,54]. Hypothetically, the 
variation in clinical results can be explained by differences in the mechanism of action. This makes a 
class-effect and a complete similar mechanical pathway less probable.  
Although many SNPs have been reported in the past decade, only a very small minority of the genet-
ic variants published have proven functional consequences. Generally, functionality remains an 
important SNP selection criterion if compared with other used criteria in our presented method. 
During our stepwise selection, however, a predicted functionality could be assessed in only 6% of the 
SNPs. Future research has to be performed to explore the functional ability of a SNP. Subsequently, 
more predictive tools for functionality may be available for scientists to use.  
A third crucial remark is related to prognostic versus predictive nature of the biomarker. A substan-
tial number of published SNPs have been described to potentially associate with drug therapy out-
come and with disease susceptibility under study [55,56]. If a high qualitative association is demon-
strated between a SNP and the susceptibility to RA, as is seen in genome-wide studies [16,57], these 
results may be of interest for pharmacogenetic studies. Moreover, next to a significant association of 
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a SNP with susceptibility to RA, a more than random chance of this SNP being related to treatment 
outcome could be intelligible. Likewise, a pharmacogenetic condition can have implications for un-
derstanding susceptibility of disease [58,59]. Still, despite the necessity of prospective validation of 
our approach compared with the other methods, so-called ‘literature-SNPs’ were not taken into 
account during our selection. Namely, significant results based on literature may influence the ob-
jectivity aiming at a systematical pathway gene method to obtain optimal, original and detectable 
SNPs. Interestingly, this is the case for the SNP TNFa -308A > G, which is extensively studied in 
association studies with responsiveness to TNF-alpha-blockers in RA. Because the heterozygosity of 
this SNP is 0.163 (according to NCBI) and its position is not within an exon region, this SNP would 
not be selected according to our objective criteria. 
Finally, costs are an important limiting factor in the SNP selection process. Costs of assays are indi-
rectly correlated with the number of SNPs that could be examined and leads to an unwanted con-
straint to objectively select SNPs [60]. 
In this paper we have presented a feasible pathway gene approach with defined selection criteria to 
effectively explore potential SNPs with adalimumab as a case study. The comparison of this ap-
proach with the candidate gene- and whole genome methods requires further investigation. 
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Adalimumab efficacy in patients with RA is about 60-70% and predictors for response are yet un-
known. This study aims at exploring predictors for adalimumab efficacy in RA patients by associat-
ing response with single nucleotide polymorphisms (SNPs) in: 1) the pharmacological pathway of 
adalimumab, and 2) disease susceptibility genes. 
 
Methods 
223 SNPs in 111 genes were analyzed in 325 genotyped rheumatoid arthritis (RA) patients treated 
with adalimumab. Treatment outcome was evaluated with the use of the 28-joint disease activity 
score criteria (DAS28) by the primary endpoints EULAR good response and remission and by the 
secondary endpoint relative change in DAS28. Initially SNPs were explored for associations under 
allelic and genotypic model using chi-square tests. Hereafter, SNPs were investigated in the most 
appropriate model with Cochrane-Armitage test for trend analysis and regression analyses under 
additive, recessive and dominant genetic model with the covariates age, gender, concomitant MTX 
therapy and DAS28 at baseline. 
 
Results 
19 SNPs, 11 SNPs and 8 SNPs were significantly associated with EULAR good response, EULAR 
remission and relative change in DAS28, respectively (p<0.05). Four SNPs, rs1126535 in CD40LG, 
rs682847 in KDR, rs1267067 in TANK and rs25648 in VEGFA, were significantly associated with 
adalimumab treatment outcome according to all three endpoints (p<0.05).  
 
Conclusion 
The SNPs, rs1126535 in CD40LG, rs6828477 in KDR, rs1267067 in TANK and rs25648 in VEGFA 
were found potential predictors for adalimumab efficacy. The results from this explorative study 
provide new insights regarding the potential of pharmacogenetics related to adalimumab efficacy in 
RA.      
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TNF inhibitors have proven to be effective in a majority of rheumatoid arthritis (RA) patients, which 
had not experienced a positive response to traditional disease-modifying antirheumatic drugs 
(DMARDs) (1-3). Consequently, these biologicals have become important agents in therapy of se-
vere RA. Still, a considerable proportion of 30 to 40% of these patients do not experience benefit 
from this treatment. If patients do not profit from TNF inhibitor therapy, disease progression and 
joint erosion proceeds while patients potentially experience serious drug related side effects. The 
idea of a priori prediction of drug response in RA patients is a highly relevant topic, as it will enable 
rheumatologists to readily identify those patients sensitive to certain drug regimens and thereby 
minimizing irreversible joint dysfunction existing in severe untreated RA (4-6).  
Variation in treatment response for patients treated with TNF inhibitors could be expected, regard-
ing interdifferential cytokine and receptor expression in patients leading to heterogeneity of cytokine 
presence and regulation in joints. Although this has not been studied intensively, indeed several 
polymorphisms have been studied over the years, which may associate with treatment outcome of 
TNF inhibitors in general (7-9).  
It has been suggested that adalimumab and other TNF inhibitors target analogous functional path-
ways (10;11). Despite the awareness that the mechanism of action of TNF inhibitors may involve 
several pathways and is, therefore not monogenetic, so far, the majority of association studies have 
analyzed only genetic variants in single genes in relation with treatment outcome.  
Alternatively, since a large group of enzymes and cytokines are likely involved in the pharmacody-
namics of TNF inhibitors and inflammatory cascade of RA, an approach concerning reciprocal com-
parison of multiple genes encoding these proteins would be more logical. Characteristically, with 
this systems pharmacology approach one considers the variability in the entire pathway without 
restricting the analysis to only one candidate gene (12). Moreover, with the single candidate gene 
method, SNPs that are responsible for the rate limiting or extending step in mechanism of action are 
easily missed. 
Therefore, the objective of this study is to explore whether the efficacy of treatment with adalimu-
mab is associated with single nucleotide polymorphisms (SNPs) in genes related to the mechanism 
of action of TNF inhibitors and/or inflammatory process of RA by using a systems pharmacology 
approach. Similarly, SNPs, which were previously associated with genetic susceptibility to RA 







Clinical data of 325 patients enrolled in this study originated from a database of ApotheekZorg, 
which facilitates the Dutch distribution of adalimumab. In the Netherlands, adalimumab is pre-
scribed according to the following protocol and is restrictive for reimbursement: 1) patients have 
used 2 DMARDs including MTX and 2) patients have a Disease Activity Score based on a 28-joint 
count (DAS28) of at least 3.2. Other inclusion criteria enclosed a diagnosis of RA according to the 
revised American College of Rheumatology criteria (ACR) (13); 18 years of age or older; an erythro-
cyte sedimentation rate (ESR) of at least 28 mm/hour; patient’s global assessment of their general 
well-being measured on a 100 mm horizontal visual analogue scale (VAS), the left end representing 
as good as can be and the right end representing as worse as possible, of at least 20 mm.  
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The local ethics committee at our hospital (Leiden University Medical Center, The Netherlands) 
approved the study protocol. Patients gave written informed consent prior to inclusion. 
 
SNP selection  
The SNPs for analysis in this study were selected primarily according to a pathway selection method, 
as previously described (12). Briefly, a systematic approach was used including rational criteria for 
the selection of potential interesting SNPs within genes related to the mechanism of action of adali-
mumab. The criteria were based on the following characteristics of SNPs: heterozygosity frequency, 
validation status, ethnicity frequency, functionality based on alteration in protein, the extent of lin-
kage disequilibrium and TAG SNPs. Included genes for SNP selection were genes encoding proteins 
involved in the mechanism of action of TNF inhibitors: neutralization and blockage (14;15); interac-
tion with Fc receptor (cross-linkage) (16); initiation of reverse signaling, leading to blockage, in-
creased apoptosis or growth arrest (17;18); reduction of inflammatory cytokine production and an-
giogenic factor expression (15;19-21); restoration of immune regulation (22); mediation of comple-
ment-dependent cytotoxicity (CDC) and antibody-dependent cytotoxicity (ADCC) (14;18); down-
regulation or discontinuation of bone and cartilage destruction (23;24). Ultimately, with this path-
way approach 186 SNPs in 111 genes out of 51,793 SNPs in 124 genes were selected. 
Additionally, a set of SNPs was selected (N=37), which included SNPs previously studied in relation 
with efficacy of TNF inhibitors and/or susceptibility to RA.   
 
DNA collection and genotyping 
After inclusion and with patients' written consent, DNA was obtained from patients by using DNA 
from single 2 ml salivary samples. Specifically, a sample of whole saliva was collected from each 
patient using a OrageneTM DNA self-collection kit (DNA Genotek Inc., Ottawa, Ontario, Canada). 
Hereafter, DNA samples were isolated according to a standard laboratory protocol for manual puri-
fication of DNA designed to optimize DNA yield (OrageneTM DNA Purification Protocol). DNA 
from 323 patients was suitable for genotyping. In 2 patients DNA was of low quality, which was 
defined as a DNA yield of lower than 10ug and/or nucleic acid purity (260nm/280nm ratio) lower 
than 1.6.  
Genotyping was performed using a custom designed array with Veracode GoldenGate GT assays on 
the Illumina BeadXpress platform. This array interrogated 384 SNP loci within a single well of a 
standard microplate.  
Before analysis for association, quality control procedures were performed: SNP genotyping plots 
for each assay were checked for degree of clustering (GenTrain score of <0.4) and samples with a 
call rate of less than 90% and assays with a call rate of less than 95% were removed. During this 
quality process, 22 SNPs and 8 patient samples were excluded for analysis.  
Additionally, genotype frequencies of each assay were calculated and these distributions were tested 
for Hardy-Weinberg equilibrium (HWE) (p<0.05). If deviation from HWE was observed, genotype 
distribution in our population was compared with allele frequencies presented in the NCBI SNP 
database (http://www.ncbi.nlm.nih.gov/SNP). Accordingly, 5 SNPs were removed for analysis. 
 
Clinical evaluation  
For association analyses, primary and secondary endpoints were chosen based on two scales: 
change in 28 joint Disease Activity Score (DAS28) between baseline and at 14 weeks. As primary 
endpoints, achievement of good response and remission at 14 weeks according to EULAR criteria 
were chosen (25). EULAR good response was defined as a change of DAS28 ≥ 1.2 and DAS28 at 14 
weeks ≤ 3.2. EULAR remission was defined as achieving DAS28 at 14 weeks ≤ 2.6. As secondary 
endpoint a relative change in DAS28 was selected (DAS28baseline-DAS2814weeks)/ DAS28baseline). 
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Initially, for the analysis of primary endpoints SNPs were explored for associations under allelic and 
genotypic model using chi-square tests. If a p-value of <0.1 was observed with either of these mod-
els, SNPs were fitted to the most appropriate model with Cochrane-Armitage test for trend- and 
logistic regression analyses for additive, recessive and dominant genetic model, respectively. 
Secondly, if SNPs were significant SNPs (p<0.05) in the logistic regression analyses of either prima-
ry endpoints, the SNPs were candidates for analysis of the secondary endpoint. For this endpoint 
linear regression analyses for associations with relative change in DAS28 were applied.  
Notably, with the analysis of SNPs previous associated with genetic susceptibility to RA and/or 
treatment outcome to TNF inhibitors, the reported genetic model (additive, recessive or dominant) 
was chosen. SNPs, which were reported under genotypic or allelic genetic model, were analyzed 
additionally according to methods described above. 
All regression analyses were adjusted for age, gender, concomitant MTX therapy and DAS28 at 
baseline. 
Since this study is explorative, no corrections for multiple testing were made. Therefore, p-values 
were presented without adjustments (p <0.05 was considered significant). 
Statistical analyses were performed using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA) and 
GPlink software (http://pngu.mgh.harvard.edu/purcell/plink/) (26). 
 
Power calculation 
With the appliance of a power calculation it was demonstrated that for our study population of 
325 patients, minimal allele frequencies (MAF) ranging from 10% to 50%, an exposure (response of) 
of 45% and a chosen type 1 error probability α=0.05, a power of >80% could be achieved to detect 
an odds ratio ranging from 1.4 (MAF of 50%) tot 2.0 (MAF of 10%). Notably, in more than 80% of 
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In total, 223 SNPs were genotyped in 323 patient samples, of which 196 (88%) SNPs were success-
fully genotyped in 315 (98%) patient samples after quality procedures and testing for HWE. Baseline 
demographic, disease characteristics and clinical response of the 325 initially included patients are 
presented in table 1. The average age of the cohort at the start of adalimumab therapy was 56 years 
with a mean disease activity (DAS28) at baseline of 5.9. Other patients received concomitant MTX 
with an average dose of 24.1 mg a week. In this cohort, 57 patients (18%) used adalimumab as mo-
notherapy during evaluation period.  
After 3 months of treatment with adalimumab, 174 (54%) and 103 (32%) of the patients responded 
according to the EULAR good response and EULAR remission criteria, respectively (table 1). No 
statistical differences in response rate between overall included patients and genotyped patients 

















Table 1. Study population characteristicsa,b   
 
a) Presented are numbers of patients (%) unless otherwise indicated. 
b) Abbreviation(s): DAS28= 28 joint disaese activity score, MTX=methotrexate, EULAR= Euro-




For EULAR good response, initial association analyses of 196 SNPs in 315 patients under allelic and 
genotypic model revealed 33 SNPs (p <0.1) as candidates for further examination according to the 
best-fit genetic model. Additionally, multivariate regression analysis including covariates age, gend-
er, concomitant MTX therapy and DAS28 at baseline, assessed for 19 SNPs significant associations 
with good response (p<0.05) (table 2). In this group, 2 polymorphisms in the TANK and TNFAIP 
genes were most significantly associated (for both SNPs p=0.008, table 2). When a multivariate 
analysis was performed with all 19 SNPs and covariates included, the SNPs CD40LG (rs1126535), 
CSF1R (rs10079250), ICAM (rs5498), PECAM1 (rs4968622), TANK (rs1267067) and TNFAIP3 
(rs2230926) remained significant (p<0.05, table 2) 
Characteristics Value 
Number of RA patients 325 
Age -years (mean, sd) 56 (12) 
Gender -female (%) 228 (71) 
  
Concurrent MTX (%) 266 
(82%) 
MTX dose/week in mg (mean, sd) 24.1 (3.8) 
  
Previous biological agent (%) 18 (6%) 
  
DAS28 at baseline (mean, sd) 5.8 
(0.98) 
DAS28 at 3 months (mean, sd) 3.1 (1.1) 
ΔDAS (mean, sd) 2.7 (1.0) 
Relative change in DAS28 in % (mean) 46.1 
  
Good response according to EULAR criteria (%) 174 (54)  
Remission according to EULAR criteria (%) 103 (32) 
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Gene SNP (rs number) MAF Best-fit genetic model P-valueb OR (95% C.I.)b 
ADAM 17 rs1048610 (C>T) 0.47 Additive: CC > CT > TT 0,035 1,4 (1,0-2,0) 
C3 rs344543 (G>C) 0.41 Additive:  CC > CG > GG  0,044 1,4 (1,0-2,1) 
CD40LGc rs1126535 (T>C) 0.17 Recessive: T-allele vs. CC 0,013 5,1 (1,4-18) 
CSF1Rc rs10079250 (A>G) 0.07 Dominant: AA vs. G-allele 0.037 2.1 (1.0-4.2) 
FCRL3 rs7528684 (A>G) 0.42 Dominant: AA vs. G-allele 0,029 1,7 (1,1-3,0) 
ICAM1c rs5498 (A>G) 0.42 Dominant: AA vs. G-allele 0,048 1,6 (1,0-2,7) 
IL1A rs1304037 (A>G) 0.33 Recessive: A-allele vs. GG 0,012 3,2 (1,3-7,9) 
IL1RAP rs13321840 (T>G) 0.29 Additive: TT>GT>GG 0,011 1,6 (1,1-2,4) 
IL4R rs1049631 (A>G) 0.47 Recessive: GG vs. A-allele 0,022 2,0 (1,1-3,6) 
KDR rs6828477 (T>C) 0.41 Dominant: TT vs. C-allele 0,041 1,4 (1,0-2,1) 
PADI4 rs2240340 (G>A) 0.42 Dominant: GG vs. A-allele 0,013 1,9 (1,1-3,2) 
PECAM1c rs4968622  (G>A) 0.45 Dominant: A-allele vs. GG 0,020 1,9 (1,1-3,2) 
TANKc rs1267067 (T>C) 0.32 Additive: CC>CT>TT 0,008 1,7 (1,1-2,5) 
TGFB1 rs1800469 (C>T)  0.28 Recessive: C-allele vs. TT  0,027 3,5 (1,1-10,5) 
TGFB1 rs2241715 (G>T)  0.27 Recessive: G-allele vs. TT 0,028 3,4 (1,1-10) 
TNFAIP3c rs2230926 (T>G)  0.04 Additive: TT>GT>GG 0,008 4,0 (1,4-11) 
TNFRSF11B rs11573885 (G>A) 0.43 Additive: AA>AG>GG 0,036 1,5 (1,0-2,1) 
TNFRSF11B rs1485286 (T>C)  0.29 Additive: CC>CT>TT 0,036 1,5 (1,0-2,2) 
VEGFA rs25648 (C>T) 0.16 Additive: TT>CT>CC 0,021 1,8 (1,1-3,0) 
 
Table 2. Association between SNPs and adalimumab efficacy (EULAR good response at 14 
weeks) according to the best-fit genetic model (p<0.05)a,b,c  
 
a) Abbreviation(s): EULAR= European League Against Rheumatism, MAF= minimal allele frequency, OR= odds 
ratio, 95% C.I.= 95 % confidence interval, SNP=single nucleotide polymorphism. Abbreviations and accessory full 
names of formal genes can be relocated in the NCBI gene database (http://www.ncbi.nlm.nih.gov). 
b) P-values and odds ratios with 95% confidence intervals are calculated by logistic regression analysis, adjusted 
for baseline DAS28, gender, age and concomitant MTX treatment according to best-fit genetic model. 




Regarding the analysis of association with EULAR remission, 27 SNPs of the included 196 SNPs 
were further analysed (p<0.1) under additive, recessive and dominant genetic model. Within this set 
of potential SNPs, 11 SNPs were significantly associated with remission (p<0.05, table 3). Specifical-
ly, associations were observed with CD69 (rs10844706,  p= 0.035), FLT1 (rs748253,  p=0.031), 
PTPN22 (rs2476601,  p= 0.031), Region Chr1p34 (rs17534243,  p= 0.010), TANK (rs1267067,  
p=0.006) and VEGFA (rs25648,  p= 0.045) according to an additive genetic model; with  KDR 
(rs6828477,  p=0.016), PECAM1 (rs12953,  p=0.042), RSBN1 (rs6679677,  p=0.030) and VWF 
(rs1063856,  p=0.022) according to a dominant genetic model and with CD40LG (rs1126535,  
p=0.048) according to a recessive genetic model (table 3). When a multivariate analysis was per-
formed with all 11 SNPs and covariates included, the SNPs KDR (rs6828477), PECAM1 (rs12953), 
Region Chr 1p34 (rs17534243), TANK (rs1267067) and VWF (rs1063856) remained significant 
(p<0.05, table 3). 
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Gene SNP (rs number) MAF Best-fit genetic model P-valueb OR (95% 
C.I.)b 
CD69 rs10844706 (C>A) 0.36 Additive: AA>AC>CC 0.035 1.5 (1.0-2.3) 
CD40LG rs1126535 (T>C) 0.17 Recessive: T-allele vs. CC 0.048 1.9 (1.0-3.6) 
FLT1 rs748253 (G>T) 0.40 Additive: TT>GT>GG 0.031 2.2 (1.1-4.4) 
KDRc rs6828477 (T>C) 0.41 Dominant: TT vs. C-allele 0.016 2.0 (1.1-3.5) 
PECAM1c rs12953 (A>G) 0.48 Dominant: AA vs. G-allele 0.042 1.8 (1.0-3.3) 
RSBN1 rs6679677 (C>A) 0.17 Dominant: CC vs. A-allele 0.030 2.0 (1.1-3.7) 
PTPN22 rs2476601 (G>A) 0.17 Additive: GG>AG>AA 0.038 1.8 (1.0-3.1) 
Region Chr1p34c rs17534243 (A>G) 0.23 Additive: GG>AG>AA 0.016 1.7 (1.1-2.7) 
TANKc rs1267067 (T>C) 0.32 Additive: CC>CT>TT 0.006 1.8 (1.2-2.7) 
VEGFA rs25648 (C>T) 0.16 Additive: TT>CT>CC 0.045 1.7 (1.0-3.0) 
VWFc rs1063856 (A>G) 0.34 Dominant: AA vs. G-allele 0.022 1.9 (1.1-3.3) 
 
Table 3. Association between SNPs and adalimumab efficacy (EULAR remission at 14 weeks) 
according to the best-fit genetic model (p<0.05)a,b,c  
 
a) Abbreviation(s): EULAR= European League Against Rheumatism, OR= odds ratio, 95% C.I.= 95 % confidence 
interval, SNP=single nucleotide polymorphism. Abbreviations and accessory full names of formal genes can be 
relocated in the NCBI gene database (http://www.ncbi.nlm.nih.gov). 
b) P-values and odds ratios with 95% confidence intervals are calculated by logistic regression analysis, adjusted 
for baseline DAS28, gender, age and concomitant MTX treatment according to best-fit genetic model. 





In total, 30 SNPs were examined for association with a relative change in DAS28 according to the 
SNPs’ best-fit model. Linear regression analyses revealed 8 significant associations (p<0.05). Specif-
ically, associations were demonstrated with ADAM17 (rs1048610, p= 0.002), TNFRSF11B 
(rs1485286, p=0.019), TANK (rs1267067, p= 0.010) and VEGFA (rs25648, p= 0.025) according to 
an additive genetic model; with FCRL3 (rs7528684, p= 0.004), KDR (rs6828477, p= 0.003), PE-
CAM (rs12953, p= 0.026) according to a dominant genetic model and with CD40LG (rs1126535, p= 
0.016) according to a recessive genetic model (data not displayed in table).     
Notably, four SNPs were significantly associated with the analyses according to all three endpoints: 
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 MAF EULAR Good re-
sponse 
EULAR Remission Relative decrease of 
DAS28 in % 
    
 P-value OR (95% C.I.) P-value OR (95% C.I.) Response differ-
ences in % 
P-value 
CD40LG (rs1126535)        
Recessive genetic model: 
T-allele carriers vs. CC 0.17 0.013 5,1 (1,4-18) 0.048 1.9 (1.0-3.6) 46.8 vs. 36.9 0.016 
KDR (rs6828477)        
Dominant genetic mod-
el: 
TT vs. C-allele carriers 
0.41 0,041 1,4 (1,0-2,1) 0.016 2.0 (1.1-3.5) 49.9 vs. 44.2 0.003 
TANK (rs1267067)        
Additive genetic model: 
CC>CT>TT 
0.32 0,008 1,7 (1,1-2,5) 0.006 1.8 (1.2-2.7) 44.1>52.3>54.8 0.010 
VEGFA (rs25648)        
Additive genetic model: 
TT>CT>CC 
0.34 0,021 1,8 (1,1-3,0) 0.045 1.7 (1.0-3.0) 44.9>54.0>57.9 0.025 
 
Table 4. Association of SNPs in CD40LG, TANK, VEGFA and KDR according to EULAR criteria 
and relative change in DAS28a,b  
 
a) Abbreviation(s): EULAR= European League Against Rheumatism, OR= odds ratio, 95% C.I.= 95 % confidence 
interval, SNP=single nucleotide polymorphism. B= regression coefficient, S.E.= standard error, KDR= kinase 
insert domain receptor, MAF= minimal allele frequency, TANK= TRAF family member-associated NFKB activa-
tor, VEGF= vascular endothelial growth factor, DAS28= 28-joint count disease activity score. 
b) P-values, odds ratios with 95% confidence intervals and regression coefficients with standard errors are calcu-
lated by logistic regression analysis and linear regression analysis, respectively. In these analyses adjustments for 
baseline DAS28, gender, age and concomitant MTX treatment according to best-fit genetic model were made. 
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Discussion 
 
In this explorative study, our aim was to determine whether SNPs in genes related to the mechan-
ism of action of adalimumab were associated with efficacy of this biological DMARD. Furthermore, 
SNPs from previous research on pharmacogenetics of TNF inhibitors in RA and susceptibility to RA 
were included for analysis. It was demonstrated that 19 SNPs, 11 SNPs and 8 SNPs were significant-
ly associated with EULAR good response, EULAR remission and relative change in DAS28, respec-
tively. Four SNPs, rs1126535 in CD40LG, rs6828477 in KDR, rs1267067 in TANK and rs25648 in 
VEGFA showed consistent associations and, therefore, they appear to be the most predictive for 
adalimumab efficacy. 
The pathway pharmacogenetic method used in this study has an advantage over the classical usage 
of the candidate gene approach and the whole genome approach. The main feature of this method is 
that a set of SNPs is selected based on a description of pathways regarding the mechanism of action 
of the drug under study (12). With the candidate gene method, SNPs that are responsible for the rate 
limiting or extending step in the mechanism of action of adalimumab are easily missed. Therefore, it 
seems likely that for most drugs and complex diseases, like RA, pharmacogenetics has more poten-
tial if information on multiple genes is used. Numerous proteins are involved in the mechanism of 
action and, therefore, genetic variability in each gene may contribute to the overall variability in drug 
response. 
The four most potential SNPs, CD40LG (rs1126535), KDR (rs6828477), TANK (rs1267067) and 
VEGFA (rs25648) are rs numbers close to genes encoding proteins involved in the mechanism of 
action of adalimumab. CD40LG is a member of the TNF superfamily, which is primarily expressed 
on the surface of activated T-cells and stimulates B-cell proliferation and secretion of proinflamma-
tory cytokines and chemokines after CD40-CD40LG ligation (27). CD40LG is an extracellular target 
for TNF inhibitors. This was also demonstrated in a study of Danese et al (28), which measured 
reduced levels of CD40LG with infliximab. Correspondingly, adalimumab may limit the inflamma-
tory process involved in RA by inhibiting CD40LG. Likewise, the observed interindividual differenc-
es in response in our study may be the result of the synonymous SNP rs1126535 in the gene encod-
ing the CD40LG protein. Concerning our results, patients genotyped for CD40LG (rs1126535) CC 
may have less binding capacity to TNF inhibitors compared with patients genotyped carrying a 
CD40LG (rs1126535) T-allele (table 4). 
Vascular endothelial growth factor (VEGF) is an important protein involved in angiogenesis. Since it 
is demonstrated that expression of VEGF is reduced in RA patients treated with TNF inhibitors, it is 
thought that these biologicals may interfere with the angiogenesis seen in the inflammatory process 
of RA (15). Regarding our selected SNP VEGFA-rs25648, patients genotyped for a homozygous 
mutant genotype (rs25648-TT) achieved a better response than patients genotyped for carrying the 
wildtype C-allele (rs25648-CT, rs25648-CC). Hypothetically, the mutant genotypes may assist TNF 
inhibitors in reduction of angionesis in RA by facilitating decreased expression of VEGFA enzyme. 
Also, VEGF acts by binding with to tyrosine kinase receptors (VEGFR), of which KDR (kinase insert 
domain receptor) is the primary receptor for mediation of VEGF’s action. In the study of Cañete et al 
it was observed that reduction of synovial angiogenesis after therapy with TNF inhibitor therapy in 
psoriatic arthritis patients could be related to modulation of molecular factors, like KDR, involved in 
this process (29). Hypothetically, regarding our results for rs6828477, indicate that carrying the C-
allele may have a decreased modulation of KDR by adalimumab leading to a lower response com-
pared with patients with a TT genotype.  
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In addition, TANK, a protein coding for TRAF family member-associated NFKB activator, is part of 
the TRAF family which mediates signals from cytokines signals through cell surface receptors and, 
hereby, activating downstream intracellular signaling cascades. TANK binds to TRAF1, TRAF2 and 
TRAF3. It is seen that the mechanism of action of TNF inhibitors includes the initiation of reverse 
intracellular signaling cascade by binding of antibodies to transmembrane TNF. This may lead to a 
decreased production of proinflammatory cytokines (like TNFα),  increased production of anti-
inflammatory cytokines (like IL10) and induction of apoptosis in cells (14;15;30). In our results, 
patients with a homozygous mutant genotype (rs1267067-CC) were more likely to achieve clinical 
response than patients carrying a wildtype allele (rs1267067-TT or rs1267067-CT). Hypothetically, 
this polymorphism may support the reverse signaling by less binding of TRAF1-TRAF3 to TANK. 
Generally, along with replication of these explored SNPs in other patient cohorts and determination 
whether these SNPs provide the strongest association compared with other adjacent variants in the 
gene, functional studies remain to be performed (31). In this way, beneficial- and/or risk genotypes 
involved in efficacy of TNF inhibitors could be biologically identified.  
Concerning susceptibility to RA, GWA studies have provided new insights in the genetic risk profile 
of an individual RA patient. These genetic variants have strong evidence to be associated with RA 
and include SNPs in the TRAF1-C5, OLIG3-AIP3 and STAT4 gene regions. Consequently, genetic 
findings led to improved knowledge regarding the pathogenesis of this immune-mediated disease. 
Likewise, these findings could have implications on pharmacogenetics in RA. As is seen in other 
medical research areas, it seems plausible that a pharmacogenetic response in RA depends on the 
interaction of genes involved in anti-rheumatic drug metabolism and genes associated with RA’s 
pathogenesis (32;33). However, several studies have been performed on the predictive value of 
these variants for response to therapy with TNF inhibitors, but with inconclusive results to answer 
the question whether in general genes contributing to disease susceptibility may play a role in de-
termining response to treatment. In our analyses, associations were detected with TNFAIP 
(rs2230926), PADI4 (rs2240340), FCRL3 (rs7528684), RSBN1 (rs6679677), Region Chr. 1p34 
(rs17534243) (tables 2 and 3). Still, these results were not as consistent as the results for rs1126535 
(CD40LG), rs6828477 (KDR), rs1267067 (TANK) and rs25648 (VEGFA) based on all three end-
points.    
In our study, no adjustment for multiple testing was performed. Assessing a large number of SNPs 
for association creates potential false positive results and additionally the need for adjustment for 
multiple testing. Generally, the need for multiple testing arises from the assumption that the inci-
dence of false positives is proportional to the number of test performed and level of significance. The 
most common method for dealing with multiple testing, the Bonferroni correction, involves adjust-
ing the significance level of each test by the total number of performed tests (34). However this me-
thod has a conservative character, since interaction and cooperation between causative genes are 
not recognized (35;36). Consequently, studies may be willing to risk higher frequencies of false posi-
tives, instead of finding no associations at all due to false negative associations. Ideally, replication in 
a second comparable cohort of patients would be optimal, but not always feasible. Therefore, we 
have decided to present the p-values of this explorative study without adjustments to make the re-
sults accessible for clear interpretation.  
Still, we would like to underline that we have performed multiple independent tests (e.g. variable 
endpoints) and that we recognize that the consideration of a cutoff value of p=0.05 for level of signi-
ficance in this study is inaccurate. Therefore our results need to be marked as suggestive for associa-
tion with adalimumab efficacy.  
Generally, future research should be done to confirm our significant results. Particularly, replication 
of our results in patients treated with different TNF inhibitors remains a challenge. However, re-
cently in a report from Bowes et al (7), stratified analysis for infliximab and etanercept was per-
145
Pharmacogenetic pathway approach detects associations with adalimumab efficacy 
                                                                                                             in rheumatoid arthritis
formed. No significant differences were observed, suggesting that response was not subject to drug-
specificity. Moreover, their results confirm the general applicability of our pathway pharmacogenet-
ic approach, since this approach is based on the mechanism action of the class of TNF inhibitors.   
In conclusion, primary analyses in this study have revealed new SNPs, rs1126535 in CD40LG, 
rs6828477 in KDR, rs1267067 in TANK and rs25648 in VEGFA, which may be involved in the effi-
cacy of adalimumab. In this way, the results from this explorative study provide new insights regard-
ing the potential of pharmacogenetics of adalimumab in RA. 
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Rheumatoid arthritis (RA) is prevalent in approximately one percent of all types of populations. 
Characteristically, this immune-mediated disease is related with symmetrically inflammation, de-
struction of the joints leading to overall functional impairment and (serious) comorbidity. 
Regardless of the increasing comprehension on the etiology and pathogenesis, a therapy resulting in 
remedy of the disease is not achieved to date. Consequently, in order to gain optimal benefit treat-
ment is aimed at remission of disease by opposing the immune response with disease-modifying 
antirheumatic drugs (DMARDs). However, in practice suboptimal results are achieved with the use 
of DMARDs including methotrexate (MTX) and Tumor Necrosis Factor (TNF) inhibitors. Namely, 
highly differential response rates in overall clinical efficacy and/or toxicity have been observed in 
clinical trials with MTX and TNF inhibitors. Partly, pharmacogenetics is responsible for this va-
riance in response. Therefore, the primary focus of this thesis is to assess the role of pharmacogenet-
ics in the variation of treatment outcome in patients diagnosed with rheumatoid arthritis and 





Initially, in the first part of this thesis an overview was presented of previously performed studies 
concerning genetic variability contributing to differences in response to MTX in RA treatment 
(chapter 2). Most pharmacogenetic studies have an insufficient sample size (power) to detect true 
associations with treatment response. In addition, other factors, like nongenetic factors, ethnicity 
and clear endpoints, influence treatment outcome. Therefore, definitive conclusions about the role 
of genetic prognostic factors in treatment outcome to MTX cannot be drawn from this literature 
study.   
As it is generally accepted that MTX may act in RA through inhibition of folate pathway enzymes, 
other reports indicate that efficacy may also be related to the release of endogenous antiinflammato-
ry adenosine. With this hypothesis, the relationship between SNPs in genes related to adenosine 
release and MTX treatment outcome in patients with recent-onset RA was explored in chapter 3. 
Results of this analysis did show an association between allelic variants in the adenosine mono-
phosphate deaminase (AMPD), 5-aminoimidazole-4-carboxamide ribonucleotide transformylase 
(ATIC), and inosine triphosphate pyrophosphatase (ITPA) genes and clinical response to MTX ther-
apy in patients with recent-onset RA. Patients carrying the AMPD1 T allele, the ATIC CC genotype, 
or the ITPA CC genotype were 2–3 times more likely to have a good clinical response, defined by a 
disease activity score (DAS) of ≤2.4, following 6 months of MTX therapy. Additionally, the rate of 
good clinical response increased substantially in patients carrying the 3 favorable genotypes. With 
regard to the occurrence of adverse drug events, the only association found was with the ATIC G 
allele. However, this association was not significant after adjustment for multiple testing. No associ-
ations between SNPs in the genes methionine synthase or methionine synthase reductase and MTX 
efficacy or toxicity were found.  
So far, most genetic variants are selected for analysis based upon their hypothetical relation to the 
mechanism of MTX or inflammatory process in RA (chapters 2 and 3). Ideally, functional genetic 
variants are chosen because the alteration in protein function is thought to influence drug action and 
thus may explain interindividual differences in drug response. Chapter 4 assessed the role of SNPs 
in genes with proven functional consequences on efficacy and toxicity of MTX in the BeSt cohort. It 
was observed that toxicity was potentially associated with ABCB1 3435C/T and TLR4 +896A/G. 
However, none of these associations remained significant after (Bonferroni) correction for multiple 
testing. No significant associations of DHFR 829C/T, ABCB1 3435C/T, ITPA IVS2 +21A/C, HLA-G 
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-/+14bp, IMPDH2 +787C/T, TGFB1 +869T/C and TLR4 +896A/G with MTX efficacy were found. 
Additionally in this chapter, results from previous research according to reported endpoints were 
replicated in our cohort. Particularly, replication analyses are important, since pharmacogenetic 
studies have the potential to result in reporting false positive findings. However, no significant re-
sults were detected with these analyses in our cohort.  
 
Previously, a clinical pharmacogenetic predictive model was developed for predicting the efficacy of 
MTX monotherapy in patients with recent-onset RA comprising the Dutch BeSt Cohort. The model 
consists of non-genetic factors sex, rheumatoid factor and smoking status, Disease Activity Score 
(DAS) before starting MTX and 4 genetic polymorphisms (MTHFD1 1958G>A, AMPD1 34C>T, 
ITPA 94A>C and ATIC 347C>G). With this model, a true positive predictive vale of 95%, true nega-
tive predictive value of 86% and categorization of 60% of the patients was achieved. In chapters 5 
and 6 the performance of the predicitve model was validated in a second Dutch cohort (chapter 5) 
and in a Swedish cohort (chapter 6).  
In chapter 5, it was demonstrated that the clinical pharmacogenetic model to predict MTX mono-
therapy efficacy in patients with established RA does not perform as good as in DMARD naïve pa-
tients with recent-onset RA (BeSt cohort). Namely, it was found that the model had lower true posi-
tive and negative predictive values  (47% and 81%, respectively) compared with the true positive and 
negative predictive values reported in the BeSt cohort (95% and 86%, respectively). Several explana-
tions may be responsible for these findings: variation in RA disease duration and history of DMARD 
use; lack of (pharmacogenetic) association with components of the model in the second cohort; the 
presence of differences in tight control strategy of RA and, consequently, the variance in dosage 
between the two cohorts leading to different response rates.  
In chapter 6, a model for predicting the efficacy of MTX monotherapy was validated in a cohort of 
DMARD naïve and early RA patients originated from the Swefot trial. Similarly as in chapter 5, 
both true predictive values observed in patients of the validation cohort were significantly lower 
compared to the values found in the original BeSt cohort (95% and 86%, respectively), since applica-
tion of this pharmacogenetic model resulted in a true positive predictive value of 70% and a true 
negative predictive value of 68%. However, for the predictive values accuracy, number of patients 
classified and discriminative ability (AUC) the results were comparable between the Swefot cohort 
and BeSt cohort (for accuracy 48% vs. 53%: p=0.572; for number of patients classified 70% vs 60%: 
p=0.182 and for AUC 75% vs. 85%: p=0.111, respectively).  
Overall, these validation data imply that efficacy of a substantial part of early RA patients treated 
with MTX could be predicted by this clinical pharmacogenetic model, but that this model may ex-
clusively be applicable in DMARD naïve RA patients with short duration of disease. Additional rep-
lication and (ideally) performance of prospectively designed studies with this model in large cohorts 
is warranted to demonstrate the legitimate predictive value in rheumatology practice.  
 
Chapter 7 evaluates the role of the haplotypes comprising the SNPs MTHFR 1298A>C and 
MTHFR 677C>T in treatment outcome to MTX in RA. Specifically, in this chapter optimalization of 
a previously designed pharmacogenetic model was aimed with addition of the number of haplotypes 
comprising MTHFR 1298A-677C alleles as additional criterion. Furthermore, the predictive value of 
the most predictive number haplotype is compared with the SNPs AMPD1 34C>T, ITPA 94C>A, 
ATIC 347C>G and MTHFD1 1958G>A involved in predicting MTX efficacy. It was observed that the 
predictive performance of the pharmacogenetic model to predict the efficacy of MTX therapy in this 
group of early RA patients was not improved when the MTHFR haplotype was included in the mod-
el. Moreover, the discriminative effect for the prediction of MTX efficacy including 1 or 2 or (solely) 2 
copies of the 1298A and 677C haplotype was significantly smaller compared with the four SNPs 
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AMPD1 34C>T, ITPA 94C>A, ATIC 347C>G and MTHFD1 1958G>A. These results suggest that a 
(leading) role for the MTHFR 1298A and 677C haplotype with regard to predicting efficacy of MTX 
monotherapy in early RA patients seems unlikely. Future research is necessary to elucidate the exact 
pharmacogenetic and biological role of MTHFR 1298A>C and MTHFR 677C>T and their haplo-





At the start of this second part of the thesis an overview was presented of reports on associations 
between genetic variants and the drug efficacy of TNF inhibitors in RA (chapter 8). Similar to re-
ports concerning pharmacogenetics of MTX in RA, the majority of pharmacogenetic studies were 
underpowered to detect accurate associations.  
In chapter 9, SNP selection for pharmacogenetic association studies was discussed. Additionally, a 
pharmacogenetic pathway approach is presented together with proposed criteria for systematic 
selection of SNPs. These comprise the following genetic characteristics of SNPs: heterozygosity, 
validation, ethnicity, functionality, linkage disequilibrium and Tag SNPs. With the application of 
these criteria, an objective selection can be achieved: 186 SNPs in 111 genes out of 51,793 SNPs in 
124 genes were included. Specifically, this method was applied for the selection of potential interest-
ing SNPs within genes related involved in the mechanism of action of adalimumab and/or inflam-
matory process of RA. This approach has several advantages over either the candidate gene ap-
proach or the genome wide SNP analysis. First, because the rate limiting step in the described path-
way is unknown, this systems pharmacology approach provides a solution: variability in the entire 
pathway is explored. In fact, the relative contribution of the different SNPs in the pathway to the 
explanation of variability to drug response can be assessed. Secondly, an important statistical advan-
tage is present: the chance of false-positive results is lower compared to the genome-wide method, 
because of decreased multiple testing.  
 
Chapter 10 put the presented systematically selection of SNPs in chapter 9 into practice: efficacy of 
treatment with adalimumab was associated with genetic variants selected by a pharmacogenetic 
pathway approach using a custom made anti-TNFα SNP array. Additionally, in this chapter SNPs 
from previous research on pharmacogenetics of TNF inhibitors in RA and susceptibility to RA were 
included for analysis. Results elucidated 19 SNPs, 11 SNPs and 8 SNPs, which were significantly 
associated with EULAR good response, EULAR remission and relative change in DAS28, respec-
tively (p<0.05). Four SNPs, rs1126535 in CD40LG, rs6828477 in KDR, rs1267067 in TANK and 
rs25648 in VEGFA demonstrated the most evidence for potentiality in determining adalimumab 
therapy outcome, since these SNPs were significantly associated according to all three primary and 
secondary endpoints (P<0.05). Notably, p-values of this explorative study were presented without 
(Bonferroni) adjustments to make the results accessible for clear interpretation. Ideally, replication 
in a second comparable cohort of patients would be optimal, but not always feasible. Nevertheless, 
results from this explorative study provide new insights regarding the potential of pharmacogenetics 















Rheumatoid arthritis (RA) is a chronic autoimmune disease, which is characterized by inflamma-
tion leading to destruction and impairment of principally the joints. Treatment is aiming at limiting 
the progress of disease activity and involves the use of disease-modifying antirheumatic drugs 
(DMARDs) including methotrexate (MTX) and Tumor Necrosis Factor (TNF) inhibitors. Many 
clinical trials have demonstrated successful results with these classes of drugs  underlining their 
suitability in the tight scheduled management of RA’s disease progress. However, a considerable 
proportion of the patients do not experience a positive response. Especially, these patients are at risk 
of developing progressive and erosive RA. In the light of optimal management of individual patients, 
the idea of a priori prediction of drug response is considered an important achievement. It will ena-
ble physicians to readily select those patients sensitive to certain drug regimens and thereby mini-
mizing irreversible joint dysfunction existing in severe untreated RA. Hereby, an important role is 
being played by pharmacogenetics as it is thought that drug response is, at least partly, a heritable 
trait.  
Important progress has been made regarding pharmacogenetics in rheumatology in the last decade. 
Basically, explorative studies focusing on the pharmacokinetics and pharmacodynamics of anti-
rheumatic agents have contributed to the introduction of new genetic markers. Still, consensus re-
garding their potential implication has not been reached. It is observed from previous research 
(chapters 2 and 8) and from the results presented in this thesis that definitive conclusions regard-
ing the influence of genetics on treatment outcome to DMARDs can not be drawn. These differences 
in outcome are the result of a several factors, in which variance in study design plays an important 
role.  
In this discussion a focus is placed on the interpretation and implication of potential pharmacoge-
netic findings. Hereby, answers are sought to the following questions: “What are the major points of 
concern in RA study design contributing to interpretation difficulties of pharmacogenetic results?” 
and “Which factors could be of influence in the implementation of proven genetic associations in 
rheumatology clinical practice?” Furthermore, an ideal study proposal for a prospective study con-
cerning MTX and TNF inhibitors in RA is presented, in which strategy for therapy is guided by 
pharmacogenetics.  In figure 1, a schematic overview of this chapter is provided. 
 
 
Design and interpretation of pharmacogenetic studies 
 
Power and sample size 
In general, appropriate sample size is characterized by consideration of statistical power, which is 
the probability of correctly rejecting the null hypothesis in favor of the alternative hypothesis. Power 
analysis comprises selection of a sample size large enough to identify either a relation or effect size 
(1). Power calculation is optimally performed prior to analysis. In chapter 10, efficacy of treatment 
with adalimumab was associated with genetic variants related to the mechanism of action of TNF 
inhibitors and/or inflammatory process of RA. A power calculation analysis was performed to rec-
ognize the range of power in which the minimal allele frequencies (MAF) of the selected single nuc-
leotide polymorphism (SNPs) would fall to find specific odds ratios (OR). In figure 2, this range is 
presented. With the appliance of a power calculation it was demonstrated that for a patient popula-
tion of 325 patients, minimal allele frequencies (MAF) ranging from 10% to 50%, a response of 45% 
and a chosen type 1 error probability α=0.05, a power of >80% could be achieved to detect an odds 
ratio ranging from 1.4 (MAF of 50%- line A) to 2.0 (MAF of 10%- line B) (figure 2). Line C 
represents a MAF of 5% indicating the lower chance of finding a reasonable odds ratio with the 
achievement of a power of >80%. Notably, in more than 80% of the selected SNPs the MAF was 
higher than 30%. Results elucidated 19 SNPs, 11 SNPs and 8 SNPs in the TNF pathway, which were 
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significantly associated for adalimumab with EULAR good response, EULAR remission and relative 
change in DAS28, respectively (p<0.05). In the majority of the associated SNPs odds ratios and 






Figure 1. Stages towards implementation of pharmacogenetic markers into clinical practice 
 
Stage 1: Before prospective validation in large studies of potential genetic polymorphisms can be performed, sev-
eral aspects have to be noticed (see most left rectangle)  
Stage 2: Next to general factors comprising cost-effective, regulatory and ethical aspects, several challenging fac-
tors appear before implementation of a pharmacogenetic marker as a tool in rheumatological clinical practice can 
take place (see most right rectangle) 
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Figure 2. Power calculation analysis to recognize the range of power in which the minimal allele 
frequencies (MAF) differ to find specific odds ratiosa,b 
 
a) For a patient population of 325 patients, minimal allele frequencies (MAF) ranging from 5% to 50%, a response 
of 45% and a chosen type 1 error probability α=0.05, a power of >80% could be achieved to detect an odds ratio 
ranging from 1.4 (MAF of 50%- A) to 2.0 (MAF of 10%- B). Line C represents a MAF of 5% indicating the lower 
chance of finding a reasonable odds ratio with the achievement of a power of >80%. Curves between lines A and B 
represent MAFs of 40% (most left), 30% and 20% (most right). 
b) Abbreviation(s): MAF= minimal allele frequency 
 
 
In many pharmacogenetic studies concerning DMARDs low power is observed due to the use of 
small sample sizes. Consequently, reported p-values and effect sizes for efficacy and toxicity are dif-
ficult to interpret. Also, with the interpretation of underpowered studies a suboptimal reference is 
provided for future studies (2;3), since replication studies could expect finding smaller effect sizes 
than originally reported (4;5). For example, if a power calculation is performed to confirm an initial 
association with an odds ratio of 3.5, hypothetically, a smaller effect size of approximately 2.0 may 
be expected. Therefore, for the performance of replication studies a larger sample size may be consi-
dered to identify the smaller effect size (see also Figure 2 of chapter 8 in this thesis).  
If the calculated power turns out to be small, cooperation with other research groups is attractive. 
Yet, in practice cooperation is challenging because of regulatory and organizational problems to 
combine patient cohorts (6).  
 
Ethnicity 
Conflicting results may be explained by different frequencies of polymorphisms among ethnic popu-
lations, which makes association studies less likely to compare (34). For example, this is highlighted 
in a study in which an association of MTHFR  677C>T and MTX-related alopecia in only African 
Americans was demonstrated (35). Therefore, to compare results between studies, considering eth-
nicity of the patient population is appropriate. For MTHFR 677C>T the MAF of this SNP in the Afri-
can American population is 0.098, compared with a MAF of 0.24 in the Caucasian population 
(NCBI database).  
These differences in frequency has also consequences for haplotypes concerning these SNPs. Signifi-
cant differences in haplotype distribution between Caucasians and African-Americans were ob-
served in the study of Hughes et al (7). Hughes et al (7) reported that the D-prime (D’) value, a value 
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ascribing linkage disequilibrium (LD), for the two SNPs was 0.955, indicating strong LD. However, 
in African-Americans the D’ value is much lower (0.408), indicating less linkage disequilibrium 
(www.hapmap.org). Chapter 7 evaluates the role of the number of haplotypes comprising the 
SNPs MTHFR 1298A>C and MTHFR 677C>T in treatment outcome to MTX in RA. Analyses were 
performed in mainly Caucasian patients, which were derived from the BeSt study. It was observed 
that the predictive performance of the pharmacogenetic model to predict the efficacy of MTX thera-
py in this group of early RA patients was not improved when the MTHFR haplotype was included in 
the model. No significant associations were seen when differences in number of haplotypes were 
considered. Alternative values of LD could explain the different results seen in the reports of Urano 
et al (8) and Taniguchi et al (9), which studied the influence of the haplotype on response in patients 
with Asian backgrounds. Therefore, if allele frequencies and corresponding haplotypes are substan-
tially differently distributed between ethnic populations, a genuine pharmacogenetic effect  is diffi-
cult to observe. More important is whether the cohort of patients under study is large enough to 
limit a random change in genetic variation and to limit a sampling effect. 
 
Nongenetic factors 
Besides genetics as factors for drug response, demographic and clinical characteristics of patients 
are important to include for analysis in pharmacogenetic association studies. For example, several 
studies linked nongenetic factors to therapy outcome in patients treated with TNF inhibitors. Like-
wise, concomitant MTX usage and low disability have been demonstrated to predict optimal re-
sponse to TNF inhibitor therapy (10;11). Moreover, Disease Activity Score (DAS) at baseline deter-
mines to a large extend the response of RA patients treated with DMARD therapy as was demon-
strated from previous studies (12;13) and chapters 3-6. Previously, reciprocal comparison in mul-
tivariate regression analyses of 17 polymorphisms and 24 nongenetic factors in the BeSt cohort DAS 
at baseline was observed as most predictive (13). Scores for prediction of response regarding DAS at 
baseline were approximately 3 times larger than the SNP ATIC 347 C>G (13). This is in correspon-
dence with the results demonstrated in chapter 5, which compared the same factors in a different 
cohort. For DAS at baseline and ATIC 347 C>G beta regression coefficient were 0.77 and -0.23, re-
spectively. 
Moreover, this was not only the case for MTX therapy, since DAS at baseline was also an important 
covariate in the multivariate-analyses for response of adalimumab, as demonstrated in chapter 10.   
In general, the results of a large influence of a nongenetic factor on therapy outcome emphasise the 
necessity of multivariate-analysis in pharmacogenetic association studies. On order to analyze this 
predictive effect, studies require longitudinal clinical data regarding the effect of a DMARD on dis-
ease activity. Moreover, if a wider focus is applied, interactions between gene and nongenetic factors 
similar to the observed interactions of genetic studies concerning susceptibility to RA may be con-
cerned (13).  
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Drug dosage 
An important feature in any pharmacogenetic study is drug dosage. In chapter 5, it was demon-
strated that with the clinical pharmacogenetic model to predict MTX mono-therapy efficacy in pa-
tients with established RA smaller predictive values were calculated, compared with the calculated 
values in the DMARD naïve patients (BeSt cohort). It was found that the model had lower true posi-
tive and negative response rates  (47% and 81%, respectively) compared with the true positive and 
negative response rates reported in the BeSt cohort (95% and 86%, respectively). Partly, different 
control strategy of RA and, consequently, the variance in dosage between the two cohorts leading to 
different response rates may have been responsible for differences of the model’s performance.  
Furthermore, drug dosage is necessary for the interpretation and comparison of a functional phar-
macogenetic effect on treatment outcome. For example, in theory the cellular amount of Tumor 
Necrosis Factor-alpha (TNFα) and, thus the amount available for inhibition by TNF inhibiting 
agents, might depend on the genotype of the TNF gene (14;15). However, a higher drug dosage may 
lead to inhibition of more TNFα and may, therefore, overshadow a genetic effect. In contrast, a ge-
netic effect may be assumed, which may be due to a lower dosage of the TNF inhibitor under study. 
Future research need to be performed concerning levels of TNFα and TNF inhibiting therapy. 
 
Alternative use of response criteria  
Various use of disease activity parameters and/or cutoff levels for the definition of response may 
contribute to different results observed in pharmacogenetic studies. In order to optimally compare 
studies or perform meta-analyses, criteria regarding efficacy and toxicity are standardized. Exam-
ples are response criteria according to the American College of Rheumatology (ACR) improvement 
criteria, which are based on a perceptual improvement (20, 50, 70 and 90%) in disease symptoms 
(termed ACR20, ACR50, ACR70 and ACR90, respectively) and EULAR criteria (defined in chapter 
10). 
Regarding pharmacogenetics and treatment outcome measurements in RA, studying defined 
groups of patients is challenging. In clinical trials frequencies of response according to disease activi-
ty scores after drug therapy are measured. Based on a selected cut off value, several types of fre-
quency distribution curves can be drawn to divide response into two groups. Rarely, the distribution 
of drug responses is ideal bimodal (16;17). Instead, the frequency distribution curve for measures of 
response is mostly unimodal distributed (16). A unimodal distribution is consistent with a multifac-
tor configuration caused by effects of many genetic and environmental factors, in which no single 
factor has a clearly large effect on response. In this way, it is difficult to study a subset of responders 
and nonresponders by the effects of a single genetic locus (18;19). 
 
 
Selection of genetic variants for association analysis 
 
Methods of selection 
A clear design in selection of genetic variants is relevant for the interpretation of results of pharma-
cogenetic association studies in RA. Predominantly, the presented candidate genetic factors in these 
studies are selected based on current knowledge of mechanism of action of the drug (20). With this 
approach functional genetic variants are chosen because the alteration in protein function is thought 
to influence drug action and, thus, may explain interindividual differences in drug response. This is 
demonstrated in chapter 4, in which 7 SNPs in genes with proven functional consequences were 
related to efficacy and toxicity of MTX in the BeSt cohort. Due to the fact that an exact mechanism of 
action of DMARDs is uncertain, a clear pathway for selection of genetic variation coding for enzymes 
influencing these agents is challenging. The results from chapter 3 may indicate that MTX therapy 
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works via the adenosine pathway, since AMPD1 34T allele, ATIC 347CC, or ITPA 94CC were asso-
ciated with clinical response, as defined by a DAS of <2,4 (OR [95% confidence interval] 2,1 [1,0–
4,5], 2,5 [1,3–4,7], and 2,7 [1,1–8.1], respectively). However, in chapter 6, no significant associa-
tions of these three SNPs with efficacy were found with a Swedish validation cohort under study 
(p>0.05). Therefore,  it remains unclear, 1] whether the three variants are true markers for MTX 
response, 2] whether other variants in the three genes are responsible for the effect on treatment 
outcome, 3] whether other genes are involved. Future research on the mechanism of action of MTX 
is therefore required. 
Since the mechanism of action of DMARDs is considered being polygenetic, selecting SNPs in a 
single gene will by definition only lead to a limited extent of explained variance of drug response. A 
solution toward these difficulties is the pathway pharmacogenetic approach, which considers varia-
bility in the entire pathway without restricting the analysis to only one gene. This method has advan-
tages over either the candidate gene approach and the genome wide SNP analysis, as highlighted in 
chapter 9. In the same chapter, selection criteria for this approach to effectively explore potential 
associating SNPs with adalimumab are presented. With the application of these criteria, an objective 
selection can be achieved: 186 SNPs in 111 genes out of 51,793 SNPs in 124 genes were included for 
analysis in chapter 10.  
Genome-wide association (GWA) studies may be a promising method for pharmacogenetic studies. 
GWA concerns a broad approach which rapidly assesses markers across the genome to elucidate 
genetic variation in patients compared to controls or responders compared to non-responders. As a 
result, in the last two years GWA studies have presented novel associations with susceptibility to RA 
taking care of its polygenetic variation (21;22). For example, SNPs within the TRAF1-C5 gene region 
have been demonstrated to influence the susceptibility for RA (22). These novel genes form a new 
source of genetic variation potentially explaining variability in disease activity and treatment re-
sponse in RA patients (23;24). Ultimately, next to the direct detection of new markers for treatment 
response, a pharmacogenetic GWA study could give new insights into the mechanism of action of 
antirheumatic agents.  
On the other hand, various remarks could be placed regarding the results from GWA studies. This is 
due to the overall found small effect sizes (25) and difficult balance between type I errors and type II 
errors in presenting new associations (26;27). 
 
Concurrent functional SNPs 
Genetic variation in metabolic processes may be a confounder for interpretation of pharmacogenetic 
results. For example, in patients and healthy volunteers with genetic polymorphisms in the cytoch-
rome P450 drug metabolizing enzymes CYP2D6 and CYP2C9 variation in pharmacokinetics of drug 
therapy have been demonstrated (38-40). CYP2D6 and CYP2C9 are involved in the pharmacokinet-
ics of therapeutics, like anticoagulants, nonsteroidal anti-inflammatory drugs and hypoglycaemic 
drugs (40). Also, cytochrome P450 enzymes play also a role in metabolism of physiological sub-
strates (41;42). Although the DMARDs in this thesis are not substrates for CYP2D6 and CYP2C9, 
genetic variation within these enzymes could be relevant for the drug response as outcome. For ex-
ample, hepatotoxicity could not only be caused by genetic variants encoding enzymes involved in the 
metabolism of MTX, but also could be enhanced by SNPs encoding the cytochrome P450 enzymes 
involved in the physiological and pathological processes of the liver.  
 
Confounding genetic variation  
Besides SNPs, other types of genetic variation exist which could have an effect on treatment out-
come. For example, a factor which can be of influence is copy number variation (CNV). CNV is de-
fined as DNA segments, which are 1 kb or larger and present at variable copy number in comparison 
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with a reference genome. These segments are collectively termed copy number variants (28). Even 
though these variants are far less abundant in the genome, CNV account for more nucleotide varia-
tion on average than SNPs (29). Subsequently, a SNP effect on treatment outcome could be misin-
terpreted due to a CNV effect in the same gene region (30). One of the selected SNPs on the custom 
made array presented in chapter 10 was the functional SNP FCGR3A -158T>G (rs396991). In 
previous studies, this SNP was associated with treatment outcome to TNF inhibitors (31-33). How-
ever, with our analyses presented in chapter 10 an association with efficacy was absent. Hypotheti-
cally, CNV may cause a different interpretation of genotypes resulting in altered findings. From ge-
nome wide studies it has been observed that in the FCGR3A gene region CNVs are present (34). In 
this way, alternative genotyping results of FCGR3A -158T>G may be due to CNV: high copy number 
(more than 2 alleles) may lead to the detection of an inaccurate number of  heterozygous genotypes 
and low copy number (one allele) may lead to more homozygous genotypes (35).  
In addition, epigenetics could also be a reasonable confounder in finding (or not finding) genetic 
associations with treatment outcome. The term epigenetics covers phenotypic changes which are 
not covered by mutations in DNA sequence. It comprises grossly three different areas in which alte-
ration could lead to changes in gene expression and enzyme activity: methylation of DNA, modifica-
tion of histones in chromatin and RNA mediated regulation of gene-expression (36). 
In summary, it is difficult to assign differences in treatment outcome solely to SNPs. Future research 
have to be performed to exactly study the weight of SNPs in differences in efficacy and/or toxicity. 
 
 
Adjustment for multiple testing 
Along with the discovery of novel causative loci for treatment response with GWA studies, testing a 
large number of loci for association creates potential false-positive results and, therefore, the need 
for adjustment for multiple testing (37). Similarly, but to a lesser extent, adjustment is necessary in 
studies applying a candidate- or pathway gene approach. The need for multiple testing arises from 
the assumption that the incidence of false positives is proportional to the number of tests performed 
and level of significance. For example, If 10,000 genes are tested, 5% or 500 genes might be found 
significant by chance alone. For this reason correction is important: it adjusts the individual p-value 
for each gene in order to keep the false positive- rate to less than or equal to the p-value cutoff. 
Chapter 10 presented associations between efficacy of adalimumab therapy and SNPs selected by 
the pharmacogenetic pathway approach (chapter 9). It was demonstrated that 19 SNPs, 11 SNPs 
and 8 SNPs were significantly associated EULAR good response, EULAR remission and relative 
change in DAS28, respectively (p<0.05) Moreover, 4 SNPs, rs1126535 in CD40LG, rs6828477 in 
KDR, rs1267067 in TANK and rs25648 in VEGFA showed consistent associations and, therefore, 
they appear to be the most predictive for adalimumab efficacy. In this chapter, no adjustment for 
multiple testing was performed. The most common method for correcting for multiple testing, the 
Bonferroni correction, involves adjusting the significance level of each test by the total number of 
performed tests (38). However, this method has a conservative character, since interaction and co-
operation between causative genes are circumvented (37;39). Also, other adjustments could be ap-
plied, like permutation testing or false discovery rate, but also these methods have specific difficul-
ties (not discussed) (37). Replication of genetic associations in a second comparable cohort of pa-
tients is essential, but not always feasible.  Therefore, we have decided to present the p-values of this 
explorative study without adjustments to make the results accessible for clear interpretation. Still, 
we would underline that multiple independent tests were applied and these results imply suggestive 
associations with adalimumab efficacy.  
All statistical adjustments are focused on a certain level of significance. However, more weight 
should be on reporting effect size and confidence interval instead of p-values. For example, a mean 
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decrease in DAS for a specific genetic variant of 1.2 with a 95% confidence interval of 0.8 to 1.6 illu-
strates a range of values for what the mean decrease might be if the entire population is studied. This 
range of values highlights the importance of clinical values instead of statistical outcomes. Conse-
quently, effect size and confidence intervals encourage meaningful qualitative decisions about quan-
titative data. In other words, a rheumatologist becomes more involved in the data and may evaluate 
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Future perspectives 
 
Prospective study design for validation of pharmacogenetics in RA 
 
In recent years, pharmacogenetic studies have revealed numerous SNPs that associated with drug 
response but only a few of these have been introduced as candidates for clinical implementation. 
Especially, prospective pharmacogenetic studies are scarce. One such prospective study concerns 
adverse drug reactions to abacavir in HIV-treatment (40). In this large study, the HLA-B*5701 po-
lymorphism was highly linked to hypersensitivity reactions in a cohort of Caucasians and successful-
ly replicated in other but similar cohorts. It was calculated that 14 patients would have to be 
screened, to prevent one hypersensitivity reaction on abacavir therapy (40). Currently, this poly-
morphism is increasingly being used as a genetic biomarker in routine clinical practice. Similar stu-
dies are needed to demonstrate the value of prospective genotyping for antirheumatic therapy in 
clinical practice. In figure 3 an ideal study proposal for a prospective study concerning MTX efficacy 
in RA is presented, in which strategy for therapy is guided by pharmacogenetics.  
For this hypothetical study proposal, adult patients with early RA and active disease are enrolled. 
First a randomization (figure 3) is performed to assign patients to undergo prospective pharmaco-
genetic screening or to undergo a standard-of-care DMARD treatment without pharmacogenetic 
screening. Patients assigned to prospective pharmacogenetic testing are divided in predicted res-
ponders and predicted nonresponders based on the pharmacogenetic test determining MTX mono-
therapy efficacy. Predicted responders are allocated to treatment with MTX monotherapy. Predicted 
nonresponders to MTX are given the alternative traditional DMARD sulphasalazine. Patients as-
signed to the control group (without pharmacogenetic screening) are given MTX monotherapy as 
standard-of-care therapy. Therapy is evaluated and adjusted after 6 months. Hereafter, patients 
with standard-of-care DMARD treatment are screened for the pharmacogenetic test. 
Primary analyses are focussed on statistical differences in response percentages between patient 
groups allocated to pharmacogenetic screening and the patient group allocated to standard-of-care 
treatment. As secondary analyses, the performance of the pharmacogenetic tests is calculated in the 
control group with standard-of-care treatment.  
Power calculation reveals that enrolment of 300 patients for evaluation of at least 100 patients per 
group is needed for this prognostic study to have a statistical power of 90% (with a chosen type 1 
error probability α=0.05) to detect an improvement in response of 50% in the groups with pharma-
cogenetic screening compared to the control group without pharmacogenetic screening.  
Likewise, a more complex study design could also be applied for a prospective study including the  
pharmacogenetics of TNF inhibitors.  
In conclusion, results of above described study could demonstrate the beneficial value of prospective 
pharmacogenetic screening compared to current standard therapy. Application of pharmacogenetic 
tests could reduce inefficacious and unnecessary drug exposure  and thus treatment delay and toxic-
ity in clinical practice. However, even with promising results from prospective studies, several chal-
lenges appear before a genetic marker can be implemented as a clinical tool (figure 1).  
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Figure 3. study proposal for a prospective study concerning MTX in RA, in which strategy for 
therapy is guided by pharmacogeneticsa  
 
a) Abbreviation(s): MTX= methotrexaat, RA= rheumatoid arthritis, TNF= tumor necrosis factor 
 
 
Challenging steps towards clinical implication of pharmacogenetics 
 
Social, ethical and legal implications of pharmacogenetics 
It is demonstrated from the literature that pharmacogenetics holds the potential to improve thera-
peutic efficacy, to minimize adverse drug events, to enhance safety and to reduce the overall cost of 
management of disease, but needs further development for clinical implementation in the near fu-
ture. Still, this development is not solely a challenge for genetic researchers and clinicians, since 
several social, ethical and legal implications form large obstacles for authorities, health care organi-
zations, regulatory organizations and individuals.      
For (pharmaco)genetic testing, privacy and informed consent may be essential in clinical usage of 
the genetic information. Personal information could be used adversely to a patient’s interests. How-
ever, overall the knowledge on genetics is limited in individual patients. As a consequence, the au-
tonomy of patients is reduced and the risk of involuntarily and abusively application of genetic data 
would be increased (41;42).   
Also, it may be considered unethical not to employ pharmacogenetic testing in patients in order to 
avoid the exposure to the inefficacy and harmful side effects of drugs (43). On the other hand, with 
the performance of genetic testing the problem of handling ‘by-catch’ arises. This by-catch is the 
result of creating a genetic profile by the performance of e.g. whole-genome testing in which not only 
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searched information is present, but also unsearched information. This was studied by Henrikson 
and colleagues (44), who demonstrated that 53% of potential pharmacogenetic variants were re-
ported to have a significant association with disease susceptibility. Hereby, genetic profiling could 
reveal susceptibility to e.g. serious diseases. In the light of self determination, is it mandatory to noti-
fy the patient on this by-catch? The psychological impact of this knowledge and concomitant re-
sponsibility could be difficult for the patient to handle in the future. This could include a change in 
health behaviour, quality of life and social surrounding (42;45).  
The question remains how the health care insurers would act based on the pharmacogenetic results 
of their clients. The focus of the health care system on clients is likely to be shifting from a general 
population view to a more personalized view (46). Likewise, this attitude of the health care system 
could advance the inclusion of pharmacogenetics in to clinical practice. This could also lead to un-
wanted situations (46;47). For example, patients that are predicted non responder to conventional 
medication would be unfavourable to insure, since these patients would require more expensive 
medication and/or their nonresponse would result in chronic disease. 
 
Economic considerations towards pharmacogenetics 
In the short term, implementation of pharmacogenetic testing could result in higher drug related 
health care costs. Partly, investment in the development and evaluation of pharmacogenetic tests 
may lead to higher expenses. Also, higher costs could be due to a higher number of individual pre-
scriptions written by confident clinicians, since choice of therapy is scientifically more gratified. In 
contrast, in the long term, the overall health care costs could be reduced, since e.g. unnecessary and 
unsuccessful expensive drugs are avoided. Moreover, overall drug related morbidity and mortality 
could be decreased (47;48).  
As in the health care system, a more individualized trend towards the patient may be expected in the 
pharmaceutical industry. Ideally, application of pharmacogenetic testing can eventually enhance 
drug discovery and development process leading to market segregation, which is increasing the 
number of new drugs available on the market for a group of patients. Furthermore, it could result in 
more effective usage of existing drugs and could assess the efficacy of previously eliminated drugs, 
which had failed in clinical trials due to e.g. toxicity reasons. However, in practice for a pharmaceuti-
cal company this market segregation is difficult to cope, which has invested a substantial time and a 
significant amount of money in developing a new therapeutic agent for a small part of patients 
(47;49;50).  
 
Impact of genetics 
The impact of the pharmacogenetic test has to be considered. Specifically, in the case of effectively 
predicting effective drug therapy to antirheumatic agents, the additional value to conventional 
treatment has to be proven. For example, consulting a rheumatologist in an early phase of RA’s dis-
ease progress and, hereby, achieving an optimal result on treatment in order to reduce joint damage 
may overshadow the genetic effects and/or demonstrate over-valuation of a clinical pharmacogenet-
ic test.  
 
Comorbidity, co-medication and adherence to therapy 
Individualizing disease and medication of patients remain a problem for clinical usage of pharma-
cogenetics. If a test is based on a population of patients with RA, mostly the general well being or 
disease status is assessed. However, regarding the genetic aetiology of RA, previous findings demon-
strated that two types of RA, ACPA-positive and ACPA-negative RA, have different genetic origins 
(51). In this way, estimating a chance of drug response and/or toxicity with a pharmacogenetic test 
could be limited by individual type of disease(s). 
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The same limitation arises for a specific test based on one type of drug instead of considering the use 
of other medication besides antirheumatic agents in RA patients. Indeed, it is demonstrated that 
statins may have moderate disease modifying effects in RA and these drugs might prevent or slow 
the development of RA (52). In this way, a clear effect of DMARDs on therapy outcome is difficult to 
observe. In order to adapt pharmacogenetic tests based on assembled patients, who will have an 
identical risk of response based on same type of disease, concomitant medication and environmen-
tal factors, remain a significant challenge.  
Finally, a patients’ suboptimal adherence to proposed therapy guidelines could be causative for er-
rors in evaluation of interindividual variability in treatment outcome and hereby interpretation of 
genotypic effects on treatment outcome. Drug adherence could increase if patients would know they 
could benefit from their personal pharmacogenetic profile to improve the response to drug therapy. 
 
Education to the clinician less trained in genetics 
Along with a growing pharmacogenetic knowledge in rheumatology arises an increasing difficulty to 
explain to clinicians the use, benefits and pitfalls of pharmacogenetics and how to interpret a phar-
macogenetic test. Therefore, additional education for clinicians is required for a successful choice 
and/or adjustment of drug therapy and, moreover, for an optimal explanation towards the patient.  
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Conclusion 
 
Results from this thesis have elucidated potential genetic markers, which were associated with 
treatment outcome to MTX and adalimumab. Furthermore, a model for predicting the efficacy of 
MTX in patients with RA was validated in two cohorts indicating that predicting efficacy by a phar-
macogenetic model is feasible in RA patients treated with MTX. Importantly, definitive conclusions 
about the role of genetic predictive factors in treatment outcome to DMARDS could not be drawn, 
since these results have to be further validated and replicated in future pharmacogenetic studies. 
Large randomized prospective studies should be planned to demonstrate its legitimate predictive 
and cost-effective value before a genetically individualized approach is applicable in daily clinical 
practice. 
The potential role of pharmacogenetics in the prediction of efficacy and adverse events in RA pa-
tients treated with DMARDs is presented in this thesis. Hereby, new knowledge is added to the rela-
tively young research field of pharmacogenetics, which may hopefully lead to a better treatment 
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Reumatoïde artritis (RA) komt in ongeveer 1 procent van de algemene populatie voor ongeacht et-
nische achtergrond. Kenmerkend voor deze immunologische ziekte is de aanwezigheid van een 
symmetrische ontsteking en schade aan de gewrichten, die leidt tot algehele functiebeperking en 
uiteindelijk tot evt. invaliditeit. Daarnaast  RA patiënten een verhoogd risico op andere (ernstige) 
aandoeningen, zoals hart-en vaatziekten.  
Ongeacht het toenemende inzicht in het ontstaan, verloop en ontwikkeling van reumatoïde artritis, 
heeft men een genezende therapie nog niet gevonden. Daarom is de huidige behandeling met het 
beste resultaat gericht op het verminderen van de ziekteactiviteit. Deze reductie kan worden behaald 
met behulp van geneesmiddelen als ‘disease modifying antirheumatic drugs’ (afgekort DMARDs) 
met een werkingsmechanisme, dat de immuunreactie betrokken bij RA onderdrukt. Toch zijn in de 
praktijk de resultaten suboptimaal bij het gebruik van DMARDs, zoals methotrexaat (MTX) en anti-
TNFalfa middelen. Er worden namelijk grote verschillen in responsepercentages waargenomen in 
de klinische praktijk evenals in klinische studies, die de effectiviteit van DMARDs hebben onder-
zocht.  
Farmacogenetica beschrijft de invloed van genetische factoren (DNA) op behandelingsuitkomst van 
geneesmiddelen. DNA is de drager van erfelijke informatie en bevat basen (chemische bouwstenen 
van het DNA) die coderen voor de productie van verschillende eiwitten waaronder enzymen. Bij de 
verschillende processen in het lichaam, waaronder de omzetting van geneesmiddelen of ontstaan 
van een ziekte, spelen eiwitten een belangrijke rol. De complete DNA volgorde van de mens bestaat 
uit 3.1 miljoen basenparen. Bij niet verwante personen is ongeveer 99.9% van deze basenparen 
identiek. Slechts 0.1% van de basenparen verschilt van mens tot mens en dit kan leiden tot ziekte of 
verschillen in uitkomst na behandeling met geneesmiddelen. De meest voorkomende variatie in 
DNA (90%) zijn zgn. ‘single nucleotide polymorphisms’ (afgekort SNPs), waarbij 1 base is verande-
rd. SNPs kunnen leiden tot een wijziging in de DNA sequentie waardoor alternatieve enzymen kun-
nen worden gevormd. SNPs, die deze veranderingen in enzymfunctie of anderszins in eiwitten ve-
roorzaken, worden functionele SNPs genoemd. Aangezien enzymen/eiwitten betrokken zijn bij 
omzettingen en werking van geneesmiddelen, kunnen SNPs leiden tot verschillen in behandeling-
suitkomst.  
 
Het doel van dit proefschrift is om de invloed van genetica (SNPs) op de behandelinguitkomst bij 
patiënten met RA die behandeld worden met MTX en/of het anti-TNFalfa middel adalimumab, te 
onderzoeken. Hierbij is dit proefschrift ingedeeld twee delen: de rol van farmacogenetica bij de be-
handeling met MTX (deel 1) en de rol van farmacogenetica bij de behandeling met adalimumab 





In het eerste hoofdstuk van dit deel werd een literatuuroverzicht gepresenteerd van onderzoeken die 
genetische variatie in behandelingsuitkomst van MTX in RA hebben onderzocht. Hiervan hebben 
de meeste onderzoeken slechts kleine patiëntenpopulaties bekeken, waardoor het eigenlijk niet goed 
mogelijk is om werkelijke associaties met therapie-uitkomst aan te kunnen wijzen. Ook andere fac-
toren, zoals niet-genetische factoren, etniciteit of onduidelijke eindpunten bemoeilijken dit. Daarom 
kunnen definitieve conclusies over de rol van genetische factoren bij de respons op MTX niet wor-
den getrokken op basis van de huidige literatuur (hoofdstuk 1).  
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Enerzijds is het werkingsmechanisme van MTX mogelijk te verklaren doordat MTX enzymen uit de 
folaat cyclus remt, anderzijds is gebleken uit studies dat MTX ook zou kunnen werken via het vrij-
zetten van adenosine, een anti-ontstekingsstof. Met deze hypothese werd in hoofdstuk 3 de relatie 
tussen SNPs in genen (DNA) coderend voor eiwitten, die betrokken zijn bij het vrijzetten van adeno-
sine, en behandelingsuitkomst met MTX onderzocht in 205 patiënten met vroege (d.w.z. korter dan 
2 jaar durende symptomen van) RA. Deze patiënten waren afkomstig uit het ‘BeSt cohort’. De resul-
taten lieten associaties zien tussen genetische variatie in de genen coderend voor adenosine mono-
phosphate deaminase (AMPD), 5-aminoimidazole-4-carboxamide transformylase (ATIC) en in-
osine triphosphate pyrophosphatase (ITPA) en klinische effectiviteit bij behandeling met MTX. Pa-
tiënten die namelijk drager waren van het AMPD1 T-allel, het ATIC CC genotype en het ITPA CC 
genotype hadden een 2-3 maal grotere kans op een gunstige klinische response (gedefinieerd als 
‘disease activity score’- DAS 2.4 punten) na 6 maanden MTX therapie. Daarnaast verbeterden de 
responspercentages aanzienlijk wanneer patiënten alle drie de genotypen hadden. Daarnaast werd 
gekeken naar associaties met bijwerkingen als gevolg van MTX therapie. Een relatie werd gevonden 
met het ATIC G-allel dragerschap. Er werden geen associaties gevonden tussen SNPs in genen code-
rend voor methionine synthase of methionine synthase reductase en effectiviteit of bijwerkingen. 
Tot nu toe zijn de meeste genetische varianten voor farmacogenetische analyse met MTX geselec-
teerd op basis van een mogelijk werkingsmechanisme van MTX of het ontstekingsproces bij RA 
(hoofdstukken 2 en 3). Maar in het ideale geval worden functionele SNPs gekozen, die verandering 
in enzym- of eiwitfunctie veroorzaken en op deze wijze de werking van MTX beïnvloeden. In 
hoofdstuk 4 is de relatie tussen functionele SNPs en de effectiviteit en bijwerkingen van MTX thera-
pie bestudeerd in patiënten met vroege RA afkomstig uit het BeSt cohort. Het optreden van bijwer-
kingen na MTX therapie bleek geassocieerd met 2 SNPs in de genen ABCB1 en TLR4. Geen associa-
tie werd gevonden tussen de effecten van MTX en functionele SNPs in de genen DHFR, ABCB1, 
ITPA IVS2, HLA-G, IMPDH2, TGFB1 and TLR4. Daarnaast werden resultaten van eerder onder-
zoek gerepliceerd in ons RA patiënten cohort. Deze replicatie analyses zijn erg belangrijk omdat 
farmacogenetische onderzoeken een hoge kans hebben op het vinden van vals positieve bevindin-
gen. Maar de associaties, die in eerdere studies gevonden werden, konden wij niet bevestigen in het 
BeSt cohort. 
Kort geleden is door onderzoekers van onze groep een klinisch farmacogenetisch predictiemodel 
ontwikkeld om de effectiviteit van MTX in patiënten met vroege RA te kunnen voorspellen. Het 
model bestond uit verschillende niet-genetische en genetische factoren waarvan was aangetoond dat 
ze van invloed zijn op de effectiviteit van MTX: geslacht, reumafactor, rookstatus, DAS bij aanvang 
van behandeling en 4 SNPs in de genen MTHFD1, AMPD1, ITPA en ATIC. Met dit model werd oor-
spronkelijk een positief voorspellend waarde van 95% en een negatief voorspellende waarde van 
86% gevonden. In totaal kon op deze manier 60% van de patiënten gegroepeerd en dus voorspeld 
worden. In hoofdstukken 5 en 6 werd het model gevalideerd door replicatie in respectievelijk een 
ander Nederlands en een Zweeds cohort RA patiënten.  
In hoofdstuk 5 werd gezien dat het farmacogenetisch model minder goed presteerde in patiënten 
met die al langer RA hadden dan in patiënten met vroege RA. De positief voorspellende waarde en 
negatief voorspellend waarde waren respectievelijk 47% en 81%. Het verschil ten opzichte van het 
oorspronkelijke onderzoek kan mogelijk worden verklaard door langere RA ziekteduur, DMARD 
gebruik in het verleden, de afwezigheid van bewezen associatie met de 4 SNPs in the model; de af-
wezigheid van nauwgezette behandelingstrategieën met RA en door lagere doseringen MTX en la-
gere responspercentages.  
In hoofdstuk 6 werd het model getest in een Zweeds cohort met RA patiënten, die nooit eerder een 
DMARD hadden gebruikt, vroege (korter dan 1  jaar durende symptomen van) RA hadden en die 
afkomstig waren uit de Swefot trial. Evenals in hoofdstuk 5, waren de voorspellende waarden lager 
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dan in het oorspronkelijke onderzoek. De positief voorspellende waarde en negatief voorspellende 
waarden in de Zweedse groep waren 70% en 68%. Echter, de resultaten voor de accuraatheid, het 
aantal patiënten gegroepeerd en onderscheidend vermogens (gedefinieerd als area under the curve-
AUC) waren overeenkomstig. 
Over het algemeen laten de resultaten van hoofdstuk 5 en 6 zien dat de effectiviteit in een groot deel 
van RA patiënten met MTX therapie voorspeld zou kunnen worden met het klinisch-
farmacogenetisch model, maar dat het model het best toegepast zou kunnen worden in patiënten 
zonder eerder DMARD gebruik en met een korte ziekteduur. Replicatie van deze resultaten in een 
onderzoek met een prospectieve studieopzet is (ideaal gezien) nodig om de meest betrouwbare re-
sultaten te kunnen verkrijgen.  
 
In hoofdstuk 7 wordt een relatie van het haplotype, bestaande uit de SNPs MTHFR 1298 A>C en 
MTHFR 677 C>T, met behandelingsuitkomst van MTX in het BeSt cohort bestudeerd. Een haplo-
type is een combinatie van allelen, die vaker dan door toeval in combinatie voorkomen in de alge-
mene populatie. Eerder bleek dat de SNPs MTHFR 1298 A>C en MTHFR 677 C>T en hun haplo-
type bestaande uit de allelen MTHFR1298A en MTHFR 677C geassocieerd te zijn met effectiviteit 
van MTX therapie. Hieruit bleek dat met het dragen van 0, 1 of 2 haplotypen MTHFR1298A-677C 
belangrijke verschillen in response percentages werden waargenomen. Met behulp van het toevoe-
gen van het aantal haplotypen (0,1 of 2), die bestaan uit de allelen MTHFR1298A en MTHFR 677C, 
werd geprobeerd om het farmacogenetisch predictiemodel uit te breiden en zo te verbeteren. Verder 
wordt in dit hoofdstuk het voorspellend vermogen (‘discriminative ability’) van het aantal haploty-
pen met de combinatie MTHFR1298A-677C geanalyseerd en vergeleken met de 4 SNPs in de genen 
MTHFD1, AMPD1, ITPA en ATIC uit het model. Resultaten lieten zien dat met de toevoeging van 
het aantal haplotypen als extra factor het model niet werd verbeterd. Ook bleek dat het voorspellend 
vermogen van het aantal haplotypen (0,1 of 2) minder was dan het voorspellend vermogen van de 4 
SNPs in de genen MTHFD1, AMPD1, ITPA of ATIC. Deze resultaten suggereren dat een voorspel-
lende rol voor MTX therapie door middel van verschillen in dragerschap van dit haplotype afwezig 
is. Toekomstig onderzoek zal uitgevoerd moeten worden om de exacte farmacogenetische rol van de 




Aan het begin van het tweede deel van dit proefschrift (hoofdstuk 8) werd een overzicht gepresen-
teerd van onderzoeken die genetische variatie in behandelingsuitkomst van anti-TNFalfa middelen 
(etanercept, infliximab en adalimumab) in RA hebben onderzocht. In overeenstemming met de 
studies die de relatie van genetische variatie met MTX beschreven, zijn ook de farmacogenetische 
studies met anti-TNFalfa middelen meestal uitgevoerd met te kleine patiëntgroepen om definitieve 
conclusies te kunnen trekken.  
In hoofdstuk 9 werd het selecteren van genetische varianten voor farmacogenetische onderzoekin-
gen beschreven. Aansluitend werd een farmacogenetische aanpak gepresenteerd waarbij met be-
hulp van criteria op systematische wijze interessante SNPs geselecteerd kunnen worden. Deze crite-
ria zijn gebaseerd op bepaalde eigenschappen, zoals bewezen kwaliteit en frequentie van SNPs. Met 
het gebruik van deze systematische aanpak kan op verbeterde wijze een objectieve selectie van SNPs 
worden bereikt. Op deze manier werden 186 SNPs in 111 genen uit een aantal van 51.793 SNPs in 
124 genen gekozen. De genen waaruit de selectie is gemaakt, coderen voor enzymen en eiwitten die 
gerelateerd zijn aan het werkingsmechanisme van anti-TNFalfa middelen of het ontstekingsproces 
dat een rol speelt bij RA. 
173
Nederlandse samenvatting
Deze benadering heeft een aantal voordelen boven de gebruikelijke selectiemethoden. Voornamelijk 
als het werkingsmechanisme (en de betrokken enzymen en eiwitten) van het desbetreffende ge-
neesmiddel nog onbekend is, is deze methode bruikbaar.  
Deze selectiemethode werd in de praktijk gebracht in hoofdstuk 10: de effectiviteit van adalimumab 
therapie werd geassocieerd met SNPs die geselecteerd waren volgens de beschreven wijze. Naast 
deze SNPs werden in dit hoofdstuk ook genetische varianten onderzocht die in eerder onderzoek 
bleken geassocieerd te zijn met de effecten van anti-TNFalfa middelen (etanercept, infliximab en 
adalimumab) en/of genetische varianten die waren geassocieerd met het ontstaan van de ziekte RA. 
Effectiviteit was onderverdeeld in de eindpunten: EULAR goede respons, EULAR remissie en een 
procentuele daling in DAS. Resultaten lieten zien dat 19 SNPs, 11 SNPs en 8 SNPs associeerden met 
respectievelijk EULAR goede respons, EULAR remissie en een procentuele daling in DAS. Vier 
SNPs in genen coderend voor CD40LG, KDR, TANK en VEGFA waren het sterkst gerelateerd met 
de effectiviteit van adalimumab therapie, omdat deze 4 SNPs associeerden met alle drie de gekozen 
eindpunten. De resultaten beschreven in dit hoofdstuk moeten gerepliceerd worden in een tweede 
onafhankelijk cohort om de waarde ervan voor het voorspellen van de effectiviteit van adalimumab 





Het in dit proefschrift beschreven onderzoek heeft geleid tot de identificatie van een aantal gene-
tische varianten die geassocieerd zijn met de behandelingsuitkomst bij therapie met MTX en adali-
mumab in RA patiënten. De bevindingen zullen gerepliceerd moeten worden alvorens de resultaten 
in de praktijk toepasbaar zijn. Het eerder door ons ontwikkelde farmacogenetisch predictiemodel 
voor MTX bleek bij replicatie wisselend succesvol. Nader onderzoek is nodig om het voorspellend 
vermogen en dus de waarde van het predictiemodel te kunnen bepalen.  
Tenslotte blijkt uit dit onderzoek dat genetische verschillen een rol kunnen spelen ten aanzien van 
de behandelingsuitkomst voor RA patiënten die met MTX of adalimumab worden behandeld. 
Daarmee is nieuwe kennis toegevoegd aan het relatief jonge vakgebied van de farmacogenetica dat 
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De periode als vreemde eend in de bijt is voorbij: De werkzaamheden als arts-onderzoeker in een 
ziekenhuisapotheek hebben geleid tot het proefschrift, dat voor u ligt. Ik ben blij dat ik de mogelijk-
heid heb gekregen dit onderzoek te mogen doen. Maar dit resultaat zou niet mogelijk zijn zonder 
hulp van vele kanten. 
Allereerst ben ik de participerende patiënten, artsen en medewerkers betrokken bij de BeSt-, Swe-
fot- en Humira studies erg dankbaar. In het bijzonder wil ik de medewerkers en apothekers van 
ApotheekZorg bedanken voor hun ruimte, tijd en inzet om het Humira-project te laten realiseren. 
Ook mijn collega’s van de Klinische Farmacie & Toxicologie ben ik erkentelijk voor hun hulp én 
gezelligheid. Ik vind het een goede ervaring dat ik als arts een kijk achter de schermen van een zie-
kenhuisapotheek heb mogen nemen. 
Daarnaast wil ik mijn familie en vrienden erg bedanken voor de nodige afleiding, die steeds weer op 
een juist moment kwam. In het speciaal dank ik mijn ouders voor de mogelijkheden, steun en ver-
trouwen die door jullie werden geboden om mijzelf te kunnen ontwikkelen in de afgelopen jaren. 
Tenslotte een laatste woord aan Evelien: Na dit proefschrift zal het niet echt rustiger gaan worden, 
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